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1Blood is essential for human life. The human hematopoietic system produces 
around 1012 highly specialized cells every day [1, 2], which can carry out different 
functions. For instance, red blood cells (erythrocytes) are necessary for oxygen 
transport, platelets (thrombocytes) for coagulation and white blood cells (leu-
kocytes) protect the body from pathogens and are a part of the immune system. 
After birth, blood formation takes place in the bone marrow, where all the differ-
ent blood cells can derive from one single cell type, the hematopoietic stem cells 
(HSCs). These cells are characterized by their ability to self-renew and differentiate 
in all abovementioned cells types in a process called hematopoiesis [2].
Healthy hematopoiesis
Hematopoiesis occurs in a hierarchical fashion, with the HSC on top, being able 
to self-renew and to differentiate into more committed progenitor- and precursor 
cells, which subsequently develop into mature blood cells (Figure 1)[3, 4]. Two 
types of HSCs have been defined, the long-term repopulating cells (LTRC), which 
are capable of self-renewal and maintaining multi-lineage differentiation potential 
throughout life and the short term repopulating cells (STRC), which are derived 
from LTRC. Although STRC maintain multipotency, they exhibit more limited 
self-renewal potential than the pluripotent LTRC. STRC reconstitute the myeloid 
and/or lymphoid compartments for a about 6 weeks [3, 5]. Mature blood cells 
have a limited life-span, and to guarantee a lifelong supply of blood cells, the 
self-renewal properties of LTRC are essential to protect this small pool of cells 
from extinction. According to the classical model, STRC give rise to multipotent 
progenitors (MPPs) which further differentiate into common myeloid progenitors 
(CMPs) or common lymphoid progenitors (CLPs), which are restricted to further 
differentiation within the myeloid or lymphoid lineage, respectively. In the my-
eloid lineage, CMPs further mature in either granulocyte monocyte progenitors 
(GMPs), which give rise to granulocytes (neutrophils, basophils and eosinophils), 
monocytes, macrophages and myeloid dendritic cells (DCs) or megakaryocyte 
erythrocyte progenitors (MEPs), which give rise to erythrocytes and megakaryo-
cytes (MKs), which ultimately form platelets. In the lymphoid lineage, CLPs 
give rise to natural killer (NK) cells, B- and T-lymphocytes and lymphoid DCs 
[3]. Nevertheless, this classical differentiation model is not set in stone. With the 
discovery of early progenitors with lymphoid and myeloid potential (EPLMs) and 
lymphoid-primed multi potent progenitors (LMPPs) it seems that the lineages are 
not as strictly separated as assumed before. ELPMs can give rise to macrophages 
and dendritic cells (myeloid) and NK cells, B- and T-lymphocytes (lymphoid), 
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while LMPPs have granulocytic, monocytic and lymphoid potential, but little 
potential for MK and erythrocyte development [6-9].
Regulation of  hematopoiesis
The potential of a cell is written in the DNA. Cell fate is regulated by genetic 
and epigenetic modifications, which results in changes in gene expression. Extra-
cellular molecules, such as cytokines (hematopoietic growth factors), hormones 
(erythropoietin (EPO)) and vitamins (vitamin D), act through signal transduction 
© Thessa Koorenhof-Scheele
Figure 1. Overview of the hematopoiesis.
All mature cells in the peripheral blood are derived from hematopoietic stem cells (HSCs), which in-
cludes the long-term repopulating cells (LTRC) and repopulating cells (STRC). Dashed lines indicate 
recently discovered alternative routes of differentiation towards mature blood cells; MPP, multipotent 
progenitors; CMP, common myeloid progenitors; CLP, common lymphoid progenitors; GMP, granu-
locyte monocyte progenitors; MEP, megakaryocyte erythrocyte progenitors.
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1pathways to instruct the intracellular molecules to control regulation of transcrip-
tion of the DNA [10-15].
Hematopoiesis takes place in the bone marrow, an architecturally complex, 
tightly organized tissue housing multiple cell lineages, including hematopoietic, 
mesenchymal and endothelial cells. This niche supports HSC survival, prolifera-
tion, migration and differentiation. The fate of HSCs and hematopoietic precursor 
cells is determined by direct interaction with surrounding cells and the stimulation 
of molecules that are secreted within (cytokines) and outside (hormones) the niche 
and bone marrow microenvironment [16-18]. Hematopoietic growth factors and 
cytokines bind to receptors on HSC and precursor cells to stimulate intracellular 
signal transduction cascades, leading to DNA transcription regulation. Control 
of gene expression occurs through the interaction of transcription factors with 
,cis- and trans-regulatory elements in the genome (promoters, enhancers etc.), 
and epigenetic regulators that chemically modify the DNA and histone proteins, 
together also called the gene regulatory network [11, 19]. During differentiation, 
self-renewal genes are repressed, while genes stimulating differentiation are up-
regulated [20]. Combinations of lineage-determiningtranscription factors drive 
the development of specific mature lineages from multipotent precursors.This is 
a tightly regulated balance of cell-type-specific transcription factors, creating a 
gene expression profile which promotes differentiation towards a certain lineage, 
while hindering the development of other lineages [21]. Disturbance of gene tran-
scription regulation, either at the (growth factor) receptor level, the subsequent 
intracellular transduction level or the transcription regulation level, can lead to 
malignant transformation [16, 20, 21].
Malignant hematopoiesis
Hematopoiesis is a tightly regulated process. There is a constant renewal of hema-
topoietic cells and therefore an enormous production of blood cells is required. 
Abnormalities in the normal production and development of blood cells can lead 
to hematological diseases.
Acute myeloid leukemia
Acute myeloid leukemia (AML) is characterized by an uncontrolled proliferation 
and a block in differentiation in the hematopoietic stem or progenitor cells. This 
results in an excess of immature cells (blasts) in the bone marrow and often also 
in peripheral blood, causing a lack of functional mature blood cells (cytopenias). 
This can lead to anemia causing fatigue, thrombocytopenia causing bleedings, and 
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leukocytopenia resulting in infections. Patients are diagnosed with AML when 
20% or more myeloid derived blasts are found in their bone marrow. In addition, 
when patients carry a specific RUNX1-RUNX1T1 t(8;21)(q22;q22), CBFB-
MYH11 inv(16)(p13.1q22)/t(16;16;)(p13.1;q22) or PML-RARA t(15;17)
(q22;q12) translocation, they are also classified as AML regardless of their blast 
counts [22, 23].
AML represents 1,2% of all cancer cases. It is more frequently found in older 
people (75% of patients are older than 60 years), with a median age at diagnosis 
of 67 years [24]. Younger (<60 years) patients with AML have a 5-year overall 
survival (OS) in the range of 40-50%, while older patients do much worse with a 
5-year OS of 10-20% [23].
Classification of  AML
AML a very heterogeneous disease, which can be subdivided in multiple sub-
groups based on differences in morphology and underlying genetic aberrations. 
Clinical history, morphology, immunophenotyping, cytogenetics and molecular 
abnormalities are important for diagnostic classification of AML [22, 25, 26]. 
Historically different classification systems for AML have been used. The French-
American-British (FAB) system subdivided AML into 8 different subtypes based 
on cell type from which the leukemia developed and the degree of maturation, as 
determined bymorphologic, cytochemical and immophenotypic features (Table 
1) [27]. The World health organization (WHO) ‘Classification of Tumours of 
Hematopoietic and lymphoid tissues’ also incorporates genetic information, to-
gether with morphologic, cytochemical, immunophenotypic and clinical features 
[22, 26]. A revision of the WHO classification has recently been published (Table 
2) [26]. In this classification, inv(3)(q21q26.2) or t(3;3)(q21;q26.2) is named 
as a separate group. This inversion/translocation does not represent a fusion 
gene, but repositions a distal GATA2 enhancer to activate MECOM expression 
and simultaneously confers GATA2 haploinsufficiency. In addition, AML with 
NPM1 mutation bi-allelic CEBPA mutations , RUNX1 mutations or BCR-ABL1 
gene fusions are now considered as separate entities. The former subgroup of 
acute erythroid leukemia, erythroid/myeloid type (≥50% bone marrow erythroid 
precursors and ≥20% myeloblasts among non-erythroid cells) was removed and 
myeloblasts should be counted as percentage of total marrow cells.
Cases with ≥50% erythroid cells and ≥20% total myeloblasts usually meet the 
criteria for AML with myelodysplasia-related changes and should be diagnosed 
as such; cases with ≥20% myeloblasts not meeting criteria for AML with myelo-
dysplasia-related changes or AML with recurrent geneticabnormalities should be 
categorized as one of the other subtypes of AML not other specified (NOS). Pure 
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1erythroid leukemia remains to be classified as AML, NOS subtype and is now the 
only type of acute erythroid leukemia. [28].The European LeukemiaNet (ELN) 
guidelines include a prognostic classification system based on cytogenetic and 
molecular data. [29](Table 3). There is a distinction between a system for clas-
sifying patients with AML for diagnostic purposes, which is stable and durable, 
based on fixed biologic features of the disease and a system for predicting outcome 
of AML, which should be flexible, adaptable and evolving to reflect advances in 
treatment [30, 31].
Table 1. French-American-British (FAB) system [27]
FAB subtype Description
M0 Undifferentiated
M1 Myeloblastic without maturation
M2 Myeloblastic with maturation
M3 Promyelocytic
M4 Myelomonocytic
M4eo Myelomonocytic with bone marrow eosinophila
M5 Monocytic
M6 Erythroleukemia
M7 Megakaryoblastic
Genetic aberrations in AML
Cytogenetic and molecular abnormalities are of increasing importance to char-
acterize AML. Genetically defined AML subclasses may have a specific prognosis 
and might need a specific treatment. A classic example is acute promyelocytic 
leukemia (APL), harboring a t(15;17), leading to a promyelocytic leukaemia/
retinoic acid receptor alpha (PML-RARA) fusion gene. This specific disease can 
be treated with all-trans retinoic acid (ATRA) combined with chemotherapy or 
arsenic trioxide (ATO) [32-35], where PML-RARA is a predictive marker for the 
response on therapy. This targeted form of therapy has changed the outcome of 
thisdisease, which was poorly responding to standard AML therapies, to a well 
treatable disease with a favorable prognosis [33, 35]. Cytogenetics at the time of 
diagnosis is an important prognostic factor in AML [36-39]. A wide range of re-
current cytogenetic aberrations are currently known, of which the most frequently 
occurring ones are recognized in the ELN classification [29]. Nevertheless, 40-
50% of AML patients have a normal karyotype (NK) [23, 29, 36-38]. Molecular 
abnormalities are of major importance for further classification [23, 29, 40, 41]. 
The ELN classification used to include three molecular aberrations in their risk 
stratification, namely Fms Like Tyrosine Kinase 3internal tandem duplications 
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Table 2. WHO classification AML of myeloid neoplasms 2016 [26]
Type Subcategories
Acute myeloid leukemia with 
recurrent genetic abnormalities
AML with t(8;21)(q22;q22.1); RUNX1-RUNX1T1
AML with inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-
MYH11
APL with t(15;17)(q22;q12); PML-RARA
AML with t(9;11)(p22;q23); MLLT3-KMT2Ab
AML with t(6;9)(p23;q34); DEK-NUP214
AML with inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); 
GATA2-MECOM(EVI1)
AML (megakaryoblastic) with t(1;22)(p13.3;q13.3); RBM15-
MKL1
Provisional entity: AML with BCR-ABL1
AML with mutated NPM1
AML with biallelic mutated CEBPA
Provisional entity: AML with mutated RUNX1
Acute myeloid leukemia with 
myelodysplasia-related changes
Therapy-related myeloid neoplasms
Acute myeloid leukemia, not 
otherwise specified (NOS)
AML with minimal differentiation
AML without maturation
AML with maturation
Acute myelomonocytic leukemia
Acute monoblastic/monocytic leukemia
Pure erythroid leukemia
Acute megakaryoblastic leukemia
Acute basophilic leukemia
Acute panmyelosis with myelofibrosis
Myeloid sarcoma
Myeloid proliferations related to 
Down syndrome
Transient abnormal myelopoiesis
Myeloid leukemia associated with Down syndrome
Blastic plasmacytoid dendritic cell 
neoplasm
Acute leukemias of ambiguous 
lineage
Acute undifferentiated leukemia
Mixed phenotype acute leukemia with t(9;22)(q34.1;q11.2); 
BCR-ABL1
Mixed phenotype acute leukemia with t(v;11q23.3); KMT2A 
rearranged
Mixed phenotype acute leukemia, B/myeloid, NOS
Mixed phenotype acute leukemia, T/myeloid, NOS
Provisional entity: Natural killer (NK) cell lymphoblastic 
leukemia/lymphoma
15
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1(FLT3-ITD), mutations in nucleophosmin 1 (NPM1) and mutations in CCAAT-
enhancer binding protein alpha (CEBPA), but recently the FLT3-ITD allelic ratio 
was also added, as well as mutations in ASXL1, RUNX1 and TP53. (Table 3) [41].
With the recent developments of next-generation sequencing (NGS), AML 
appears to be a complex and dynamic disease, which changes over time, with mul-
tiple competing clones co-existing at any time [30, 31]. Relatively few genes are 
mutated at a high frequency, however a high number of genes are mutated at a low 
frequency (Figure 2) [30, 42]. NGS gave insight in the spectrum and frequency 
of mutations, their distinct patterns of cooperation and mutual exclusivity. NGS 
also gave insight in the order in which mutations occur during the development of 
the disease. For example, it, has been suggested that mutations in genes involved 
in epigenetic regulation (like DNMT3A, ASXL1, IDH2, and TET2) occur early 
in the evolution of AML [28, 30].
Accurate prognostification of patients is, together with the patients preferences 
and fitness, the most important parameter for treatment decisions. The more is 
Table 3. Stratification of molecular genetics and cytogenetics alterations, according to 
2017 ELN recommendations [29]
Risk profile Subsets
Favorable t(8;21)(q22;q22); RUNX1-RUNX1T1
inv(16)(p13.1q22) or t(16;16)(p13.1;q22); CBFB-MYH11
Mutated NPM1 without FLT3-ITD or with FLT3-ITDlow (<0.5)
Biallelic mutated CEBPA
Intermediate Mutated NPM1 and FLT3-ITDhigh (≥0.5)
Wild type NPM1 without FLT3-ITD or with FLT3-ITDlow(<0.5) (w/o 
adverserisk genetic lesions)
t(9;11)(p21.3;q23.3); MLLT3-KMT2A
Cytogenetic abnormalities not classified as favorable or adverse
Adverse t(6;9)(p23;q34.1); DEK-NUP214
t(v;11q23.3); KMT2A rearranged
t(9;22)(q34.1;q11.2); BCR-ABL1
inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2,MECOM(EVI1)
-5 or del(5q); -7; -17/abn(17p)
Complex karyotype monosomal karyotype
Wild type NPM1 and FLT3-ITDhigh(≥0.5)
Mutated RUNX1
Mutated ASXL1
Mutated TP53
Chapter 1
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known about the genetic aberrations and driver mutations which are causal of the 
disease, the more targeted therapies can be developed and the more personalized 
patients can be treated.
FLT3-ITD
FLT3 is a member of the class III receptor tyrosine kinase family. This family 
plays a central role in hematopoiesis, of which the KIT receptor (binding SCF) 
is another well known family member. FLT3 ligand (FLT3L) is secreted by cells 
in the hematopoietic bone marrow microenvironment, including stromal cells. 
This ligand is a growth factor for HSC and immature myeloid cells and induces 
expansion CD34+ cells in vivo and in vitro [43].
FLT3 expression is restricted to hematopoietic stem and early progenitor 
cells and plays a role in the development of multiple hematopoietic lineages, 
both myeloid and lymphoid [43-46]. In primary human leukemia cells, FLT3 
is expressed at high levels in 70-100% of the cases. Moreover, in AML, FLT3 
is aberrantly expressed, meaning it is no longer tightly associated with CD34 
expression [46-49]. Primary leukemic blasts and leukemia cell lines frequently 
respond to the addition of FLT3L in vitro, or co-express FLT3L themselves, 
all leading to the stimulation of proliferation and inhibition of apoptosis [46, 
50]. The FLT3-ITD mutations were first discovered through the use of a reverse 
transcriptase-polymerase chain reaction (RT-PCR). Unexpectedly, when primers 
flanking the juxtamembrane (JM) portion of the FLT3 coding sequence were used 
to amplify copy-DNA (cDNA), a longer amplification product was observed in 
5 out of 22 AML samples. DNA sequencing revealed these samples to harbor 
(in-frame) internal tandem duplications of nucleotide sequences within exon 
Figure 2. Mutations found in AML (adjusted from [149])
17
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114 [51]. Figure 3 shows a FLT3 PCR assay used in diagnostics. FLT3-ITDs can 
range in size from 3 to more than 400 basepairs (bp). A correlation between size 
and prognosis has been demonstrated in some studies but not in others [52-55]. 
The FLT3-ITD alteration induces constitutive activation (by phosphorylation) 
of the intracellular kinase domain, by disrupting the auto-inhibitory interaction 
between the JM domain and the activation loop that normally stabilizes the ki-
nase in its inactive conformation by protecting the ATP binding pocket [43, 56]. 
Figure 3. Example of FLT3, internal tandem duplications (ITD) assay, made visible using 
fluorescent PCR primers and separating amplicons on size with 3710 Genescan. FLT3 wild type gives 
an amplicon of 328 bp and FLT3-ITD of 331 bp or larger.
Chapter 1
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Also activating loop mutations have been described, of which a change in FLT3 
aspartate 835 is the most common [43, 46]. The constitutive activation of FLT3 
is suggested to play an important role in leukemogenesis [43, 46, 57]. About 20% 
of all AML patients harbor a FLT3-ITD mutation, which increases in NK-AML 
(28-34%) [43-46, 58, 59]. Clinically, FLT3-ITD mutations are associated with 
elevated mean white blood cell (WBC) counts at diagnosis and an inferior survival 
compared to patients with wild type (WT) FLT3. Several studies have suggested 
that the level of the mutant allele relative to the wild-type allele has prognostic im-
plications. A high mutant-to-wt allelic ratio (AR) has been associated with a poor 
clinical outcome, however the exact cut-off point dividing high and low AR varies 
among different studies. Most studies, suggest that poor clinical outcome is due to 
loss of heterozygosity (AR > 0.5) (figure 4) [52, 53, 60-64]. FLT3-ITD mutations 
and the AR are incorporated in the ELN risk classification [29] (Table 3).
© Thessa Koorenhof-Scheele
Figure 4. Proposed oncogenic mechanism of action of FLT3-ITD.
A. Normal FL3 signaling occurs after binding of the FLT3 ligand. B. FLT3 mutant monomers lead to 
constitutive signaling in the absence of ligand bining, however also normal FLT3 signaling is present. 
C. FLT3 mutant dimers lead to constitutive signaling, no normal signaling is present.
NPM1
NPM1 is a nuclear-cytoplasmic shuttling phosphoprotein, which plays a role in 
ribosome biogenesis, centrosome duplication during mitosis, cell proliferation 
and the regulation of the p14ARF alternate-reading-frame protein (ARF)–p53 
tumor-suppressor pathway [39, 53, 65]. In 2005, it was discovered that mutations 
in the C-terminus of this gene resulted in an abnormal cytoplasmic localization of 
19
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1the protein [65]. Therefore, the WHO synonym for AML with mutated NPM1 
used to be NPMc+ (c+ indicates “cytoplasmic positive”)[22].
NPM1 mutations have been suggested to be an early initiating event in AML. 
Since usually all leukemic cells carry the NPM1 mutation, it generally precedes 
other associated mutations and it is usually present during relapse. Therefore 
NPM1 mutations are often used is a tool to evaluate minimal residual disease 
(MRD) [66, 67]. NPM1 mutations define a subgroup of AML with a distinct 
gene expression profile. How the NPM1 mutations contribute to leukemogenesis 
remains is not completely elucidated. The fact that NPM1 mutations always 
results in aberrant cytoplasmic localization of the protein, suggests that this delo-
calization plays a critical role [66, 68]. In Npm1+/- mice, the loss of Npm1 led to 
genomic instability, leading to enhanced in vitro and in vivo cancer susceptibility. 
These mice frequently developed hematological malignancies, mainly myeloid, 
but also lymphoid [69].
Mutations in NPM1 are found in approximately 30% of all AML patients and 
in about half of the NK AML patients [39, 53, 58, 59]. They often co-occur with 
FLT3 abnormalities (40% of the NPM1 mutated AMLs [65]), but are also found 
with IDH1/2, DNMT3A, TET2, RUNX1 and N/K-Ras mutations [70]. Muta-
tions in NPM1 are associated with a favorable prognosis, provided that the patient 
does not have a FLT3-ITD mutation [34, 38, 39, 52, 53, 55, 58, 59, 61-65].
In chapter 5 of this thesis, we investigated the best post remission treatment 
(PRT) in NK AML patients based on NPM1 mutations and FLT3-ITD allelic 
ratio.
Treatment options in AML
The importance of biologic heterogeneity is well established, but in AML, the 
translation into improved therapy is just beginning [28]. Up to date most patients 
are still treated with standard regimes, that have not changed substantially in 
decades. Outside the setting of a clinical trial, patients considered fit with newly 
diagnosed AML are offered the combination of 7 days cytarabine with 3 gifts of 
an anthracycline (daunorubicin or idarubicin), the so-called 7 + 3 regimen [28, 
29, 71, 72]. After remission, this is consolidated with a second course of intensive 
chemotherapy (depending on the study group either called second induction or 
consolidation treatment), generally also consisting of 7 days cytarabine with 3 
gifts of an anthracyline. As post remission treatment (PRT), favorable-risk pa-
tients are offered additional chemotherapy, generally containing intermediate/
high-dose cytarabine or mitoxantrone / etoposide (HOVON) or autogous (auto) 
hematopoietic cell transplantation (HCT). As PRT, intermediate or adverse-risk 
disease patients are offered allogeneic (allo) hematological cell transplantation 
Chapter 1
20
(HCT) [28, 72-75]. For patients who are not eligible for intensive treatment, 
many treatment options have been shown in prospective randomized trials to be 
superior to best supported care (BSC): e.g. low-dose cytarabine (LDAC) [76], 
Gemtuzumab Ozogamicin [77] or hypomethylating agents (HMA, like decitabine 
and 5-azacitidine) [28, 29, 75, 78-80]. Of course, optimal supportive care with 
transfusions and appropriate antibiotics is standardly included in all treatment 
options. An important task for the clinician is to determine who is fit for intensive 
treatment (and who is not) and to discuss the various treatment options with the 
patient, in the perspective of his/her general health, the risk factors of the disease 
and the wishes of the patient.
Allogeneic SCT
For fit intermediate and poor risk AML patients, PRT with an allo HCT with 
a HLA-matched sibling or a matched unrelated donor (MUD) is a potentialy 
curative option, with a better verall survival (OS) rate compared to chemotherapy 
[81-84] . Allo HCT consist of a conditioning regimen followed by stem cell 
transplantation. The conditioning regimen should at least allow engraftment of 
the transplant and, depending on the intensity, can also have direct anti-leukemic 
effects. This therapy provides the strongest anti-leukemic effect in AML, because 
of the (intensive) conditioning and especially also the graft-versus-leukmia (GVL) 
effect [28, 75, 85]. Less intensive conditioning strategies have been developed 
the last decade, which highly rely on the GVL effect. Next to the conventional 
myeloablative conditioning (MAC), also reduced-intensity conditioning (RIC) 
and nonmyeloablative (NMA) conditioning have been established. Assignment 
to these categories is based on the duration of cytopenia and on the require-
ment for stem cell (SC) support. MAC regimens cause irreversible cytopenia and 
SC support is mandatory. NMA regimens cause minimal cytopenia and can be 
given also without SC support. RIC regimens do not fit criteria for MA or NMA 
regimens, they cause cytopenia of variable duration and should be given with 
SC support, although cytopenia may not be irreversible [86]. NMA and RIC 
are taken together in various studies and their differences in survival has not yet 
been established. Overall, MAC has a stronger anti-leukemic effect, but also a 
higher non-relapse mortality (NRM) than RIC/NMA and therefore generally a 
comparable OS as with RIC/NMA is achieved [85]. Insight in the characteristics 
of the disease and the patient are therefore extremely important to decide upon 
the best conditioning strategies prior to transplantation.
21
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When no eligible donor can be found for alloHCT, autologous (auto) HCT can 
be considered. Because of the lack of a GVL effect, autoHCT is considered as a 
less potent anti-leukemia treatment, however, it has a lower NRM than alloHCT 
(especially after MAC). Generally, patients receiving an autoHCT seem to perform 
similar to those receiving alloHCT in good risk AML, however in intermediate 
and poor risk AML patients, allo HCT is generally considered to be a better PRT 
than auto HCT or chemotherapy [73, 74, 87, 88].
New therapies
New therapies that are currently tested in clinical trials can be categorized into 4 
groups, based on their mechanism of action: cytotoxic agents, epigenetic drugs, 
small-molecule inhibitors and monoclonal antibodies.
Cytotoxic agents
Vosaroxin is a quinolone derivative that intercalates into DNA and inhibits DNA 
topoisomerase II (as do anthracyclines) and induces double-stranded (ds) DNA 
breaks. In contrast to anthracyclines, vosaroxin is not associated with the for-
mation of free radicals, reactive oxygen species or toxic metabolites, potentially 
reducing its cardiotoxicity. Furthermore vosaroxin can induce p53-independent 
apoptosis. In preclinical and clinical trials in relapsed and refractory (R/R) AML, 
vosaroxin has shown to be efficient as a single agent and in combination with 
cytarabine [28, 72, 89, 90].
CPX-351 is a nano-scale liposome which contains a fixed molar ratio of ara-C 
and daunorubicin of 5:1. This therapy is based on the conventional 7+3 regimen, 
but aims to reduce extramedullary toxicity and increase exposure of leukemic 
cells to these agents. In phase II studies, CPX-351 suggested a clinical benefit, 
especially in elderly and poor risk AML, because of a lower 60-day mortality and 
improved response rate [28, 72, 91, 92]. Moreover, in patients with poor risk 
AML, patients receiving CPX-351 performed better than patients who received 
the conventional 3+7 regimen [29, 93].
Epigenetic drugs
Over the years, in older AML patients who are unfit for intensive therapy, 
hypomethylating agens (HMA) have shown improved outcomes compared to 
conventional therapies [79, 80, 94]. Moreover, prolonging the treatment with 
decitabine from 5 to 10 days have led to enhanced survival [95, 96]. SGI-110 
or guadecitabine is a second generation HMA. It is a dinucleotide of decitabine 
and deoxyguanosine linked by a phosphodiester bond that increases the in vivo 
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exposure of decitabine by protecting it from degradation by cytidine deaminase 
[28, 72]. This agent has been proven clinically active in a phase II study [97] and 
phase III studies are under way [28, 72]. Moreover, inhibitors of DOT-1L, a selec-
tive methyltransferase capable of catalyzing methylation of H3K79, have shown 
promising results in mice with MLL-rearranged AML [98, 99] and DNMT3A 
mutated AML [100] and are now under clinical investigation. Panobinostat is 
a pan-histone deacetylase (HDAC) inhibitor, which keeps chromatin in an ac-
tive state, which has transcriptional and non-transcriptional effects, leading to 
inactivation of intracellular signaling (STAT5) and transcriptional mechanisms 
such as the NFkB pathway, and proteins involved in cell motility, apoptosis, and 
cell proliferation [101].
Panobinostat as part of induction and maintenance therapy showed activity in 
elderly patients with newly diagnosed AML in a phase Ib/II study [102] and 
is now tested in combinational therapies (e.g. with HMA and LSD1 inibitors 
[101]). In addition, LSD1 (KDM1A) is a histone demethylase, which demethyl-
ates di- and mono-methylated K4H3, reducing the permissive H3K4Me3 and 
thus reducing gene activity [103]. LSD1 has been found upregulated in multiple 
cancers [104]. It is a key effector of the differentiation block in MLL rearranged 
leukemia [105], and inhibition of LSD1 down-regulated expression of several 
leukemia-relevant genes, induced apoptosis and differentiation, and inhibited 
self-renewal of leukemic stem cells, due to increased H3K4 methylation [106]. 
In non-MLL rearranged and non-APL AMLs, inhibition of LSD1 reactivates the 
all-trans retinoic acid receptor pathway and induces differentiation [107]. LSD1 
inhibitor GSK2879552 showed promising in vitro results in various AML cell 
lines and is now tested in clinical trials [108, 109].
Small-molecule inhibitors
Volasertib is a small-molecule selective inhibitor of polo-like kinases. This family 
of highly conserved serine/threonine protein kinases plays a role in cell division, 
including centrosome maturation, spindle formation and cytokinesis during 
mitosis. Plk1 is aberrantly highly expressed in leukemia cells. Volasertib binds 
specifically to the adenosine triphospate binding pockets of Plk1 as well as Plk2 
and -3 and inhibits their enzymatic activities. In a randomized phase II study 
of patients not eligible for intensive induction therapy, LDAC with or without 
volasertib showed a higher response rate for the combination arm with no differ-
ences in 60-day mortality [72, 110]. Isocitrate dehydrogenase (IDH) has been found 
mutated in 20% of patients with NK AML, leading to an aberrant production 
of the onco-metabolite 2-hydroxyglutarate (2-HG) which deregulates enzymes 
involved in epigenetic functions. Inhibitors of IDH2 and IDH1, AG-221 and 
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terminal differentiation in leukemic blasts in AML with IDH mutations [28, 72, 
111, 112]. These results, in defined subsets of patients, are a step in the direction 
of individualizing AML treatment [72].
Instead of targeting IDH mutant proteins directly, also mutation-specific de-
pendencies can be targeted. IDH1 and IDH2 mutated cells are highly dependent 
on anti-apoptotic protein BCL2 expression for survival, and are therefore more 
sensitive to the BCL2 inhibitor ABT-199 (venetoclax)[28]. In general, AML 
blasts are dependent on BCL2 for survival, while normal hematopoietic cells are 
dependent on anti-apoptotic protein MCL-1. In a phase II trial, ABT-199 showed 
clinical activity in patients with poor prognosisR/R AML, where patients with 
IDH mutations were particularly sensitive [113].
Sorafenib is a multikinase inhibitor that that blocks various pathways potentially 
involved in the development and progression of acute myeloid leukaemia, such 
as RAS/RAF, c-KIT, VEGF receptor, PDGF receptor, and FLT3. In younger pa-
tients, the addition of sorafenib to standard chemotherapy seemed to enhance the 
antileukaemic effect (improved EFS and RFS), but also increased toxicity, leading 
to no difference in OS [114]. In older patients, addition of sorafenib resulted in 
lower response rates and higher earlier deaths, thus was not beneficial for older 
patients with AML [115]. Midostaurin is another multikinase inhibitor with 
inhibitory activity against FLT3-ITD and FLT3-TKD [72]. A placebo-controlled 
phase III study combining the standard 7+3 regime with or without midostaurin 
in patients with newly diagnosed FLT3-mutated AML demonstrated a significant 
improvement in EFS and OS, without any additional toxicity, for the midostaurin 
arm [116]. Less intensive treatment combinations with midostaurin are recently 
being studied [72].
Quizartinib is a small-molecule tyrosine kinase inhibitor (TKI), specifically 
designed as FLT3 inhibitor. R/R AML patients treated with quizartinib as mono-
therapy showed a short lasting complete remission in around 50% of FLT3-ITD 
positive patients and 30% of FLT3-ITD negative patients [72]. Overall, FLT3-
ITD inhibitors seem to achieve clinical responses, however toxicity still seems 
a problem. Furthermore, often these clinical responses were lost over time. In 
some relapsed patients, the mutated clone was no longer detectable, suggesting 
that a co-existing clone without FLT3-ITD causes the relapse. Also secondary 
TKD mutations (like D835) have been suggested as a mechanism of resistance, 
which occurs in approximately 20% of patients with FLT3-ITD AML treated 
with a FLT3 inhibitor, which has no activity against TKD mutations [72, 117]. 
Newer FLT3 inhibitors, targeting both FLT3-ITD and FLT3-D835 mutations, 
like crenolanib are currently being studied [72].
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Monoclonal antibodies
Monoclonal antibodies have significantly improved outcome in lymphoid he-
matological malignancies [118]. In AML, CD33 is expressed on the surface of 
myeloblasts in 85 to 90% of patients regardless of age, risk factors, or underlying 
mutational heterogeneity. In 2000 an anti-CD33 linked to calicheamicin as the 
toxic moiety, called Gemtuzumab ozogamicin (GO), came on the market after 
an accelerated approval by the Food and Drug Administration (FDA) for the 
therapy of relapsed AML in older patients unsuitable for other intensive therapies. 
In 2010, GO was withdrawn, since a randomized controlled trial indicated lack 
of benefit and also suggested increased mortality with GO. A confounding role 
for the unexpectedly low mortality in the control group of the study, as well 
as anthracycline dosage differences between the cohorts continues to be a sub-
ject of debate [119]. In recent studies, GO in combination with chemotherapy 
demonstrated improved RFS and OS in a selected subgoup of patients, without 
increased toxicity, suggesting CD33 as a promising target in AML [72, 119, 
120]. Therefore, the anti-CD33 treatment is currently further explored. SGN-
33A is a humanized anti-CD33 monoclonal antibody conjugated to a potent 
DNA-crosslinking toxin, a pyrrolobenzobiazepine dimer [120]. Preliminary data 
from a phase I trial showed a clearance of marrow blasts in 47% with accept-
able tolerability [121]. Another CD33 targeting agent is AMG-330. This is a 
CD33/CD3 bispecific T-cell engaging antibody, using CD3+ T-effector cells to 
target the CD33+ blasts and trigger immune cytotoxicity. In pre-clinical studies, 
AMLG-330 has shown significant anti-leukemic activity [122] and clinical trials 
are under way [72]. Another monoclonal target is the interleukin-3 receptor alpha 
chain, CD123. CD123 has been identified to be significantly over-expressed in 
a large proportion (40–93%) of patients with AML and has been suggested to 
be particularly expressed on leukemic stem cells. A CD123-CPT conjugate was 
designed coupling an anti-CD123 antibody with a chemotherapeutic agent, 
Camptothecin (CPT), via a disulfide linker. The linker is biodegradable in the 
presence of Glutathione (GSH, an endogenous component in cells), which leads 
to release of CPT. So far, anti-CD123 antibody conjugates showed significant 
higher cellular uptake in CD123-overexpressing tumor cells, with inhibitory ef-
fects on CD123-overexpressing tumor cells [123] and might be a novel target for 
AML treatment.
Overall, many new therapies are currently tested in clinical trials. Maximal 
specificity of a new drug and accordingly minimal toxicity is of great importance 
for the drug to be successful. Especially taken into account that the largest group 
of AML patients is older and still have dismal outcomes. A risk of targeted 
therapies, however, is that by specifically targeting one clone, another co-existing 
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and its molecular parameters remains very important. Further developments in 
molecular insights of the disease are indispensable for the ongoing developments 
and implementation of new drugs.
Basic helix-loop-helix proteins
Basic helix-loop-helix (bHLH) proteins and its inhibitors, inhibitor of DNA 
binding (ID) proteins, have often been associated with human cancer [124-127] 
and with hematological malignancies specifically [128-130]. The bHLH family 
contains more than 240 transcriptional regulatory proteins, which are key players 
in a wide array of developmental processes, including neurogenesis, myogenesis 
and hematopoiesis [131]. Developmental processes can be positively and nega-
tively regulated by bHLH proteins and their inhibitors. Class II bHLH proteins 
show a tissue-restricted pattern of expression and are involved in development 
of distinct cell types. For instance, human achaete-scute homolog-1 (HASH-1) 
[132], neurogenin [133], and NeuroD7 [134] are all involved in neurogenic 
development, whereas MyoD [135] and myogenin [136] are required for normal 
muscle differentiation [131]. In hematopoiesis, the class II bHLH protein SCL/
TAL1 is essential in the development of HSCs towards all hematopoietic cell lin-
eages. Disruption of the scl/tal1 gene in mice leads to a complete absence of blood 
[131, 137]. To perform their function, class II bHLH proteins form heterodimers 
with members of class I bHLH proteins. These omnipresent partners are called 
E-proteins and include E12 and E47, which arise through alternative splicing of 
the E2A gene (TCF3), E2-2 (TCF4) and HEB(TCF12) [129, 131]. E-proteins 
recognize the Ephrussi-box (E-box) DNA sequences (CANNTG), which are 
present in a variety of tissue specific enhancers and promoters [129, 131, 138]. 
They can either activate or repress genes, since they have two highly conserved 
regions referred to as activation domains AD1 and AD2, that function to recruit 
co-activators, like histone acetyltransferases CBP and p300, or co-repressor com-
plexes, like histone deacetylase ETO [139]. E-proteins can, in contrast to class II 
bHLH proteins also form homodimers [131].
The inhibitor of DNA binding (ID) proteins constitute another HLH subfamily, 
which contains four members (ID1-4) that act as dominant-negative regulators of 
bHLH proteins. Because ID proteins contain the HLH domain, they can bind to 
other members of the bHLH family, but since they lack the basic DNA binding 
domain, the heterodimers they form are unable to bind DNA. Consequently, ID 
proteins prevent the bHLH protein complex from regulating downstream targets 
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[99, 129, 140, 141]. Interestingly, the binding affinity of ID proteins is higher for 
ubiquitously expressed E-proteins than for tissue-specific class II bHLH proteins, 
thus they can control the transcriptional repertoire of a wide variety of cell types 
using the same biochemical mechanism (Figure 5)[141, 142].
Transcription factor 4
Transcription factor 4 (TCF4, also E2-2, ITF2, SEF2) is an E-protein and thus 
member of the bHLH class I family. It has been suggested as a downstream target 
of the Wnt/β-catenin signalling pathway [143]. Human TCF4 is found at chro-
mosome 18q21.1 and this gene encodes at least 18 different proteins with distinc-
tive N-terminal sequences [144]. Two TCF4 isoforms, TCF4-A and TCF4-B have 
been mostly studied (figure 6). TCF4-B is the full length protein, containing both 
AD1 and AD2 activation domains and a nuclear localization signal (NLS), which 
restricts this isoform to the cell nucleus. TCF4-A lacks the AD1 domain and NLS 
and localizes in the nucleus as well as the cytoplasm. It is proposed that TCF4-A 
traffics to the nucleus by a piggy-back mechanism, when heterodimerizing with 
another, NLS containing, bHLH factor. Additionally, TCF4-A can be exported 
from the nucleus by heterodimerization with nuclear export signal (NES) contain-
ing HLH proteins, like ID2 [144, 145].TCF4-A is still able to activate reporter 
gene transcription, but to a far lesser extent than TCF4-B, since both activation 
domains (AD1 and AD2) act synergistically [144].
© Thessa Koorenhof-Scheele
Figure 5. Function regulation of bHLH factors by ID proteins.
A. Class I and class II basic helix-loop-helix (bHLH) proteins form a dimer and consequently bind to 
the DNA to regulate transcription. B. ID proteins bind to the class I bHLH protein, making this pro-
tein unavailable for binding with class II bHLH proteins. ID does not contain a DNA binding domain 
and prevents binding of the bHLH dimers to DNA and, consequently, regulation of transcription by 
bHLH transcription factors.
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TCF4 is implicated in B- and T-cell development [139, 146] and crucial for 
plasmacytoid DC (pDCs) development [147, 148]. Deletion of murine tcf4 
completely blocked the development of pDCs, since TCF4 directly activates pDC 
enriched genes (SpiB, Irf8, Irf7) [147, 148]. TCF4 has been found mutated in a 
low frequency in AML and myeloid dysplastic syndromes (MDS) patients [42, 
149] and therefore is an example of a gene included in the long tail of infrequently 
mutated genes in AML (partly shown in figure 4). TCF4 has been described both 
as oncogene and tumorsuppressor gene [128, 143, 150-154]. In adenoma, TCF4 
is highly expressed, but strongly down regulated in the majority of colorectal car-
cinomas, suggesting a tumorsuppressive role in the adenoma-carcinoma transition 
[152]. Also, TCF4 levels are correlated with favorable prognosis in patients with 
colorectal carcinomas [150]. Furthermore, inactivation of Tcf4 in a colorectal 
carcinogen mice model (Apcmin/+) promotes intestinal tumorigenesis [151]. In 
contrast, in other studies knockdown of TCF4 in colon cancer cell lines decreases 
proliferation [154] and TCF4 was found to promote neoplastic transformation 
in human cancer with β-catenin defects [143]. Furthermore, in AML models 
with translocations of the Mixed Lineage Leukemia gene (MLL) and its common 
partner AF9 (MLL-AF9), TCF4 has been described to be strongly up-regulated 
[20, 128, 155]. Moreover, over-expressing its inhibitor ID2 or knocking down 
TCF4 itself in MLL-AF9 AML cells leads to inhibited cell growth and prolonged 
survival in mice [128], indicating that TCF4 supports the oncogenic acitvity of 
MLL-AF9 [128].
In chapter 2 of this thesis we show that a high mRNA expression level of TCF4 
is an independent poor prognostic factor in AML and that the TCF4 expression 
levels can give insight in the favorable treatment of the patients. In chapter 3 we 
identify that RUNX1 can regulate the TCF4promoter and TCF4 expression. In 
chapter 4 we will discuss the impact of enforced TCF4 expression on healthy 
hematopoiesis.
Figure 6. TCF4 gene and its most common isoforms.
TAD = transactivation domain, NLS =nuclear localization signal, b=basic, HLH= helix-loop-helix.
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Mutations in Transcription factor 4 (TCF4) have recently been described in 
myeloid dysplastic syndromes (MDS) and acute myeloid leukemia (AML). 
We analyzed the impact of TCF4 mRNA expression on clinical outcome in 
AML patients (n=525). Patients with high TCF4 expression (TCF4high, de-
fined as the 25% highest TCF4 expressors) had a significantly worse overall 
survival (OS) and event free survival (EFS) than patients with lower TCF4 
expression (TCF4low)(5-year OS 18% vs 44% p<0.0001; 5-year EFS 15% vs 
34%, p<0.0001, respectively). This was confirmed in an independent cohort 
(n=436). Multivariate analysis showed that TCF4high is an independent prog-
nostic factor for OS and EFS in the whole cohort and in patients carrying a 
normal karyotype.
Importantly, TCF4high patients benefited most from an allogeneic hema-
topoietic cell transplantation (HCT), compared to an autologous HCT or 
additional chemotherapy (CT) (5-year OS 39%, 8%; 10%, p<0.0001; 5-year 
EFS 31%, 0%, 10%, p=0.001, respectively), while TCF4low patients seemed 
to benefit most from an autologous HCT, compared to allogenic HCT or 
additional CT (5-year OS: 61%, 45%, 39% p=0.002; 5-year EFS: 42%, 32%, 
34%, p=0.102, respectively).
In summary, we demonstrate that high expression of TCF4 is an indepen-
dent adverse prognostic factor in AML that could guide treatment decisions.
TCF4 plays a role in a variety of developmental processes, including hematopoi-
esis. TCF4 is part of the basic helix-loop-helix (bHLH) class 1 family, also called 
E-proteins. These E-proteins recognize an E-box DNA binding site (CANNTG), 
which are present in a variety of tissue specific enhancers.1,2 Recently, Papaem-
manuil and colleagues reported mutations in TCF4 in MDS patients.3 A total 
of 9 mutations were found in 7 of the 738 (0.9%) sequenced MDS patients. 
The TCF4 mutations were found in various MDS subclasses. Mutations in TCF4 
have also been reported for AML cases (0.5%)4 and were associated with a poor 
prognosis5, suggesting a potential role of TCF4 in the pathogenesis of these my-
eloid malignancies. Here we report that TCF4 mRNA expression levels are an 
independent prognostic factor in AML patients.
TCF4 expression values measured using Affymetrix HGU133 plus 2.0 arrays 
were derived from a database which contains a cohort of 525 AML patients treated 
according HOVON protocols (AML -04, -04A, -29, -32, -42, -43; available at 
http://www.hovon.nl).6 Both bone marrow aspirates or peripheral-blood samples 
(at the time of diagnosis) have been analyzed. Blasts and mononuclear cells were 
purified by Ficoll–Hypaque (Nygaard) centrifugation and cryopreserved. The 
AML samples contained 80 to 100 percent blast cells after thawing, regardless 
of the blast count at diagnosis. To determine the TCF4 expression, the average 
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of 5 probe sets (which bind at different locations of the gene) were used. The 
microarray expression data were confirmed by qPCR (Supplementary figure 1). 
In addition, the TCF4 expression levels of healthy CD34+ control cells (hCD34+; 
n=11) and mononuclear cell fractions derived from normal bone marrow (NBM; 
n=5) were available. A second,independent cohort of 436 AML patients was used 
for validation.7 Patients were divided into genetic risk groups according to the 
European LeukemiaNet (ELN) guidlines.8
In the studied cohort of 525 AML patients, TCF4 is differentially expressed in 
AML blasts compared to NBM and hCD34+ (Figure 1A). To study the impact of 
TCF4 expression levels on survival, the cohort was divided based on differences 
in expression levels; expression below or above the median, tertiles, quartiles, 
quintiles, sixtiles and septiles. In all these cohorts univariate analysis showed that 
high expression of TCF4 was associated with pooroutcome. The highest expres-
sors of TCF4 showed a (more than) 2-fold shorter 5-year OS than the lowest 
expressors (Supplementary figure 2). Since we found that TCF4 expression is not 
normally distributed and because approximately 25% of the patients showed a 
much higher expression (Figure 1B), a distribution of the cohort based on the 
highest 25% (TCF4high) and the lowest 75% TCF4 expression (TCF4low) was 
used for further analysis. Characteristics of the patients in TCF4low and TCF4high 
groups are described in supplementary Table 1. TCF4high patients more often 
had high risk cytogenetic abnormalities (p<0.0001), FLT3-ITD (p<0.0001) and 
their morphology more frequently corresponded with M0 or M1 FAB-subgroups 
(p<0.0001). TCF4low patients, were more likely to have biallelic CEBPA mutations 
(p=0.011). No associations between TCF4 expression and age, sex, WBC count, 
or other cytogenetic or molecular abnormalities could be identified.
Survival analysis according to the Kaplan-Meier method showed that TCF4high 
patients had a worse survival than patients classified as TCF4low (5-year OS 18% 
vs 44%, p<0.0001; 5-year EFS 15% vs 34%, p<0.0001, respectively) (Figure 1C-
D). We confirmed the impact of TCF4 expression levels on survival in the second 
cohort of 436 AML patients7 (OS: p=0.001; EFS: p<0.0001) (Supplementary 
figure 3). In the multivariate Cox regression analysis, patients classified as TCF-
4high had a significantly higher risk of death (HR 1.7, CI 1.3–2.1, P<0.0001), 
relapse or not obtaining a CR than TCF4low patients (HR 1.6, CI 1.3–2.0, 
p<0.0001) (Table 1A). In addition, multivariate Cox regression analysis revealed 
TCF4 expression, as a continuous variable per 100 arbitrary units (AU), was a 
significant predictor of OS and EFS (HR 1.04, CI 1.01-1.07, p=0.024; HR 1.05, 
CI 1.02-1.08, p=0.002, respectively) (Supplementary table 2A). When selecting 
for AML patients with a normal karyotype, TCF4high patients again showed a 
worse OS and EFS than TCF4low patients (5-year OS 21% vs 41%, p<0.0001; 
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Figure 1. TCF4 expression and survival curves in the first cohort.
A. Expression of TCF4 in AML patients (n=525), NBM (n=5) and hCD34+ (n=11). B. TCF4 expres-
sion ranked from lowest to highest expression (n=525). C. OS curves for AML patients with available 
follow-up data (n=518) stratified by TCF4high (n=129) and TCF4low (n=389). D. idem for EFS. E. OS 
curves for TCF4high AML patients with available follow up and consolidation treatment data (n=129) 
stratified for conditioning with alloHSCT (n=36), autoHSCT (n=13) or additional CT (n=80). F. OS 
curves for TCF4low AML patients with available follow up and consolidation treatment data (n=386) 
stratified for conditioning with alloHSCT (n=99), autoHSCT (n=57) or additional CT (n=212).
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5-year EFS 18% vs 33%, p<0.0001, respectively) (Supplementary figure 4). In 
the multivariate Cox regression analysis of normal karyotype AML patients, TCF4 
expression is also an independent predictor of survival (OS: HR 1.7, CI 1.2-2.5, 
p=0.003; EFS: HR 1.7, CI 1.2–2.4, p=0.005) (Supplementary table 2B). Also as a 
continuous variable TCF4 expression remained an independent prognostic factor 
in this cohort (OS: HR 1.07 (per 100 AU), CI 1.02-1.13, p=0.004; EFS: HR 1.08 
(per 100 AU), CI 1.03-1.13, p=0.003) (Supplementary table 2C).
Interestingly, survival analysis according to the Kaplan-Meier method showed 
that TCF4high and TCF4low patients of the first cohort demonstrated a different 
survival benefit depending on consolidation treatment they received, i.e, an ad-
ditional cycle of chemotherapy (CT), autologous or allogeneic hematopoietic 
cell transplantation (autoHCT, alloHCT, respectively) (OS: Figure 1E-F; EFS: 
Supplementary figure 5). TCF4high patients who received alloHCT showed a 
superior survival compared to TCF4high patients who received autoHCT or who 
received additional CT (5-year OS 39%, 8%; 10%, p<0.0001; 5-year EFS 31%, 
0%, 10%, p=0.001, respectively). In contrast, patients classified as TCF4low showed 
a trend towards significant superior survival after autoHCT, compared to TCF4low 
patients who received alloHCT or additional CT (5-year OS: 61%, 45%, 39% 
p=0.002; 5-year EFS: 42%, 32%, 34%, p=0.102, respectively). Moreover, this 
difference in outcome, depending on type of consolidation treatment between the 
TCF4high and the TCF4low patients, was confirmed in multivariate Cox regression 
analysis (Supplementary table 3). In the second cohort only 7 patients in the 
TCF4high group received autoHCT, hampering validation of our observations in 
this subgroup. Nevertheless, also in this cohort consolidation treatment with al-
loHCT (n=44) resulted in significant better OS for TCF4high patients compared to 
TCF4high patients who received additional chemotherapy (n=58) (5-year OS 41% 
vs 8%, p<0.0001, respectively). Furthermore, in this cohort TCF4low patients who 
received autoHCT (n=52),showed a superior OS compared with those patients 
Table 1. Multivariate Cox Regression survival analysis.
Factors predicting OS and EFS in AML patients of the first cohort with available complete data of all 
cytogenetic and molecular parameters (n=506).
 
Variable ˮ2 (Wald) DF P HR (95% CI)  ˮ2 (Wald) DF P HR (95% CI)
Favorable ELN risk group,  (reference) 40.11 3 <0.0001 36.75 3 <0.0001
Intermediate-I ELN risk group 16.55 1 <0.0001 1.92 ( 1.40 - 2.63) 13.12 1 <0.0001 1.72 (1.28 - 2.30)
Intermediate-II ELN risk group 9.36 1 0.002    1.65 (1.20 - 2.28) 9.05 1 0.003 1.58 (1.17 - 2.12)
Adverse ELN risk group 39.36 1 <0.0001 3.01 (2.13 - 4.24) 36.49 1 <0.0001 2.72 (1.97 - 3.76)
Age (above 60 years) 18.06 1 <0.0001 1.81 (1.41 - 2.52) 9.82 1 0.002 1.57 (1.18 - 2.08)
WBC (>100 *109) 11.02 1 0.001 1.59 (1.21 - 2.09) 14.78 1 <0.0001 1.66 (1.28 - 2.15)
TCF4 high expression 16.07 1 <0.0001 1.65 (1.29 - 2.11) 14.86 1 <0.0001 1.59 (1.26 - 2.02)
ELN indicates European LeukemiaNet, DF indicates degrees of freedom, HR indicates Hazard ratio, CI indicates Confidence Interval
OS, n = 506 EFS, n = 506
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who received alloHCT (n=86) or additional CT (n=186) (5-year OS, 61%, 48% 
vs 26%, p<0.0001, respectively), confirming the observations from the first co-
hort.
The biological role of TCF4 is poorly understood2 and in the literature opposing 
observations are described. For example, enforced expression of members of the 
bHLH class A family, including TCF4, suppresses colony forming efficiency of 
various cell lines due to up-regulation of p21, p15 and p16, suggesting that these 
bHLH proteins act as negative regulators of cell growth.9 In contrast, Tcf4 expres-
sion appeared increased in rat-E1A-immortalized RK3E cells following β-catenin 
induced neoplastic transformation and aberrant expression of Tcf4 promoted 
neoplastic transformation of RK3E cells.10These different observations might be 
explained by differences in cellular context, or by the different transcript variants 
of TCF411–14, which could affect the function of the protein.10 Possibly, TCF4 
can either stimulate or inhibit cell growth, depending on its environment, which 
might indicate that an aberrant expression is not only a prognostic marker, but 
also a pathological feature. This would be in line with the report of mutations in 
TCF4 in MDS and AML.3,4
TCF4 has also been reported to be highly expressed in hematopoietic stem cells 
(HSC) and to show a decreased expression in committed progenitors.15 Since the 
frequency of TCF4 mutations is relatively low (0.5% in AML), obviously, not all 
patients with high expression of TCF4 can have mutated TCF4. Interestingly, in 
MLL-AF9 mediated transformation of progenitor cells, TCF4 has been shown 
to be upregulated.15 In the first cohort, patients with high TCF4 expression are 
significantly more classified in the M0 or M1 FAB-subgroups than TCF4low pa-
tients, suggesting that the leukemic cells of the TCF4high patients derive from more 
immature cells. In addition, TCF4 expression of patients in the TCF4high group 
is comparable to the level of TCF4 expression of hCD34+ cells. Furthermore, 
when looking at the CD34 expression in the first cohort, 73.3% of the TCF4high 
patients show a high CD34 expression (above the median), compared to 42.1% of 
the TCF4low patients. When including CD34 expression in the multivariate Cox 
regression analysis, CD34 expression is an independent prognostic factor in OS 
and EFS, nevertheless TCF4 expression also remains an independent prognostic 
factor (data not shown).
Our observations report on the prognostic relevance of the level of TCF4 ex-
pression in AML and demonstrate that high TCF4 expression is associated with a 
worse survival. In addition, the TCF4 expression levels seem to provide additional 
information in the response to treatment. Before implementing TCF4 expression 
levels in clinical decisions, additional validation studies, also to define optimal cut 
Chapter 2
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off levels, are needed. Further mechanistic studies are warranted on the role of 
TCF4 in myeloid diseases.
Acknowledgement:
The authors would like to thank dr. P. Valk for providing cDNA.
45
High expression of transcription factor 4
C
h
ap
te
r 
2
References
 1. Ellenberger T, Fass D, Arnaud M. & Harrison SC. Crystal structure of transcription factor E47: E-box 
recognition by a basic region helix-loop-helix dimer. Genes Dev. 1994;8(8):970–80.
 2. Massari ME & Murre C. MINIREVIEW Helix-Loop-Helix Proteins : Regulators of Transcription in 
Eucaryotic Organisms. Mol Cell Biol. 2000;20(2):429–40.
 3. Papaemmanuil E, Gerstung M, Malcovati L, Tauro S, Gundem G, Van Loo P, et al. Clinical and biologi-
cal implications of driver mutations in myelodysplastic syndromes. Blood. 2013;122(22):3616–27.
 4. Cancer Genome Atlas Research Network. Genomic and epigenomic landscapes of adult de novo acute 
myeloid leukemia. N Engl J Med. 2013;368(22):2059–74.
 5. Makishima H, LaFramboise T, Przychodzen JP, Yoshida K, Ruffalo M, Gómez-Seguí I, et al. Clinical 
“MUTATOME” Of Myelodysplastic Syndrome; Comparison To Primary Acute Myelogenous Leuke-
mia. Abstract 518 of the 55th ASH annual meeting and exposition; 2013 dec 7-10; New Orleans, LA, 
USA: Blood; 2013.
 6. Wouters BJ, Löwenberg B, Erpelinck-Verschueren CA, van Putten WL., Valk PJ., Delwel R et al.Double 
CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia 
with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood. 
2009;113(13):3088–91.
 7. Kharas MG, Lengner CJ, Al-Shahrour F, Bullinger L, Ball B, Zaidi S et al. Musashi-2 regulates normal 
hematopoiesis and promotes aggressive myeloid leukemia. Nat Med. 2010;16(8):903–8.
 8. Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, et al.Diagnosis and manage-
ment of acute myeloid leukemia in adults: recommendations from an international expert panel, on 
behalf of the European LeukemiaNet. Blood. 2010;115(3):453–74.
 9. Pagliuca A, Gallo P, De Luca P & Lania L. Class A helix-loop-helix proteins are positive regulators of 
several cyclin-dependent kinase inhibitors’ promoter activity and negatively affect cell growth. Cancer 
Res. 2000;60(5):1376–82.
 10. Kolligs FT, Nieman MT, Winer I, Hu G, Van Mater D, Feng Y, et al.ITF-2, a downstream target of the 
Wnt/TCF pathway, is activated in human cancers with beta-catenin defects and promotes neoplastic 
transformation. Cancer Cell. 2002;1(2):145–55.
 11. Corneliussen B, Thornell A, Hallberg B & Grundström T. Helix-loop-helix transcriptional activators bind 
to a sequence in glucocorticoid response elements of retrovirus enhancers. J Virol. 1991;65(11):6084–93.
 12. Henthorn P, Kiledjian M & Kadesch T. Two distinct transcription factors that bind the immunoglobulin 
enhancer microE5/kappa 2 motif. Science. 1990;247(4941):467–70.
 13. Liu Y, Ray SK, Yang XQ, Luntz-Leybman V & Chiu IM. A splice variant of E2-2 basic helix-loop-
helix protein represses the brain-specific fibroblast growth factor 1 promoter through the binding to an 
imperfect E-box. J Biol Chem. 1998;273(30):19269–76.
 14. Skerjanc IS, Truong J, Filion P & McBurney MW. A splice variant of the ITF-2 transcript encodes a 
transcription factor that inhibits MyoD activity. J Biol Chem. 1996;271(7):3555–61.15. Krivtsov AV, 
Twomey D, Feng Z, Stubbs MC, Wang Y, Faber J, et al. Transformation from committed progenitor to 
leukaemia stem cell initiated by MLL-AF9. Nature. 2006;442(7104):818–22.
Chapter 2
46
Supplementary data
Supplementary Table 1. Patients characteristics.
Characteristics for TCF4high (n=131) and TCF4low patients of the first cohort (n=394). Good risk (de-
fined as patients with t(8;21), inv(16), t(16;16) or t(15;17); 2) Poor risk (defined as patients with ≥ 3 
cytogenetic abnormalities (complex karyotype), monosomy of chromosome 5 or 7, deletion of 5q or 
7q, abnormalities in 3q, t(6;9), t(9;22) or t(9;11); 3) Intermediate risk (defined as all other patients).
 TCF4lo w (n = 394) TCF4h igh  (n = 131) P  value
Age 0.292
  Under 60 years 331 (85.1%) 113 (87.6%)
  Above 60 years 58 (14.9%) 16 (12.4%)
Sex 0.520
  Male 194 (49.9%) 64 (49.6%)
  Female 195 (50.1%) 65 (50.4%)
Cytogenetic risk classification <0.001
  Good 96 (24.9%) 8 (6.3%) <0.001
  Intermediate 240 (62.3%) 93 (72.7%) 0.023
  Poor 49 (12.7%) 27 (21.1%) 0.017
ELN risk classification <0.001
 Favourable risk group 143 (37.1%) 13 (10.2%) <0.001
 Intermediate-I 85 (22.1%) 58 (45.3%) <0.001
 Intermediate-II 101 (26.5%) 29 (22.7%) 0.422
 Adverse risk group 56 (14.5%) 28 (21.9%) 0.053
Flt3-ITD <0.001
  Negative 308 (78.2%) 74 (56.5%)
  Positive 86 (21.8%) 57 (43,5%)
NPM1 mutation 0.338
  Negative 273 (69.3%) 94 (71.8%)
  Positive 121 (30.7%) 37 (28.2%)
CEBPA biallelic mutation 0.005
  Negative 369 ( 93.7%) 130 (99.2%)
  Positive 25 (6.3%) 1 (0.8%)
White Bloodcell Count  (*109) 0.133
  Less than 100 326 (82.7%) 102 (77.9%)
  More than 100 68 (17.3%) 29 (22.1%)
FAB classification <0.001
  M0 8 (2.1%) 10 (7.9%) 0.005
  M1 55 (14.4%) 45 (35.7%) <0.001
  M2 102 (26.6%) 29 (23.0%) 0.230
  M3 23 (6.0%) 0 (0.0%) 0.001
  M4 77 (20.1%) 16 (12.7%) 0.035
  M5 90 (23.5%) 26 (20.6%) 0.279
  M6 7 (1.8%) 0 (0.0%) 0.132
  Raeb-t 17 (4.4%) 0 (0.0%) 0.007
  Raeb 4 (1.0%) 0 (0.0%) 0.316
FAB classification indicates French-American-British classification
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Supplementary Table 2. Multivariate Cox Regression survival analysis.
Factors predicting OS and EFS in AML patients of the first cohort with available complete data of all 
molecular parameters (n=506), with TCF4 as a continues variable per 100 AU. B. Factors predicting 
OS and EFS in AML patients of the first cohort with normal karyotype (n=214), with TCF4 as a 
categorical variable per 100 AU. C. Factors predicting OS and EFS in AML patients of the first cohort 
with normal karyotype (n=214), with TCF4 as a continuous variable per 100 AU.
A. 
 
Variable  χ2 (Wald) DF P HR (95% CI)  χ2 (Wald) DF P HR (95% CI)
Favorable ELN risk group,  (reference) 44.83 3 <0.0001 38.52 3 <0.0001
Intermediate-I ELN risk group 22.01 1 <0.0001 2.10 ( 1.54 - 2.86) 16.12 1 <0.0001 1.81 (1.35 - 2.41)
Intermediate-II ELN risk group 10.86 1 0.001 1.71 (1.24 - 2.36) 9.51 1 0.002 1.59 (1.19 - 2.14)
Adverse ELN risk group 42.74 1 <0.0001 3.17 (2.24 - 4.48) 37.53 1 <0.0001 2.78 (2.00 - 3.85)
Age (above 60 years) 15.61 1 <0.0001 1.80 (1.34 - 2.40) 8.56 1 0.003 1.52 (1.15 - 2.01)
WBC (>100 *109) 11.52 1 0.001 1.61 (1.22 - 2.12) 15.97 1 <0.0001 1.70 (1.31 - 2.20)
TCF4  expression (continuous per 100 
AU)
5.09 1 0.024 1.04 (1.01-1.07) 9.20 1 0.002 1.05 (1.02-1.08)
ELN indicates European LeukemiaNet, DF indicates degrees of freedom, HR indicates Hazard ratio, CI indicates Confidence Interval
OS, n = 506 EFS, n = 506
B. 
 
Variable  χ2 (Wald) DF P HR (95% CI)  χ2 (Wald) DF P HR (95% CI)
ELN risk group 6.76 1 0.009 1.68 (1.14 - 2.47) 6.57 1 0.010 1.61 (1.12 - 2.31)
Age (above 60 years) 5.19 1 0.023 1.72 (1.08 - 2.73) 2.17 1 0.141 1.40 (0.90 - 2.19)
WBC (>100 *109) 8.63 1 0.003 1.74 (1.20 - 2.51) 9.62 1 0.002 1.75 (1.23 - 2.49)
TCF4 high expression 8.56 1 0.003 1.75 (1.20 - 2.54) 7.83 1 0.005 1.66 (1.16 -2.37)
ELN indicates European LeukemiaNet, DF indicates degrees of freedom, HR indicates Hazard ratio, CI indicates Confidence Interval
OS, n = 214 EFS, n = 214
C. 
 
Variable  χ2 (Wald) DF P HR (95% CI)  χ2 (Wald) DF P HR (95% CI)
ELN risk group 7.77 1 0.005 1.73 (1.18 - 2.54) 6.78 1 0.009 1.62 (1.13 - 2.33)
Age (above 60 years) 4.21 1 0.040 1.61 (1.02 - 2.54) 1.66 1 0.198 1.34 (0.86 - 2.08)
WBC (>100 *109) 9.27 1 0.002 1.79 (1.23 - 2.59) 10.32 1 0.001 1.80 (1.26 - 2.57)
TCF4  expression (continuous per 100 
AU)
8.18 1 0.004 1.07 (1.02-1.13) 8.83 1 0.003 1.08 (1.03-1.13)
ELN indicates European LeukemiaNet, DF indicates degrees of freedom, HR indicates Hazard ratio, CI indicates Confidence Interval
OS, n = 214 EFS, n = 214
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Supplementary Table 3. Multivariate Cox Regression survival analysis including con-
solidation treatment.
Factors predicting OS and EFS in TCF4high patients of the first cohort (n=126). B. Factors predicting 
OS and EFS in TCF4low patients of the first cohort (n=359).
A. 
 
Variable  χ2 (Wald) DF P HR (95% CI)  χ2 (Wald) DF P HR (95% CI)
Favorable ELN risk group,  (reference) 8.73 3 0.033 10.89 3 0.012
Intermediate-I ELN risk group 6.64 1 0.010 2.89 (1.29 - 6.47) 7.86 1 0.005 3.15 (1.41 - 7.02)
Intermediate-II ELN risk group 4.18 1 0.041 2.48 (1.04 - 5.94) 6.67 1 0.010 3.10 ( 1.31 - 7.29)
Adverse ELN risk group 8.30 1 0.004 3.55 (1.50 - 8.39) 10.84 1 0.001 4.25 (1.80 - 10.06)
Age (above 60 years) 5.31 1 0.021    2.10 (1.12 - 3.95) 2.75 1 0.097    1.68 (0.91 - 3.09)
WBC (>100 *109) 6.29 1 0.012    1.86 (1.15 - 3.02) 3.47 1 0.063    1.58 (0.98 - 2.57)
Additonal CT (reference) 16.78 2 <0.0001 12.15 2 0.002
AutoHSCT 0.85 1 0.356 0.73 (0.37 - 1.43) 0.26 1 0.609 0.84 (0.43 - 1.63)
AlloHSCT 16.78 1 <0.0001 0.35 (0.21 - 0.58) 11.99 1 0.001 0.42 (0.26 - 0.69)
ELN indicates European LeukemiaNet, DF indicates degrees of freedom, HR indicates Hazard ratio, CI indicates Confidence Interval
EFS, n = 126OS, n = 126
B. 
 
Variable  χ2 (Wald) DF P HR (95% CI)  χ2 (Wald) DF P HR (95% CI)
Favorable ELN risk group,  (reference) 36.02 3 <0.0001 31.49 3 <0.0001
Intermediate-I ELN risk group 11.70 1 0.001 1.93 (1.32 - 2.81) 6.89 1 0.009 1.60 (1.13 - 2.28)
Intermediate-II ELN risk group 5.03 1 0.025 1.52 (1.05 - 2.18) 3.87 1 0.049 1.40 (1.00 - 1.96)
Adverse ELN risk group 34.36 1 <0.0001 3.40 (2.26 - 5.12) 31.05 1 <0.0001 3.09 (2.08 - 4.59)
Age (above 60 years) 4.82 1 0.028 1.51 (1.05 - 2.19) 2.47 1 0.116 1.33 (0.93 - 1.90)
WBC (>100 *109) 4.12 1 0.042 1.43 (1.01 - 2.02) 11.03 1 0.001 1.73 (1.25 - 2.38) 
Additonal CT (reference) 11.42 2 0.003 5.24 2 0.073
AutoHSCT 7.89 1 0.005 0.53 (0.34 - 0.82) 3.39 1 0.065 0.69 (0.47 - 1.02)
AlloHSCT 6.27 1 0.012 0.66 (0.48 - 0.92) 3.30 1 0.069 0.75 (0.56 - 1.02)
ELN indicates European LeukemiaNet, DF indicates degrees of freedom, HR indicates Hazard ratio, CI indicates Confidence Interval
EFS, n = 359OS, n = 359
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Supplementary Figure 1. 
To confirm the microarray expression data, qPCRs were performed on cDNA of 10/20 highest expres-
sors (by microarray) and of 10/20 lowest expressors. The highest expressors by microarray had also 
the highest expression by qPCR (normalized for β-actin) (A); and the lowest expressors by microarray 
had also the lowest expression by qPCR (normalized for β-actin). The difference in expression level by 
qPCR by high expressors vs low expressors was about 1000 fold; and differed significantly (P < 0.0001; 
T test). The correlation between the microarray values and the qPCR values was high: Spearman’s cor-
relation coefficient 0.8887 (95% CI 0.73-0.96, P < 0.0001) (B). Of note: The following primers were 
used: TCCAGGTTTGCCATCTTCAGT (F) GCCTGGCGAGTCCCTATTG (R).
Chapter 2
50
A.     B. 
C. D. 
E.  F 
Supplementary Figure 2. OS curves for 518 AML patients of the first cohort.
A. Patients with TCF4 expression stratified by above median (n=257) and below median (n=261) 
TCF4 expression. B. Patients with TCF4 expression stratified by lowest tertile (n=174), middle ter-
tile (n=173), highest tertile (n=171). C. Patients with TCF4 expression stratified by quartiles, lowest 
quartile (n=131), 2nd quartile (n=130), 3rd quartile (n=128), highest quartile (n=129). D. Patients with 
TCF4 expression stratified by quintiles, lowest quintile (n=105), 2nd quintile (n=104), 3rd quintile 
(n=104), 4th quintile (n=100), highest quintile (n=105). E. Patients with TCF4 expression strati-
fied by sixtiles, lowest sixtile (n=87), 2nd sixtile (n=87), 3rd sixtile (n=87), 4th sixtile (n=86), 5th sixtile 
(n=84), highest sixtile (n=87). F. Patients with TCF4 expression stratified by septiles, lowest septile 
(n=75), 2nd septile (n=74), 3rd septile (n=75), 4th septile (n=74), 5th septile (n=72), 6th septile (n=73), 
highest septile (n=75).
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A.       B. 
Supplementary Figure 3.
A. OS curves for 436 AML patients of the second cohort stratified by TCF4high (n=109) and TCF4low 
(n=327). B. EFS curves for 436 AML patients of the second cohort stratified by TCF4high (n=108) and 
TCF4low (n=324)
A.  B. 
 
Supplementary Figure 4.
A. OS curves for AML patients with a normal karyotype and available follow-up data (n=214) strati-
fied by TCF4high (n=62) and TCF4low (n=152). B. idem for EFS.
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A.       B.  
Supplementary Figure 5.
A. EFS curves for TCF4high AML patients with available follow up and consolidation treatment data 
(n=129) stratified for conditioning with alloHSCT (n=36), autoHSCT (n=13) or additional CT 
(n=80). B. EFS curves for TCF4low AML patients with available follow up and consolidation treatment 
data (n=386) stratified for conditioning with alloHSCT (n=99), autoHSCT (n=57) or additional CT 
(n=212).


Chapter 3
R UNX1 regulates the TCF4 locus
 Florentien E. M. in ’t Hout1, Mylène Gerritsen2, Lars Bullinger3, Gorica 
Nikoloski1, Jolanda van Duren1, Bert A. van der Reijden1, Edo Vellenga4, 
Gerwin Huls4*, Joop H. Jansen1*
1Department of Laboratory medicine, Laboratory of Hematology, Radboud University medical centre, 
Nijmegen, Th e Netherlands
2Department of Experimental Hematology, Cancer Research Center Groningen, University Medical 
Center Groningen, University of Groningen, Groningen, Th e Netherlands
3Department of Internal Medicine, University Hospital of Ulm, Ulm, Germany
4Department of Hematology, University medical centre Groningen, Groningen, Th e Netherlands
*Th ese authors contributed equally to this article
Chapter 3
56
Abstract
RUNX1 aberrations are frequently found in various myeloid malignancies, 
including acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) 
and chronic myelomonocytic leukemia (CMML) . RUNX1 point mutations and 
deletions are generally considered to represent a poor prognostic factor, while 
patients with a translocation t(8;21) leading to the RUNX1-RUNX1T1 fusion 
protein have a favorable prognosis. Transcription factor 4 (TCF4) is a basic 
helix-loop-helix (bHLH) protein which is involved in the development of B- and 
T-lymphocytes and dendritic cells (DCs). TCF4 mutations are found in AML, 
albeit in a low frequency, and high TCF4 mRNA expression is an independent 
prognostic factor in AML. In a cohort of 436 AML patients, we found that RUNX1 
mutated patients showed a distinct clustering of genes, with TCF4 being one of 
the most consistently upregulated genes. In contrast, patients with a t(8;21) had 
a significantly lower TCF4 expression compared to patients without a t(8;21) 
(mean 0.788 vs -0.015, p=0.0002 and -0.908 vs -0.015, p<0.0001, respectively).
We show that RUNX1 directly binds to the TCF4 promoter. Co-transfection of 
wild-type RUNX1 and its cofactor CBFβ showed repression of TCF4 promoter 
activity, while the frequently found RUNX1 R201Q mutant lost this repression 
capacity (mean: CBFβ alone 0.91, RUNX1 wt 0.21, p=0.0006; RUNX1 mut 
0.79; p= 0.4372), in line with the high expression of TCF4 found in AML patients 
with a RUNX1 mutation. Furthermore, RUNX1-RUNX1T1 showed repression 
of transcription from the TCF4 promoter (mean: CBFβ alone 0.91,RUNX1-
RUNX1T1 0.41, p=0.0209), in line with the low TCF4 expression found in 
t(8;21) AML patients.
In a cohort of 436 AML patients, patients with a high TCF4 expression showed 
an inferior overall survival (OS) and event free survival (EFS) compared to patients 
with low TCF4 expression (5-year OS 27% vs 41%, p=0.002; 5-year EFS 19% 
vs 34%, p<0.0001). The presence of a RUNX1 mutation and t(8;21) showed the 
expected impact on survival (5-year OS 14% vs 38%, p=0.014, EFS; 0% vs 31%, 
p=0.001; 5-year OS 49% vs 33%, p=0.035, 5-year EFS 51% vs 25%, p=0.004, 
respectively). In multivariate Cox regression analysis including age (>60years), 
white blood cell count (WBC), cytogenetic risk group, TCF4 expression and 
RUNX1 mutational status, high TCF4 expression was an independent prognostic 
factor in OS and EFS (OS Hazard Ratio (HR) 1.42 (95% Confidence interval 
(CI) 1.06-1.92), p=0.020; EFS HR 1.45 (95% CI 1.10-1.90), p=0.008), while 
RUNX1 mutation was not (OS HR 1.24 (95% CI 0.77-1.99), p=0.374; EFS HR 
1.43 (95% CI 0.92-2.22), p=0.110). This indicates that high TCF4 expression is a 
stronger predictor of survival than RUNX1 mutational status in this model. Since 
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RUNX1 regulates the TCF4 locus
RUNX1 directly regulates the TCF4 promoter, these data indicate that TCF4 
may be an important mediator of the biological and clinical effects of RUNX1 
aberrations. More research is warranted to establish whether TCF4 is an essential 
mediator of the pathogenic effect of RUNX1-RUNX1T1 and/or RUNX1 point 
mutations and deletions.
Introduction
Runt related transcription factor 1, RUNX1 (also called AML1, CBFalpha2 or 
PEBP2alphaB), is a transcription factor which belongs to the family of Runt-
related transcription factors (RUNXs) [1]. RUNX1 directly contacts DNA via 
a N-terminal RUNT domain, but the binding affinity for DNA significantly 
increases after dimerizing with its cofactor core binding factor-β (CBFβ). CBFβ 
does not contact DNA itself, but also binds to RUNX1 via the RUNT domain 
[2, 3].
RUNX1 plays a key role in definitive hematopoiesis [4-7], and disruption of 
RUNX1 results in abnormal hematopoiesis [2, 7]. In various hematological ma-
lignancies including acute myeloid leukemia (AML), myelodysplastic syndromes 
(MDS), myeloproliferative neoplasms (MPN) and chronic myelomonocytic 
leukemia (CMML), RUNX1 mutations are frequently found [2, 8]. In addition, 
heterozygous germline mutations of the RUNX1 gene result in familial platelet 
disorder with a predisposition for the development of AML [9]. The mutational 
spectrum of RUNX1 includes N-terminal missense mutations, affecting mostly 
the RUNT domain, and C-terminal truncating mutations, deleting the transac-
tivation domain. Both missense and truncating mutations were reported to have 
a dominant negative effect on the transactivational capacity of wild type RUNX1 
[8, 10, 11]. Furthermore, chromosomal translocations affecting either RUNX1 
or CBFβ are amongst the most common cytogenetic aberrations found in AML. 
A recurrent t(8;21)(q22:q22) results in a RUNX1-RUNX1T1 fusion gene in ap-
proximately 10% of the cases, whereas an inv(16)(p13;q22) or t(16;16)(p13.1q22) 
leads to a CBFβ-MYH11 fusion gene in approximately 8% of AML patients [2, 
7, 12, 13]. RUNX1-RUNX1T1 and CBFβ -MYH11 were incorporated in the 
world health organization (WHO) classification of myeloid neoplasms and acute 
leukemia in 2008 [14] and in the European Leukemia Net (ELN) recommenda-
tions of diagnosis and management of AML [15]. In the recent WHO update, 
AML with a RUNX1 mutation has been added as a provisional entity [16] and 
this category of AML has also been included in the ELN recommendations as a 
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poor prognostic group [17]. The exact mechanism via which RUNX1 contributes 
to leukemogenesis, however, is largely unknown.
Transcription factor 4 (TCF4, E2-2, ITF2) is a basic helix-loop-helix (bHLH) 
class I protein (E-protein), which plays a role in a wide range of developmental 
processes [18, 19]. This transcription factor can form homo- or heterodimers 
with bHLH proteins and bind to the DNA Ephrussi-box (CANNTG) to regulate 
transcription [18, 19]. TCF4 is implicated in B- and T-cell development [18, 
20] and is crucial for plasmacytoid DC (pDCs) development [21]. In blastic 
plasmacytoid dendritic cell neoplasms (BPDCN) TCF4 has been shown to be 
the master regulator of the oncogenic program [22]. A role for TCF4 in normal 
and malignant hematopoiesis is further indicated as mutations in TCF4 are found 
in a low frequency in AML [23] and MDS [24], and high expression of TCF4 
correlates with an adverse, independent prognostic factor in AML [25]. TCF4 has 
been described up-regulated in RUNX1 mutated AML patients in various reports 
[10, 26, 27].Here, we describe that RUNX1 directly regulates the TCF4 gene by 
binding to the TCF4 promoter.
Methods
AML patients and TCF4 expression
TCF4 expression values were derived from a previously reported cohort of 436 
AML patients [28, 29]. Gene expression profiling was performed as previously 
described using the Stanford cDNA microarray platform [29]. Following Ficoll 
enrichment, all samples contained at least 80% leukemic cells. To determine the 
TCF4 expression, an average of 7 probe sets (which bind at different locations of 
the gene) was used. In 330 patients the RUNX1 mutationalstatus was established.
Luciferase reporter assays
RUNX1c wt and RUNX1c mutant R201Q (602G>A, NM_001754.4) with an 
N-terminal FLAG-tag were cloned into pCDNA3.1 (Addgene). Using published 
CHIP-seq data (http://genome.ucsc.edu/)[30, 31], the TCF4 gene was screened 
for RUNX1 binding, the identified RUNX1 binding region (HG19; chromosome 
18, 53251152 - 53250262) was synthesized by GeneArt (Life Technologies) and 
cloned into a pGL3basic vector (Promega). At day 0, 1,2 x 105 HEK293 cells/
well were seeded in 24-well plates, and cultured in Dulbecco modified Eagle 
medium (DMEM; GIBCO) supplemented with 10% non-heat-inactivated fetal 
calf serum (GIBCO). The next day, the cells were transfected with a total of 2,7 
µg of DNA using calcium phosphate precipitates, and the medium was refreshed 
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the following day. 48 Hours later, cells were harvested and lysed and luciferase was 
measured using Dual-Luciferase Reporter Assay (Promega) on a Fluorstar optima 
microplate reader (BMG labtech). Luciferase activity was normalized for input 
using renilla activity.Each condition was tested in duplicate.
Westernblot
Proteins of total cell lysates were separated on 8% polyacrylamide gels and 
transferred onto polyvinylidenefluoride (PDVF) membranes (BioRad). PVDF 
membranes were probed with anti-FLAG (Abcam) primary antibodies, followed 
by HRP-conjugated secondary antibodies. Antibody signal was visualized by 
chemiluminescence using a Bio-Rad ChemiDox XRSþ.
Statistics
SPSS version 22.0 software (SPSS Inc, Chicago, IL) and Graphpad Prism 5.03 
were used for statistical analysis. Differences in patient groups were calculated 
using the Mann-Whitney U test. The overall and event free survival (OS, EFS) 
were calculated from the date of AML diagnosis to a relevant event date (death 
and first recurrence, respectively), or the last follow-up date. Survival curves were 
calculated by the Kaplan-Meier method and compared using the logrank test. 
Multivariate survival analysis was carried out using the Cox proportional hazards 
model, and covariates included were TCF4 expression (expression above median), 
RUNX1 mutation, age (>60 years), white blood cell count (WBC >100 *109/L) 
and cytogenetics risk group. Luciferase reporter assay results were analyzed using a 
paired t-test. P-values equal or inferior to 0.05 were considered significant.
Results
RUNX1 status is associated with TCF4 expression in AML patients
In a cohort of 436 AML patients, we investigated the association between TCF4 
expression and RUNX1 aberrations.Patients with a RUNX1 mutation (n=26 
(7.9%), Figure 1) had a significantly higher TCF4 expression compared to patients 
without a RUNX1 mutation, while patients with a t(8;21) had a significantly 
lower TCF4 expression (Table 1; Figure 2A; mean 0.788 vs -0.015, p=0.0002 
and -0.908 vs -0.015, p<0.0001, respectively). Patients with an inv(16) (affecting 
the CBFβ gene, which serves as a dimerization partner for RUNX1), did not 
show a deviating TCF4 expression compared to the whole cohort (Figure 2A). 
Furthermore, patients with a RUNX1 mutation were almost 2 times more likely 
to have a high TCF4 expression (above median, TCF4high), than patients with 
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Figure 1. Schematic overview of mutations found in 26 AML patients of the study cohort 
of 436 AML patients.
Linear structure of the RUNX1 protein (NP_001745.2) includes N-terminal RUNT domain and C-
terminal transcription activation domain (TAD).
A B
Figure 2. A. AML patients with: wild type RUNX1 and no t(8;21) or inv(16)(n=245), RUNX1 mu-
tations (n=26), t(8;21) (n=24), inv(16) (n=35), correlated to TCF4 expression. B. AML patients with 
wild type RUNX1 (n=304), RUNX1 mutations found with VAF≥40% (n=16), RUNX1 mutations 
found with VAF<40% (n=10).
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RUNX1 wt (Table 1A; 85 vs 46%, p<0.0001, respectively). Previously, we have 
shown that high TCF4 expression is an independent poor prognostic factor in 
AML [25]. Interestingly, when taking the clone size of cells carrying the RUNX1 
mutation (measured by the variant allele frequency, VAF) into account almost all 
patients with a high RUNX1 mutational burden (VAF≥40%) were classified as 
TCF4high (Table 1B; 94% vs 47% ,p<0.0001). In addition, patients with RUNX1 
mutations with a VAF≥40% showed a significantly higher TCF4 expression than 
patients in whom a RUNX1 mutation was found at a lower VAF (Figure 2B; mean 
1.02 vs 0.42 p=0.045). There was no significant difference in TCF4 expression 
between RUNX1 mutations with a VAF<40% and RUNX1 wild type (wt) (Figure 
2B; mean 0.42 vs -0.11, p=0.17).
RUNX1 directly regulates the TCF4 promoter
Next we investigated if RUNX1 might be able to directly regulate TCF4 gene ex-
pression by binding to its promoter region, and whether the correlation between 
TCF4 expression and RUNX1 aberrations could be explained by a deregulated 
function of RUNX1. Guided by published ChIP-sequencing data [31], RUNX1 
binding could indeed be identified on the TCF4 promoter, approximately 1500 
bp upstream of the translation start site (Supplementary figure 1A-B). To further 
validate these finding, this region (-62 to 795 of the transcription start site) was 
Table 1. Correlation between TCF4 expression (divided by median) and A. RUNX1 mutational sta-
tus; B. RUNX1 mutational status based on variant allele frequency (VAF); C. t(8;21) status. P-values 
are based on Fisher’s exact test.
A. 
RUNX1
wild type
RUNX1
mutation
p-value
low TCF4 164 (54%) 4 (15%) <0.0001
high TCF4 140 (46%) 22 (85%)
B. 
RUNX1 wild type
or VAF<40%
RUNX1 mutation
VAF≥40%
p-value
low TCF4 167 (53%) 1 (6.3%) <0.0001
high TCF4 147 (47%) 15 (93.8%)
C. 
other cytogentics t(8;21) p-value
low TCF4 192 (47%) 26 (84%) <0.0001
high TCF4 213 (53%) 5 (16%)
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cloned into a luciferase reporter construct on which the activity of wild type and 
mutant RUNX1 was tested. The RUNX1 mutant (RUNX1mut) used for lucif-
erase reporter assays was the R201Q RUNT domain mutant, which is a com-
mon RUNX1 mutant in AML, and which was also found 3 times in our cohort 
(Supplementary table 1).
Co-transfection of RUNX1 wild type (wt) with the TCF4 promoter construct, 
reduced the activity of the TCF4 promoter, while the RUNX1mut did not show any 
repression (Figure 3; mean: control set on 1, RUNX1 wt 0.64, RUNX1 mut 0.95, 
p=0.0035). Moreover, when also co-transfecting the cofactor CBFβ, RUNX1 
wt inhibited the promoter activity even further, while this was not the case for 
the RUNX1mut (Figure 3; mean: CBFβ alone 0.91, RUNX1 wt 0.21, p=0.0006; 
RUNX1mut 0.79; p= 0.4372). In these experiments, both wild type and mutant 
RUNX1 were expressed at equal levels as shown by Western blot (Supplementary 
figure 2). Furthermore, RUNX1mut showed a dominant negative effect over the 
wild type RUNX1 proteinexemplified by the fact that RUNX1mut inhibited the 
repression mediated by RUNX1 wt (Figure 3). The finding that RUNX1mutinhib-
its TCF4 repression in a dominant-negative manner is in line with the observa-
tion that AML patients with heterozygous RUNX1 mutations have high TCF4 
expression. Interestingly, RUNX1-RUNX1T1 showed strong repression of the 
TCF4 promoter (Figure 3; mean: CBFβ alone 0.91,RUNX1-RUNX1T1 0.41, 
p=0.0209). This is in line with the low TCF4 expression observed in t(8;21) posi-
tive AML patients.
Figure 3. Relative luciferase activity on the TCF4 promoter (n=3-4).
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TCF4 but not RUNX1 mutation is an independent prognostic factor
Patients with a high TCF4 expression showed an inferior overall survival (OS) 
and event free survival (EFS) compared to patients with a low TCF4 expression 
(Figure4A; Supplementary figure3A; Supplementary table 2A; 5-year OS 27% 
vs 41%, p=0.002; 5-year EFS 19% vs 34%, p<0.0001). As expected the pres-
ence of a RUNX1 mutation correlated with inferior survival, whereas a t(8;21) 
or inv(16) correlated with better survival (Figure 4B-D; Supplementary figure 
3B-D; Supplementary table 2B-D; 5-year OS 14% vs 38%, p=0.014, EFS; 0% 
A B
C D
Figure 4. Overall survival (OS) curves for AML patients with available data stratified on 
A. TCF4 expression, under the median (n=218), above median (n=218); B. RUNX1 mutational sta-
tus, RUNX1 wild type (n=304), RUNX1 mutation (n=26); C. Presence (n=31) or absence of t(8;21) 
(n=405); D. Presence (n=47) or absence of inv(16) (n=389)
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vs 31%, p=0.001; 5-year OS 49% vs 33%, p=0.035, 5-year EFS 51% vs 25%, 
p=0.004; 5-year OS 63% vs 31, p<0.0001, 5-year EFS 45% vs 24%, p=0.001, 
respectively). Multivariate Cox regression analysis including age, white blood cell 
count (WBC), cytogenetic riskgroup, TCF4 expression and RUNX1 mutational 
status was performed. Cytogenetics, age and WBC all were independent factors 
influencing outcome (Table 2A-B). Moreover, high TCF4 expression was an 
independent prognostic factor in OS and EFS (Table 2A-B; OS Hazard Ratio 
(HR) 1.42 (95% Confidence interval (CI) 1.06-1.92), p=0.020; EFS HR 1.45 
(95% CI 1.10-1.90), p=0.008), while RUNX1 was not (Table 2A-B; OS HR 1.24 
(95% CI 0.77-1.99), p=0.374; EFS HR 1.43 (95% CI 0.92-2.22), p=0.110). 
This indicates that high TCF4 expression is a stronger predictor of survival than 
RUNX1 mutational status in this model and suggests that TCF4 is an important 
down-stream effector of RUNX1.
Table 2. Multivariate Cox Regression analysis.
A. Overall survival (OS); B. Event free survival (EFS). DF= degrees of freedom, HR= Hazard Ratio, 
CI= Confidence interval.
A. 
OS; Variable Wald df p value HR (95% CI)
TCF4 above median 5.42 1 0.020 1.42 (1.06-1.92)
RUNX1 mutation 0.79 1 0.374 1.24 (0.77 - 1.99)
White Bloodcell Count >100*109/L 9.84 1 0.002 1.85 (1.26 - 2.71)
Age >60years 17.71 1 0.000 2.00 (1.45 - 2.76)
Cytogenetic risk good (Ref ) 31.89 2 0.000
intermediate 4.79 1 0.029 1.58 (1.05-2.37)
Poor 27.78 1 0.000 3.43 (2.17-5.42)
B. 
EFS; Variable Wald df p value HR (95% CI)
TCF4 above median 6.96 1 0.008 1.45 (1.10-1.90)
RUNX1 mutation 2.56 1 0.110 1.43 (0.92 - 2.22)
White Bloodcell Count >100*109/L 7.00 1 0.008 1.65 (1.14 - 2.38)
Age >60years 9.65 1 0.002 1.63 (1.20 - 2.22)
Cytogenetic risk good (Ref ) 33.95 2 0.000
intermediate 7.21 1 0.007 1.65 (1.14-2.37)
Poor 32.14 1 0.000 3.36 (2.21-5.12)
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Discussion
RUNX1 is frequently affected in AML. Mutations and translocations involving 
RUNX1 are both recurrently found in AML, but have a distinct impact on prog-
nosis. RUNX1 mutations are identified as poor prognostic factors, and are now 
included in the WHO classification (as provisional entity) of myeloid diseases and 
the ELN risk classification, while t(8;21) is an established favorable prognostic fac-
tor [2, 7, 10, 16, 17, 26, 32, 33]. TCF4 expression associated with RUNX1 aberra-
tions in AML patients as shown in Figure. 1, confirming data from other cohorts 
[10, 26, 27, 29]. We show that in AML, RUNX1 mutations are associated with a 
high TCF4 expression while patients with a t(8;21) and a RUNX1-RUNX1T1 fu-
sion gene showed a low TCF4 expression. RUNX1-RUNX1T1 is associated with 
a suppressive role on the RUNX1 target genes, based on RUNX1T1’s interaction 
with co-repressors and the ability of RUNX1 to bind to the RUNT homology 
domain [2, 34]. We found that RUNX1 directly binds to the TCF4 promoter and 
has a repressive function. In line with the high TCF4 expression found in RUNX1 
mutated AML patients, the RUNX1 R201Q mutation fails to repress the TCF4 
promoter. This mutation was present in 3 patients in our AML cohort. All three 
showed a high TCF4 expression, and higher expression correlated with a higher 
VAF (Supplementary table 1). In transactivation assays using the TCF4 promoter, 
RUNX1-RUNX1T1 had a repressive effect, comparable to wild-type RUNX1, in 
line with the low TCF4 expression found in t(8;21) patients. The relation between 
RUNX1 function and TCF4 expression seems not restricted to AML. In juvenile 
myelomonocytic leukemia, RUNX1 is highly activated due to dephosphorylation 
by Shp2 and in these cells TCF4 was found strongly down-regulated [35]. AML 
patients with inv(16), affecting the dimerization partner of RUNX1 did not show 
altered TCF4 expression. Furthermore, in luciferase reporter assays we show that 
RUNX1 wt can already repress the TCF4 promoter activity without the addition 
of CBFβ (Figure 3).
We reported before that AML patients with a high TCF4 expression have a poor 
prognosis, both when the cohort was divided based on median or quartiles. 5-year 
OS was 29.4% vs 44.7% (p<0.0001) in patients with a TCF4 expression above or 
under the median with a HR of 1.4 (p<0.003) (considering ELN status (2010), 
age and white blood cell count (WBC)) for high TCF4 expressing patients [25].
RUNX1 mutations have been identified as a poor prognostic factor in AML 
[10, 26, 32, 33], however the exact mechanism via which RUNX1 contributes 
to leukemogenesis has not yet been elucidated. We show a direct repression of 
the TCF4 promoter by wild type, but not by mutated RUNX1. 85% of patients 
with a RUNX1 mutation were classified as high TCF4 expressors, and the level 
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of expression correlated with the variant allele frequency in patients carrying a 
RUNX1 mutations.
Nevertheless, 80% of patients with a high TCF4 expression do not have a RUNX1 
mutation, indicating that there are other factors leading to a high TCF4 expres-
sion in AML. In AML cell and mouse models with translocations of the Mixed 
Lineage Leukemia gene (MLL) and its most common partner AF9 (MLL-AF9), 
TCF4 has been reported strongly up-regulated [36-38] and has been identified as 
being part of the “self-renewing signature” [36]. Furthermore, in MLL-rearranged 
AML, down-regulation of TCF4 or upregulation its inhibitor, inhibitor of DNA 
binding 2 (ID2), results is loss of growth capacity in these cells [38], indicating 
TCF4 is required for MLL-arranged AML. Also, in leukemic GMPs, transduced 
with various oncogenes, TCF4 was up-regulated and therefore was proposed to 
be part of the ‘leukemia initiation signature’ [39]. These data suggests that TCF4 
could be a downstream target of multiple oncogenic pathways. Therefore, TCF4 is 
an interesting target for further understanding leukemogenesis and in the light of 
its prognostic significance might even be a potential therapeutic target. Whether 
RUNX1 mutated AML, like MLL-rearranged AML is depending on TCF4 up-
regulation for transformation or maintenance, has not yet been established and 
should be further investigated.
In univariate analysis, all tested factors showed the expected impact on survival 
[10, 17, 25, 32, 33]. TCF4 high expression and RUNX1 mutations had a signifi-
cant adverse impact on prognosis, while t(8;21) and inv(16) showed a significant 
advantage in survival. In our multivariate model, including age, white blood cell 
count, cytogenetic risk groups, high TCF4 expression and RUNX1mutation, 
TCF4 expression showed to be a more powerful predictor of survival (OS and 
EFS) than RUNX1 mutational status (Table 4). In addition, when performing a 
backward stepwise elimination (wald) Cox regression analysis, RUNX1 mutation 
is the only covariate not included in the equation, confirming our first model. 
This means that TCF4 expression could be the major factor influencing outcome 
in RUNX1 mutated patients, since RUNX1 mutational status and TCF4 expres-
sion are closely associated factors. Moreover, when adding t(8;21) and inv(16) 
into the model instead of cytogenetic risk group, TCF4 expression (and age and 
WBC) remained an independent prognostic factor, while RUNX1 mutation and 
t(8;21) did not show an independently significant impact on survival (Supp. Table 
1). Inv(16) remained an independent predictor of survival in this analysis, which 
further confirms our model, since we showed inv(16) was not associated with 
TCF4 expression. Thus, TCF4 expression is a independent prognostic factor in 
AML and the prognostic value of RUNX1 could work via TCF4. The pathogenic 
relevance, however, has to be conducted in laboratory experiments.
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Taken together we show that RUNX1 regulates the TCF4 locus. We found that 
RUNX1 mutations are correlated with an increased TCF4 expression in AML pa-
tients, while t(8;21) was associated with a decrease of TCF4 expression. RUNX1 
had a direct repressing effect on the TCF4 promoter, which was lost in RUNX1 
R201Q mutant, but maintained with RUNX1-RUNX1T1. These data point 
toward a direct role of RUNX1 in the regulation of TCF4. In multivariate survival 
analysis, TCF4 showed to be an independent prognostic factor, while RUNX1 
mutation (or translocation) was not. More research is warranted to investigate 
whether the pathogenic effect of RUNX1 mutations is mediated by altering the 
TCF4 expression level.
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Supplementary data
A. 
B. 
 
 
 
Supplementary figure 1. A. Chipsequencing data of RUNX1 in Kasumi cells, extracted from 
http://genome.ucsc.edu/. The green arrow point towards the sequence used as TCF4 promoter. 
B. Zoomed in 30 times.
RUNX1    RUNX1 
 mut   wt 
 Rabbit anti-Flag       
Mouse anti-GAPD   
Supplementary figure 2. Protein expression of RUNX1 mutant-FLAG and RUNX1 wild 
type-FLAG transfected in HEK293 cells.
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RUNX1 regulates the TCF4 locus
A.      B. 
           
C.      D.   
Supplementary figure 3. Event free survival (EFS) curves for AML patients with available data 
stratified on A. TCF4 expression, under the median (n=218), above median (n=218); B. RUNX1 mu-
tational status, RUNX1 wild type (n=304), RUNX1 mutation (n=26); C. Presence (n=31) or absence 
of t(8;21) (n=405); D. Presence (n=47) or absence of inv(16) (n=389).
Supplementary table 1. RUNX1 mutation p.R201Q found in AML (mean TCF4 expression: 
-0.01418).
RUNX1 VAF mutation TCF4 expression
p.R201Q 56,3 1.460
p.R201Q 42,1 0.867
p.R201Q 27,1 0.244
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Supplementary table 2. Overall and event free survival rates based on TCF4, RUNX1 mu-
tational status, presence of t(8;21) and presence of inv(16).
5-year OS p value 5-year EFS p value
high TCF4 (median) 40.7% 0.002 34.3% <0.0001
low TCF4 27.3% 18.8%
RUNX1 wt 38.8% 0.014 31.0% 0.001
RUNX1 mut 14.4% 0.0%
t(8;21) 48.9% 0.035 51.0% 0.004
other cytogenetics 33.0% 24.6%
inv(16) 63.0% <0.0001 44.7% 0.001
other cytogenetics 30.8% 24.2%
Supplementary table 3. Overall survival (OS) multivariate Cox Regression analysis. 
DF= degrees of freedom, HR= Hazard Ratio, CI= Confidence interval.
OS; Variable Wald df p value HR (95% CI)
TCF4 above median 6.81 1 0.009 1.48 (1.10-1.99)
RUNX1 mutation 0.29 1 0.589 1.14 (0.71 - 1.82)
t(8;21) 0.64 1 0.423 0.77 (0.41 - 1.45)
inv(16) 9.78 1 0.002 0.36 (0.19 - 0.68)
White blood cell count >100*109/L 9.08 1 0.003 1.80 (1.23 - 2.63)
Age >60years 18.89 1 0.000 2.04 (1.48 - 2.81)
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Transcription factor 4 (TCF4, ITF2, E2-2), is a basic helix-loop-helix (bHLH) 
transcription factor that belongs to the family of E-box binding proteins. These 
proteins recognize CANNTG (Ephrussi-box) DNA sequences, present in a variety 
of tissue specific enhancers and promoters. E-proteins are widely expressed and 
can form both homodimers with other E-proteins or heterodimers with tissue 
specific bHLH proteins. Dimerization of bHLH transcription factors results in 
the formation of a four helix bundle, which allows the DNA binding domains 
to associate with the E-box recognition site, to regulate transcription [1]. TCF4 
is important in normal development and Tcf4-/- mice die shortly after birth [1]. 
In hematopoiesis, TCF4 is involved in the development of B- and T- cells and 
crucial for the development of plasmacytoid dendritic cells (pDC) [1]. Recently, 
TCF4 has been identified as the master regulator of the oncogenic program in 
blastic plasmacytoid dendritic cell neoplasm (BPDCN) [2]. Furthermore, TCF4 
is mutated (albeit at a low frequency) in acute myeloid leukemia (AML) [3] and 
myelodysplastic syndromes (MDS) [4]. Additionally, high mRNA expression 
levels of TCF4 were found to be an independent adverse prognostic factor in 
AML [5]. The exact role of TCF4 in myelopoiesis, however, is largely unknown. 
To study the role of TCF4 in myelopoiesis, we overexpressed TCF4 in um-
bilical cord blood (UCB) derived CD34+ cells using a pRRL lentiviral vector. 
Overexpression of TCF4 (TCF4 OE) had no impact on white colony forma-
tion compared to the empty vector control (EV) (Fig. 1a, mean 1.06, p=0.584, 
Supplementary Fig. 1a). TCF4 OE did also not increase replating potential of 
these white colonies (data not shown), in line with previous reports [6]. Instead, 
overexpression of TCF4 enhanced the number of erythroid colonies (Fig. 1b, 
mean 1.44, p=0.02) without affecting their size (data not shown). To investigate 
if enforced TCF4 expression might reduce erythropoietin (EPO) dependence, 
we performed CFU-GM colony assays with increasing concentrations of EPO. 
Without EPO, both the empty-vector transduced and TCF4 over-expressing 
cells were unable to form erythroid colonies, indicating that TCF4 OE did not 
induce EPO-independence (data not shown). To further understand whether the 
increased number of red colonies could be a result of an enhanced expansion of 
the Megakaryocyte-Erythrocyte Progenitors (MEP) compartment, we performed 
immune-phenotypical profiling. Our analyses showed no difference between EV 
and TCF4 OE in the proportion of cells falling within the MEP compartment 
(CD34+CD38+CD123-CD45RA-) compared to the common myeloid progenitor 
compartment (CMP, CD34+CD38+CD123+CD45RA-) and granulocyte-macro-
phage progenitor compartment (GMP, CD34+CD38+CD123+CD45RA+) after 
7 days of liquid culture (Fig. 1c, supplementary Fig. 2). Since MEPs have the 
potential to differentiate into both erythroid and megakaryocytic lineages, we 
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subsequently investigated megakaryocyte (MK) development by performing a 
CFU-MK assay. Enforced expression of TCF4 in CD34+ UCB hampered MK 
colony formation compared to EV (Fig. 1d, mean EV set on 1, mean TCF4 wild 
type 0.82, p=0.05), suggesting that TCF4 does not drive differentiation towards 
the MEP compartment, but specifically skews MEPs into the erythroid lineage, 
A
C
B
D
Figure 1. 
A. Proportion of MEPs after transduction of UCB CD34+ cells after 7 days of culture (n=3). B. MK 
colonies of CFU-MK, counted blindly 10-12 days after 10.000-15.000 GFP+ and CD34+ UCB cells 
were seeded in megacult medium (n=6). C. Impact of TCF4 over-expression (TCF4 OE) on colony 
formation. White colonies of CFU-GEMM counted blindly, 10-14 days after 1000-1500 GFP+ and 
CD34+ UCB cells were seeded in methylcellulose (n=16); D. Erythroid colonies of CFU-GEMM 
counted blindly, 10-14 days after 1000-1500 GFP+ and CD34+ UCB cells were seeded in methylcel-
lulose (n=16).
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while at the same time inhibiting the MK lineage. These results might indicate a 
role for TCF4 as a novel switch factor in erythroid-megakaryocytic differentiation.
To investigate if the role of TCF4 in erythropoiesis has clinical value, we mea-
sured the TCF4 expression by qRT-PCR in bone marrow samples of 95 IPSS-low 
and intermediate-1 risk MDS patients, with available hemoglobin (Hb) levels and 
blood transfusion data, treated in the HOVON89 protocol (available at http://
www.hovon.nl).Interestingly, the absolute Hb value was higher in patients with 
high TCF4 expression compared to patients with low TCF4 expression (Fig 2, 
mean 9.0 vs 8.55 g/dL, p=0.02, respectively). Moreover, the 6 patients in this 
cohort with normal Hb or only a mild anemia (Hb levels ≥11.0 g/dL), all had a 
high TCF4 expression (Supplementary Table 1). Furthermore, after dividing Hb 
levels based on WHO guidelines into no-, mild-, moderate- and severe anemia 
[7], we found that patients with a TCF4 expression under the median were twice 
as likely to have a severe anemia than patients with a higher TCF4 expression 
(Supplementary Table 1, 33% vs 17% p=0.04, respectively).
Patients with high TCF4 expression had received less red blood cell units 8 weeks 
prior to inclusion in the study than patients with low TCF4 expression, however 
this was not significant (Supplementary figure 3, mean 5.15 vs 4.62, p=0.39). 
We did not see a correlation between TCF4 expression and platelet counts nor 
absolute neutrophil count (data not shown).
Although, TCF4 has not been implicated in the regulation of erythropoiesis, 
other bHLH proteins have [8]. For example TAL1 (SCL), a hematopoiesis specific 
Figure 2. Hemoglobin levels (g/dL) in MDS patients with low TCF4 expression(n=48) and high 
TCF4 expression (n=46).
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bHLH protein, has been shown to play a fundamental role in the regulation of 
erythroid and megakaryocyte-specific gene expression programs [8]. TAL1, par-
ticipates in the erythropoiesis stimulating multiprotein complex with GATA1, 
LMO2 and LDB1. This complex binds DNA elements containing an E-box and 
a GATA-specific site, separated from each other by 9 or 10 base pairs [9]. In 
this multiprotein complex, TCF3 is commonly identified as the DNA-binding 
E-protein [8, 9], but also TCF4 has been reported as one of the proteins in this 
complex [10]. Furthermore, direct binding of TAL1 and TCF4 has been shown 
[11] and enforced expression of TAL1 alone also enhances erythroid differentia-
tion [12]. Possibly, the enhancing effect of enforced TCF4 expression on erythroid 
colony formation, can be explained by the interaction between TAL1 and TCF4. 
Another possible mechanism via which TCF4 could operate to enhance erythroid 
differentiation is through one of its downstream targets, like BCL11a. BCL11a 
is a major determinant in fetal-to-adult hemoglobin (Hb) switching [13] and 
has been identified as a direct downstream target of TCF4 [2]. Further, Bcl11acko/
cko mice showed a mild anemic phenotype [14]. Enforced expression of TCF4 in 
UCB CD34+ cells, could lead to more effective erythropoiesis due to upregulation 
of BCL11a. Interestingly, BCL11A has also been suggested as a downstream target 
of TAL1 [15], which makes a cooperation of both suggested mechanisms possible.
In conclusion, we found that enforced expression of TCF4 enhances erythroid 
differentiation while inhibiting megakaryocytic differentiation. Moreover, low 
risk MDS patients with a high TCF4expression had higher Hb levels and a trend 
towards lower red blood cell transfusion dependency compared to patients with 
low TCF4 expression. These data suggest that TCF4 may act as a switch factor in 
erythroid-megakaryocytic differentiation.
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Supplementary figure S1. TCF4 mRNA expression of harvested CFU-GEMM colonies (n=10)
Supplementary figure S2. Example of flow cytometry histogram of CD45RA and CD123, gated 
on GFP+ and CD34+/CD38+ cells.
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Supplementary figure S3. Number of red blood cell transfusions in MDS patients with low TCF4 
expression(n=48) and high TCF4 expression (n=46).
Supplementary Table 1. Percentage of patients with normal, mild, moderate and severe anemia in 
low and intermediate-I MDS patients with low and high TCF4 expression levels.
Normal Hb Mild anemia Moderate anemia Severe anemia p-value
low TCF4 0 (0%) 0 (0%) 32 (67%) 16 (33%) 0.035
high TCF4 2 (4%) 4 (9%) 32 (70%) 8 (17%)
Supplementary Table 2. The number of red blood cell transfusions that patients received 8 weeks 
prior to start of the study, correlated to TCF4 expression divided by median in low and intermediate-I 
MDS patients.
Red blood cell transfusion
0-3 units >3 units p-value
low TCF4 11 (23%) 37 (77%) 0.051
high TCF4 20 (43%) 27 (57%)
Methods
Primary cell isolation.Umbilical cord blood (UCB) was obtained after informed 
consent from healthy full-term pregnancies from the obstetrics department of 
the Radboud University Medical Center (RadboudUMC) in Nijmegen, the 
Netherlands. Mononuclear cells were isolated using ficoll (GE healthcare) den-
sity isolation and CD34+ were enriched using magnetic bead isolation (Stemcell 
technologies).
Cloning, lentiviral virus production and transduction.TCF4 lentiviral over-expres-
sion construct was made by cloning TCF4 (DNASU Plasmid Repository, Arizona 
State University) into pRRL-PGK-IRES-GFP construct. Lentiviral particles were 
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produced by cotransfection of 293FT cells using calcium phosphate precipitates 
with 7.4 µg pLP1, 3.6 µg pLP2, 4.5 µg pLP/VSVG and 24ug pRRL-PGK-TCF4-
IRES-GFP or pRRL-PGK -IRES-GFP (empty vector, EV). Medium was refreshed 
16 hours later and the lentiviral supernatants were collected 48 hours afterwards. 
To concentrate the virus, polyethylene glycol (PEG) and sodium-chloride were 
added to a final concentration of 5% and 0.15M, respectively. 24-48 Hours later 
the lentiviral particles were spun down at maximal speed for 30 minutes to be used 
directly or to be stored at -80°C until further use. UCB CD34+ cells were cultured 
for 48-72 hours in StemSpan ACF medium (Stemcell technologies) with rh-SCF 
(100ng/µl, Immunotools), rh-TPO (50ng/µl, Immunotools), rh-IL3 (10ng/µl, 
Immunotools), rh-IL6 (10ng/µl, Immunotools) and Penicillin-Streptomycin (life 
technologies) and subsequently transduced for 72 hours.
Flow cytometry. Cell immunostainings were performed with PE-conjugated 
antihuman CD34 (Beckman Coulter) for colony assays. For progenitor com-
partment stainings Brilliant Violet421-conjugated anti-CD34 (Biolegend), PE-
cy7-conjugated anti-CD38 (Beckman Coulter), APC-conjugated anti-CD45RA 
(Beckman Coulter) and PE-conjugated anti-CD123 (BD Bioscience) were used. 
Live cells were gated based on forward and sideward scatter. Cells were analysed 
and sorted using the BD FACSAria flow cytometer (BD Biosciences).
In vitro functional assays. 1000-1500 GFP and CD34 double positive cells were 
sorted into methylcellulose (miltenyi biotec) containing cytokines for Colony 
Forming Units (CFU)-Granulocyte, Erythrocyte, Monocyte/macrophage, Mega-
karyocyte (GEMM) assays or CFU-Granulocyte/ Monocyte/macrophage (GM) 
assays (STEMCELL technologies). To the CFU-GM assay, either 0, 0.1, 0.5, 
1 or 3 Units erythropoietin beta (Neorecormon Roche), was added. For CFU-
Megakaryocyte (MK) assays, 10.000-15.000 GFP and CD34 double positive 
cells were sorted into Megacult medium (STEMCELL technologies). The assays 
were performed according manufactures instructions. After 10-14 days, colonies 
were counted blindly. The number of colonies were normalized to the number of 
colonies obtained after transduction with the EV.
MDS patients and quantitative reverse transcription PCR (qRT-PCR). RNA of 
MDS patients bone marrow samples treated according to the HOVON89 study 
were harvested and enriched using ficoll (GE healthcare) density isolation. cDNA 
was synthesized using reverse transcriptase (Invitrogen). TCF4 qRT-PCR was per-
formed (forward primer TCCAGGTTTGCCATCTTCAGT and reverse primer 
GCCTGGCGAGTCCCTATTG) using Applied biosystems 7500 real-time PCR 
machine with the 9600 emulation. Measurements were performed in triplets and 
Ct values were normalized for input using the GAPDH (Applied Biosystems) 
housekeeping gene. Patients with GAPDH values of over 25 Ct were excluded. 
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95 patients with available hemoglobin, red blood cell transplantation status and 
TCF4 expression were selected. Hb levels were stratified using WHO anemia 
classification [7]; normal Hb: ≥12.0/13.0 g/dL (female/male), mild anemia: 11.0-
12.0/13.0 g/dL (female/male), moderate anemia <11.0 g/dL, severe anemia <8.0 
g/dL.
Statistics. Unpaired t-test was used to assess differences in Hb levels in the dif-
ferent TCF4 expression groups.Colony data were analyzed using a paired t-test 
or theWilcoxon matched-pairs signed rank test if the data was not normally 
distributed. P-values equal or lower than 0.05 were considered significant.
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Abstract
Post-remission treatment (PRT) in patients with cytogenetically normal (CN) 
AML in first complete remission (CR1) is debated. We studied 521 patients with 
CN-AML in CR1, for whom mutational status of NPM1 and FLT3-ITD was 
available, including the FLT3-ITD allelic ratio. PRT consisted of reduced inten-
sity conditioning (RIC) alloHSCT (n=68), myeloablative conditioning (MAC) 
alloHSCT (n=137), autoHSCT (n=168), or chemotherapy (n=148). Favorable 
overall survival (OS) was found for patients with mutated NPM1 without FLT3-
ITD (71±4%). Outcome in patients with a high FLT3-ITD allelic ratio appeared 
to be very poor with OS and relapse-free survival (RFS) of 23±8% and 12±6%, 
respectively. Patients with wild-type NPM1 without FLT3-ITD or with a low 
allelic burden of FLT3-ITD were considered as intermediate-risk group because 
of similar OS and RFS at 5 years, in which PRT by RIC alloHSCT resulted in 
better OS and RFS as compared to chemotherapy (HR 0.56, p=0.022 and HR 
0.50, p=0.004, respectively) or autoHSCT (HR 0.60, p=0.046 and HR 0.60, 
p=0.043, respectively). The lowest cumulative incidence of relapse (23±4%) was 
observed following MAC alloHSCT. These results suggests that alloHSCT may 
be preferred in patients with molecularly intermediate-risk CN-AML, while the 
choice of conditioning type may be personalized according to risk for NRM.
Introduction
Acute myeloid leukemia (AML) is a cytogenetically and molecularly heteroge-
neous disease. Cytogenetically normal AML (CN-AML) is the largest cytogenetic 
subgroup (40-50% of AML patients),1 which currently can be further refined 
based on molecular markers. Mutations in nucleophosmin 1 (NPM1) and fms-like 
tyrosine kinase 3 internal tandem duplications (FLT3-ITD) are found in respec-
tively 50% and 30% of patients with CN-AML.2Molecular diagnostic analyses 
provide additional prognostic information that may be used for a risk adapted 
treatment approach.3-6FLT3-ITD, particularly FLT3-ITD with a high mutant 
to wild-type ratio, is associated with an unfavorable prognosis, while NPM1 
mutations in the absence of FLT3-ITD are associated with a relatively favorable 
outcome.2,3,7-11Patients who obtain a first complete remission (CR1) are subse-
quently treated with post-remission treatment (PRT), including an additional cycle 
of chemotherapy, high dose chemotherapy followed by autologous hematopoietic 
stem cell transplantation (autoHSCT), or allogeneic HSCT (alloHSCT) follow-
ing either myeloablative conditioning (MAC) or reduced intensity conditioning 
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(RIC). PRT in patients with CN-AML CR1 is a subject of continued debate, 
especially taking molecular markers into account.12-19 AlloHSCT is generally not 
associated with better survival in patients with NPM1 mutations without FLT3-
ITD, while the role of autoHSCT and alloHSCT in patients with FLT3-ITD 
is not definitely settled.3,9,10,12,19-21 In addition, large comparative studies of PRT 
including autoHSCT are lacking in molecularly defined subgroups. In the present 
study, we addressed the impact of NPM1 and FLT3-ITD including the FLT3-
ITD allelic ratio on outcome in patients with CN-AML, treated upfront within 
four prospective, consecutive HOVON-SAKK, and EORTC studies. Secondly, 
we compared outcome of PRT with alloHSCT and autoHSCT versus chemo-
therapy by time-dependent analysis in patients with AML in CR1, according to 
molecularly defined subgroups.
Methods
Patients
A total number of 521 patients with newly diagnosed CN-AML were included, 
treated between 1995 and 2010 and who obtained CR1 after one or two in-
duction cycles of chemotherapy. Patient data were derived from two cohorts 
including consecutive, prospective HOVON-SAKK phase III trials (AML29, 
AML42/42A, and AML92; n=399),22-24 and a prospective EORTC phase III trial 
(AML12; n=122).25 Patients were excluded if molecular information was not 
available or if EVI1 overexpression was present. Figure 1 shows the total numbers 
of patients enrolled in the different trials and reasons why patients were excluded 
in the present analysis. The ratio of FLT3-ITD mutant to wild-type, defined by 
FLT3-ITD divided by FLT3-ITD plus FLT3-wild-type, was available for 86% 
of the patients with FLT3-ITD AML. A predefined cut-off of >0.50 was applied 
to define subgroups with a low or high allelic ratio of FLT3-ITD. Patients were 
considered as having a low allelic ratio in case the ratio was not available in order 
to define a mere poor risk group. Details of the molecular analysis are provided in 
the Supplementary Appendix. All studies were approved by the ethics committees 
of participating institutions and were conducted in accordance with the Declara-
tion of Helsinki. All participants had given written informed consent. A detailed 
description of the inclusion and exclusion criteria of the studies can be found in 
the Supplementary Appendix.
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Treatment protocols
Treatment in the HOVON-SAKK AML29, AML42/42A, and AML92 studies 
involved a maximum of two remission induction cycles consisting of an anthra-
cycline with cytarabine chemotherapy, as previously described.22-24 Induction che-
motherapy was followed by three types of PRT in patients in CR1 according to a 
predefined strategy as outlined in the study protocols, including either a third cycle 
of chemotherapy with mitoxantrone and etoposide, high-dose chemotherapy with 
busulfan and cyclophosphamide followed by autoHSCT, or alloHSCT following 
either MAC or RIC. These different therapeutic modalities were applied accord-
ing a risk-adapted strategy as previously described.22-24,26,27 Induction treatment in 
the EORTC AML12 study consisted of a combination of anthracycline, etopo-
Figure 1. Patient flow chart.
Patients with AML, included in EORTC and HOVON-SAKK trials, who were eligible for the present 
analysis with CN-AML in CR1 with available molecular analysis who received PRT.
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side, and cytarabine-based chemotherapy.25 All patients in the EORTC AML 12 
study received PRT with at least one cycle of chemotherapy after obtaining CR1 
followed by continued PRT with either autoHSCT or alloHSCT. The preferred 
type of PRT in patients below the age of 50 years with an available donor was 
alloHSCT, while in patients above the age of 50 years or patients lacking a donor 
autoHSCT was performed as the preferred PRT.25Conditioning with either RIC 
or MAC was performed based on center’s choice.
Transplantation protocols
Patients received either a MAC or a RIC regimen followed by the infusion of 
donor cells. RIC alloHSCT was introduced in patients below 60 years as from 
2001, whereby the indication for RIC or MAC was selectively determined by age 
and consistently adhered to by the individual center throughout the HOVON 
AML42/42A and AML92 studies. While some center’s maintained their policy of 
MAC alloHSCT for all patients up to the age of 60, a number of center’s changed 
their policy by setting the age limit for MAC at <40 and RIC forpatients of 40 
years and beyond. The MAC regimen contained high-dose cyclophosphamide with 
total body irradiation (TBI) in 61 out of 81 (84%) HOVON patients, whereas 
the remainder received busulfan with cyclophosphamide. RIC regimens varied, 
but the vast majority consisted of 2.0 Gray TBI preceded by fludarabine (n=51, 
93%). MAC alloHSCT in the EORTC study preferably consisted of high-dose 
cyclophosphamide with TBI and alternatively busulfan with high-dose cyclo-
phosphamide. The most frequently used RIC regimen in the EORTC study was 
busulfan combined with fludarabin. A calcineurin inhibitor (either ciclosporin or 
tacrolimus) plus mycophenolate mofetil or methotrexate was given as prophylaxis 
for graft versus host disease (GVHD).
Endpoints
The primary endpoint of the study was overall survival (OS), according to the 
type of PRT received. OS and relapse-free survival (RFS) were measured from the 
date of starting the first PRT. OS was based on death from any cause, and patients 
were censored at the date of last contact if alive. The events for RFS were death in 
CR1, designated as non-relapse mortality (NRM), or hematological relapse. The 
cumulative risks of relapse and NRM over time were calculated as competing risks 
with actuarial methods, where patients alive in continuing CR1 were censored at 
the date of last contact.
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Statistical Methods
A time-dependent analysis of PRT was performed as described previously,27,28 by 
applying multivariable Cox regression with time-dependent covariates autoHSCT 
and alloHSCT following MAC or RIC.
The multivariable analysis is conceptually similar to a Mantel-Byar analysis,29 
but more general as it allows for adjustment of other factors. A number of patients 
received PRT with chemotherapy (n=28) first before they proceeded to alloHSCT. 
In both the multivariable analysis and the estimation of the survival curves, these 
patients were counted as at risk in the chemotherapy group from start of PRT 
until alloHSCT and after that as at risk in the MAC or RIC alloHSCT group. 
Multivariable Cox regression analysis for OS, RFS, relapse, and NRM was applied 
stratified by study cohort with adjustment for age, sex, white blood cell count 
(WBC) at diagnosis, and late CR (after cycle II instead of I). Outcome estimates 
are at 5 years unless explicitly stated otherwise. All p-values were based on log 
likelihood ratio tests, except when explicitly stated otherwise. Log likelihood ratio 
tests were also used to test for interactions. The proportional hazard assumption 
was tested on the basis of Schoenfeld residuals.29,30 P-values were not adjusted for 
multiple testing. All analyses were done with Stata Statistical Software: Release 
13.1 (2013, College Station, TX: Stata Corporation).
Results
Patients
A total of 521 patients with CN-AML proceeded to PRT with either chemo-
therapy (n=148), autoHSCT (n=168), or alloHSCT following MAC (n=137) 
or RIC (n=68). Patient characteristics are presented in Table 1. Recipients of 
MAC alloHSCT were younger as compared to the other types of PRT. Patients 
with wild-type NPM1 received RIC alloHSCT more frequently as compared to 
chemotherapy and autoHSCT. More allografted patients obtained a relatively late 
CR1 (achieved after 2 cycles of induction chemotherapy). In addition, time from 
remission to PRT was longer for recipients of autoHSCT, andRIC alloHSCT was 
performed more frequently in the recent years. The median follow-up of patients 
still alive was 77 months and differed between patients receiving chemotherapy 
(100 months), autoHSCT (70 months), MAC alloHSCT (79 months) and RIC 
alloHSCT (72 months). Patients characteristics by the different study cohorts 
are presented in supplementary Table 1. Due to different study protocols, time 
from CR1 to PRT was significantly longer for patients treated by the EORTC. 
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All patients treated by the EORTC received PRT with chemotherapy followed by 
final PRT with either autoHSCT or alloHSCT with RIC or MAC conditioning.
Table 1. Patient characteristics.
Post-remission treatment
Chemotherapy AutoHSCT AlloMAC AlloRIC
(N=148) (N=168) (N=137) (N=68)
Sex
  Male 72 49% 87 52% 67 49% 36 53%
  Female 76 51% 81 48% 70 51% 32 47%
Age (years)
  Median 50 48 44 54
  Range 18–60 16–61 16–59 37-60
WBC at diagnosis
  Median 34 28 26 11
  Range 0.8-400 0.8-278 0.6-291 0.9-182
NPM1
  Mutated 95 64% 96 57% 72 53% 30 44%
  Wild-type 53 36% 72 43% 65 47% 38 56%
FLT3-ITD
  Not present 94 64% 116 69% 92 67% 44 65%
  Low ratio 39 26% 48 29% 37 27% 20 29%
  High ratio 15 10% 4 2% 8 6% 4 6%
CR reached after
  Cycle 1 (early CR) 126 85% 155 92% 97 71% 49 72%
  Cycle 2 (late CR) 22 15% 13 8% 40 29% 19 28%
Time from CR to PRT (months)
  Median 2.1 2.6 2.4 2.3
  IQ range 1.4-2.7 2.0-2.9 1.0-2.9 1.2-2.8
Year of PRT
  <2005 104 70% 86 51% 76 55% 20 29%
  ≥2005 44 30% 82 49% 61 45% 48 71%
Abbreviations: AutoHSCT indicates autologous hematopoietic stem cell transplantation; AlloMAC, 
allogeneic hematopoietic stem cell transplantation following myeloablative conditioning, AlloRIC, 
alloHSCT following reduced intensity conditioning; WBC, white blood cell count; NPM1, nucleo-
phosmin 1; FLT3-ITD, fms-like tyrosine kinase 3 internal tandem duplication; IQ, interquartile 
range; CR, complete remission; and PRT, post-remission treatment.
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Treatment Outcome
OS and RFS of all patients was 53±2% and 47±2%, respectively, at 5 years from 
start of PRT. Outcome by molecular subgroups demonstrated distinct favorable 
and poor risk subgroups (Figure 2). Outcome of patients with mutated NPM1 
was clearly determined by the absence or presence of FLT3-ITD with OS of 
71±4% and 39±4%, respectively. In contrast, OS of patients with FLT3-ITD 
appeared to be not influenced by NPM1 mutational status (NPM1mut 39±4%, 
NPM1wt 39±8%), but by the ratio of mutant to wild-type FLT3-ITD (low ratio 
42±3%, high ratio 23±8%). Patients with mutated NPM1 without FLT3-ITD 
had a favorable outcome with OS and RFS of 71±4% and 65±4%, respectively. 
In contrast, AML patients with a high FLT3-ITD mutant to wild-type ratio ap-
peared to exhibit a very poor outcome with OS and RFS of 23±8% and 12±6%, 
respectively. A large group of AML patients, designated as molecular intermediate 
risk, with either a low FLT3-ITD ratio (mutant or wild-type NPM1) or wild-type 
NPM1 without FLT3-ITD showed fairly similar OS and RFS estimating about 
45% and 40%, respectively, allowing us to consider these three subgroups as one 
intermediate risk group.
Outcome by PRT in molecular subgroups
Favorable risk (NPM1 mutant without FLT3-ITD AML). Patients with mutated 
NPM1 without FLT3-ITD shared similar OS following chemotherapy, autoHSCT, 
MAC alloHSCT, or RIC alloHSCT (68±7% and 71±6%, 74±7% or 67±14%, 
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Figure 2. OS and RFS by molecular subcategory.
Kaplan-Meier estimates of overall survival (OS, panel A) and relapse-free survival (RFS, panel B) 
by molecular subcategory of patients with CN-AML in first complete remission from start of post-
remission treatment. Abbreviations: NPM1, nucleophosmin-1, FLT3neg, no fms-like tyrosine kinase 
3 internal tandem duplications; FLT3low, low allelic ratio of FLT3-ITD; FLT3high, high allelic ratio 
of FLT3-ITD. F, number of failures (i.e., death whatever the cause); and N, number of patients.
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respectively, p=0.94, Figure 3A, Table 2). Although autoHSCT or alloHSCT 
following either MAC or RIC reduced relapse more strongly, RFS appeared not 
statistically significantly different as compared to chemotherapy (66±6%, 71±7% 
or 67±14 versus 58±7%, respectively, p=0.78, Figure 3B, Table 2 and supplemen-
tary Table 2). Limiting the analysis to strictly favorably risk patients with an early 
CR (after one cycle of induction chemotherapy) did not show any differences in 
OS or RFS.
Intermediate risk (NPM1 wild-type without FLT3-ITD or low FLT3-ITD allelic 
ratio). Recipients of RIC alloHSCT showed significantly better OS as compared 
to chemotherapy (63±7% versus 39±6%, respectively, p=0.046). AutoHSCT and 
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Figure 3. OS and RFS in molecular subcategories by post-remission treatment.
Overall survival (OS) and relapse-free survival (RFS) in molecularly favorable risk (panels A and B) 
and molecularly intermediate risk (panels C and D) patients with CN-AML in first complete remis-
sion from start of post-remission treatment. Molecularly favorable includes patients with mutated 
NPM1 without FLT3-ITD, and molecularly intermediate includes patients with wild-type NPM1 
without FLT3-ITD or patients with a low allelic ratio of FLT3-ITD. Of note, numbers of patients at 
risk (indicated below the x-axis) differ from the patient numbers (indicated in Table 1 and within the 
figure) because of the time-dependent nature of this analysis, which allows for time to transplantation 
by switching patients at the time of allograft in CR1 to the transplantation curve. Abbreviations: CT, 
chemotherapy; Auto, autologous hematopoietic stem cell transplantation (HSCT); MAC, myeloab-
lative conditioned allogeneic HSCT (alloHSCT). RIC, reduced intensity conditioning alloHSCT, 
MAC; F, number of failures (i.e., death whatever the cause); N, number of patients; and Cox LR, cox 
likelihood ratio.
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MAC alloHSCT had similar OS, which was not significantly different as compared 
to chemotherapy or RIC alloHSCT. RFS was improved by RIC alloHSCT as 
compared to chemotherapy (59±7% versus 30±5%, respectively, p=0.008, Figure 
3D). AutoHSCT and MAC alloHSCT reduced relapse more strongly as compared 
to chemotherapy, but RFS was not significantly different (40±5%, 44±5% versus 
30±5, respectively, p=0.20, Figure 3D, Table 2 and supplementary Table 2). These 
results remained similar in patients with an early CR with improved OS and RFS 
by RIC alloHSCT as compared to chemotherapy.
Poor risk (FLT3-ITD high mutant to wild-type ratio). OS and RFS in patients 
with a FLT3-ITD mutant to wild-type ratio of >0.50 are very poor (Supple-
mentary Figure 1A and 1B). Numbers of patients were low hampering a reliable 
comparison of the different types of PRT.
Multivariable analysis in molecularly intermediate risk patients
Table 3 shows the results of the multivariable analysis with adjustment for type of 
PRT, sex, age, WBC below or above 100, and late CR. OS and RFS were better 
by RIC alloHSCT as compared to chemotherapy (HR 0.56, p=0.022 and HR 
0.50, p=0.004, respectively), and autoHSCT (HR 0.60, p=0.046 and HR 0.60, 
p=0.043, respectively), while NRM was not significantly different comparing RIC 
alloHSCT with chemotherapy or autoHSCT (HR 2.54, p=0.16 and HR 1.58, 
p=0.42, respectively). Although no significant differences were found comparing 
autoHSCT and chemotherapy, the risk of relapse after autoHSCT was reduced 
with a HR of 0.71, p=0.087. RFS was improved comparing MAC alloHSCT with 
chemotherapy (HR 0.67, p=0.048), with a strongly decreased risk of relapse (HR 
0.20, p<0.001) and counterbalancing increased risk of NRM following MAC 
alloHSCT (HR 9.14, p<0.001). OS and RFS following autoHSCT or MAC al-
loHSCT yielded similar results with an reduced risk of relapse following MAC 
alloHSCT as compared to autoHSCT (HR 0.29, p<0.001), but increased risk 
of NRM (HR 5.70, p<0.001). Furthermore, increasing age exhibited a signifi-
cant HR for worse OS. In addition, late CR was associated with a significantly 
increased HR for OS, RFS and relapse as compared to CR after one cycle of 
induction chemotherapy. Of note, time from CR1 to start of PRT and year of 
treatment (before and after 2005) were added as factors to the model but showed 
no significant effects on OS, RFS, relapse or NRM. In addition, a sensitivity 
analysis of only patients receiving PRT after 2005 showed similar results for PRT 
on all outcome parameters.
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Discussion
The preferred type of PRT in patients with CN-AML in CR1 continues to be 
debated. Molecular diagnostics provide additional prognostic information to 
further stratify patients with CN-AML in CR1. Here, we demonstrate that type 
of PRT does not differentially affect outcome in the favorable group of patients 
with mutated NPM1 without FLT3-ITD. Outcome in patients with a high allelic 
ratioof FLT3-ITD appeared very poor, with low patients numbers hampering a 
comparison by type of PRT. In contrast, outcome by type of PRT appeared to 
differ in a larger intermediate group, characterized by FLT3-ITD with a low allelic 
ratio and wild-type NPM1 without FLT3-ITD AML. RIC alloHSCT appeared 
associated with significantly better OS and RFS as compared to chemotherapeutic 
PRT, while MAC alloHSCT and autoHSCT yielded similar OS, which did not 
significantly differ from PRT by chemotherapy.
The FLT3-ITD is an important molecular determinant of AML risk classifica-
tion and outcome.4,5,31 Here, not only FLT3-ITD itself, but especially the mutant 
to wild-type ratio strongly affected outcome with poor outcome for patients with 
a high allelic ratio. Based on these and previous results, the FLT3-ITD allelic ratio 
should be included in AML risk classifications and PRT decision making.7-10,19,32 
PRT has not extensively been studied in patients with AML with a high allelic 
burden of FLT3-ITD, but improved outcome following alloHSCT has been sug-
gested in patients with a FLT3-ITD allelic ratio of >0.50.10,19,32 In our study, the 
few surviving patients with a high allelic burden of FLT3-ITD were recipients of 
an alloHSCT in either CR1 or CR2, which compares well to recent results by Ho 
et al,19 suggesting improved outcome by alloHSCT.
Studies evaluating PRT by alloHSCT in patients with FLT3-ITD irrespec-
tive of the allelic ratio reported different results. While a study from the French 
GOELAMS study group reported improved outcome by alloHSCT,33 a recent 
prospective matched pair study failed to show such a survival benefit.34 The 
evaluation of all FLT3-ITD patients, including an unknown number of patients 
with a high allelic ratio, may have impacted on those results, questioning the 
comparability of those and other studies, focusing on FLT3-ITD. We combined 
patients with a low FLT3-ITD allelic ratio (irrespective of NPM1 mutations) 
and patients with wild-type NPM1 without FLT3-ITD into an intermediate risk 
group because of similar OS and RFS in these subgroups. In that molecularly 
intermediate risk group, OS and RFS were significantly better following RIC 
alloHSCT as compared to chemotherapy, which was confirmed by multivariable 
analysis stratified by study cohort and following adjustment for covariates. Of 
note, with a median follow-up of 72 months, NRM was low and a graft-versus-
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leukemia (GVL) effect was preserved as evidenced by a HR of 0.35 for relapse as 
compared to chemotherapy. While MAC alloHSCT showed an even stronger HR 
of 0.20, that anti-leukemic activity was counterbalanced by a significantly higher 
NRM (HR 9.14). Although a number of studies have shown a higher relapse rate 
following RIC alloHSCT as compared to MAC alloHSCT,35-41 the net effect in 
terms of OS and RFS in well-defined and sufficiently sized subcategories of AML 
CR1 patients is still underreported. Here, we show that the balance of a preserved 
GVL and a low NRM eventually resulted in favorable outcome in molecularly 
intermediate risk AML CR1 recipients, who proceeded to RIC alloHSCT. MAC 
alloHSCT and autoHSCT yielded similar outcome in that intermediate risk cat-
egory of patients. Most comparative PRT studies in molecular subgroups compare 
alloHSCT with chemotherapy, but lack a group of autoHSCT recipients. Here, 
also a large subgroup of recipients of an autograft was included. Although au-
toHSCT was not significantly associated with improved outcome as compared to 
chemotherapy or MAC alloHSCT, autoHSCT may provide a valuable alternative 
PRT in these subgroups, especially in patients lacking a well matched donor or 
in patients at higher risk for NRM determined by risk scores.42-44 In addition, 
the incorporation of minimal residual disease (MRD) status assessed by flow 
cytometry45,46 or molecular analysis47 may add to that decision making, by the 
preferred application of autoHSCT in MRD negative, molecularly intermediate 
risk patients in CR1. Of note, while RFS following autografting estimated 40% in 
the intermediate risk group, OS was 47%, indicating that a considerable number 
of relapsing patients may be rescued by an allograft in CR2, as previously reported 
in AML patients.48-50
Combining results from two cooperative groups may implicate limitations. 
Although the induction chemotherapeutic regimens varied among the different 
study groups, all patients received cytarabine/anthracycline-based chemotherapy, 
obtained a hematological CR1 within two cycles of induction chemotherapy, and 
outcome was not significantly different among the different study groups. In ad-
dition, differences in PRT approach among the study groups may have resulted 
in selection bias, although that bias is presumably similar among the three mo-
lecularly defined groups in the analysis, which were not differentially approached 
by the study groups. The analysis presented did not prospectively compare RIC 
and MAC regimens prior alloHSCT, which withholds us from conclusions in that 
regard. Given the significant lower NRM associated with RIC, as shown in many 
studies, the presentation of RIC alloHSCT and MAC alloHSCT as two distinct 
categories is, however, warranted. The latter notion is supported by results of the 
prospective randomized US study, showing different outcome following either 
conditioning type.51 While MAC alloHSCT is associated with a significantly 
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stronger anti-leukemic effect, its counterbalancing effect on NRM need to be 
taken into account, especially in older patients with comorbidities. Therefore, as 
advocated before,5 we prefer to apply either treatment modality in a personalized 
fashion, tailored by risk factors, predicting NRM.52
Collectively, these results suggest that RIC alloHSCT may provide better 
survival than chemotherapeutic PRT in patients with CN-AML with wild-type 
NPM1 without FLT3-ITD or FLT3-ITD with a low allelic burden. AutoHSCT 
may be applied if not eligible, if no well-matched donor is available in CR1, or 
in case of absence of MRD. Although MAC alloHSCT is associated with the 
strongest anti-leukemic effect, our results suggest that it might preferentially be 
applied in patients with an acceptable risk for complications and NRM.
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Supplementary data
Supplementary table 1. Patient characteristics by cohort.
EORTC HOVON
(N=122) (N=399) p value
Sex 0.13
  Male 54 44% 208 52%
  Female 68 56% 191 48%
Age (years) 0.038
  Median 47 49
  Range 16-61 18-60
NPM1 0.34
  Mutated 64 52% 229 57%
  Wild-type 58 48% 170 43%
FLT3-ITD 0.062
  Not present 87 71% 259 65%
  Low ratio 33 27% 111 28%
  High ratio 3 2% 29 7%
CR reached after <.001
  Cycle 1 (early CR) 114 93% 313 78%
  Cycle 2 (late CR) 8 7% 86 22%
Time from CR to start PRT (months) <.001
  Median 3 2.3
  IQ range 2-4 1-3
PRT <.001
Chemotherapy 0 0% 148 37%
AutoHSCT 71 58% 97 24%
MAB 47 39% 90 23%
RIC 4 3% 64 16%
Year of PRT 0.4
  <2005 71 58% 215 54%
  ≥2005 51 42% 184 46%
Abbreviations: AutoHSCT indicates autologous hematopoietic stem cell transplantation; AlloMAB, 
allogeneic hematopoietic stem cell transplantation following myeloablative conditioning, AlloRIC, 
alloHSCT following reduced intensity conditioning; WBC, white blood cell count; NPM1, nucleo-
phosmin 1; FLT3-ITD, fms-like tyrosine kinase 3 internal tandem duplication; IQ, interquartile 
range; CR, complete remission; and PRT, post-remission treatment.
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Supplementary figure S1. OS and RFS in molecularly poor subgroup.
Supplementary methods - Molecular analysis
FLT3 ITD detection and FLT3 ITD/wild type ratio
Total RNA was extracted with phenol chloroform and reverse transcribed using 
Superscript II RT (Invitrogen, Breda, the Netherlands). The presence of FLT3 
ITD and NPM1 mutations in the AML samples were determined as described 
previously.1,2 AML samples harboring a FLT3 ITD were subsequently analyzed 
by Roche 454 next generation sequencing (NGS). Amplicon fusion primers for 
bi-directional sequencing were designed according to the manufacturers protocols 
(Roche, Amplicon Library Preparation Method Manual-Lib-A, GS-Junior Tita-
nium Series, May 2010 (Rev June 2010)) and consisted of an adapter sequence 
for the GS-Junior 454 system, a sample specific barcode sequence (MID – mul-
tiplex identifier) for both forward and reverse primers, and the template-specific 
sequence: FLT3 exon 12: FLT3ex12: 5’-TAAACTCTCCAGGCCCCTTC-3 and 
FLT3 exon 16: FLT3ex16: 5’-TGAGTGCCTCTCTTTCAGAGC-3. PCR and 
cycling conditions: 0.25mM dNTP, 0.4 µM primer, 2mM MgCl2, Taq polymerase 
and 1x buffer (Invitrogen, Breda, the Netherlands), cycling: 1 cycle 4’ 94˚C, 35 
cycles 1’ 94˚C, 1’ 60˚C, 1’ 72˚C, and 1 cycle 10’ 72˚C. Pooled PCR products 
were purified, diluted, clonally amplified by emulsion PCR and sequenced on 
the Roche 454 GS junior system and analyzed according to the manufacturer’s 
protocols (Roche, Amplicon Library Preparation Method Manual-Lib-A, GS-
Junior Titanium Series, May 2010, Rev June 2010). Samples with > 50% FLT3 
ITD as defined by (FLT3 ITD reads/ (FLT3 ITD reads + FLT3 wild type reads) 
were indicated as homozygous FLT3 ITD. The threshold of 50% was chosen to 
ascertain that true FLT3 ITD homozygous were included in the study. Samples 
lacking FLT3-ITDs were used as control.
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Transcription factor 4 in acute myeloid leukemia and healthy 
hematopoiesis
Transcription factor 4 (TCF4) is a basic helix-loop-helix (bHLH) class 1 protein, 
which can regulate DNA transcription by specific binding to the Ephrussi-box 
(E-box) [1-3]. It is involved in a wide range of developmental processes. In hema-
topoiesis TCF4 is crucial for development of plasmacytoid dendritic cells (pDC) 
and it is implicated in the development of T- and B-cells [2, 3]. Mutations in 
TCF4 have been found in acute myeloid leukemia (AML) and myelodysplastic 
syndromes (MDS) at a low frequency [4, 5].
In chapter 2, we analyzed the effect of TCF4 expression on survival in two large 
AML cohorts (HOVON (Dutch-Belgian Cooperative Trial Group for Hematolo-
gy-Oncology) cohort and AMLSG (GermanAustrian AML Study Group) cohort). 
We show that AML patients with high TCF4 mRNA expression levels (highest 
25%) have a worse overall and event free survival (OS and EFS) compared to AML 
patients with a low TCF4 expression. This held true for the whole cohort, but also 
for patients with a normal karyotype, where the risk stratification is generally 
more difficult. When re-analyzing previous report, AML samples with poor out-
come showed a cluster of genes, which included TCF4[6]. Interestingly, we found 
that patients with a high TCF4 expression benefited most from an allogeneic 
(stem) cell transplantation (alloHCT), compared to autologous HCT (autoHCT) 
or additional chemotherapy, while patients with a low TCF4 expression showed a 
trend towards superior survival after autologous HCT (autoHCT). TCF4 mRNA 
expression may serve as a prognostic -, as well as a predictive factor in AML, since 
patients with a high TCF4 expression had poor outcome after chemotherapy or 
autoHCT as post remission treatment, but an improved outcome after alloHCT 
as post remission treatment (Figure 1 a-c). Whether TCF4 is the actual factor 
in AML influencing outcome, or merely a bystander, is difficult to establish. In 
a multivariate model, including ELN-status, age and white blood cell (WBC) 
count, TCF4 expression remained an independent prognostic factor, albeit corre-
lations were found with intermediate and poor risk cytogenetic abnormalities and 
FLT3-ITD. In addition, we observed a positive correlation between FAB M0 and 
M1 and high TCF4 expression, suggesting a more immature phenotype. TCF4 
expression was indeed closely correlated to CD34 expression. In spite of this, 
when CD34 expression was added in the multivariate model, TCF4 expression 
still remained an independent prognostic factor.
Various reports have suggested TCF4 to be an oncogene [7-9]. TCF4 promoted 
neoplastic transformation in human cancer with β-catenin defects [7] and knock-
down of TCF4 in colon cancer cell lines decreased proliferation [8]. Furthermore, 
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in cell and mouse AML models, based on overexpression of Mixed Lineage Leu-
kemia gene (MLL)/AF9 (MLL-AF9) fusion gene, TCF4 was strongly up-regulated 
[10-12]. Upregulation of TCF4 appeared to be of functional importance, as these 
cells lost their growth capacity when TCF4 was down-regulated or when its in-
hibitor, inhibitor of DNA binding 2 (ID2), was up-regulated [12]. Also in GMPs 
transformed with various oncogenes, TCF4 was up-regulated and therefore has 
been proposed to be part of the ‘leukemia initiation signature’ [13]. This indicates 
that TCF4 might be an important factor in the initiation or maintenance of AML.
A B
C
Figure 1.
A. Overall survival (OS) curves for AML patients receiving chemotherapy as post remission treat-
ment (PRT) (n=292), stratified by TCF4high (n=80) and TCF4low (n=212). B. For patients receiving 
autoHCT as PRT (n=70), stratified by TCF4high (n=13) and TCF4low (n=57). C. For patients receiving 
alloHCT as PRT (n=135), stratified by TCF4high (n=36) and TCF4low (n=99).
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Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive 
subtype of acute myeloid leukemia which is characterized by clonal proliferation 
of precursors of plasmacytoid dendritic cells (pDCs). According to the WHO clas-
sification, this disease belongs to the “AML and related precursor neoplasms” [14]. 
Recently, TCF4 was identified as a master regulator of the BPDCN oncogenic 
program. Bromodomain and extra-terminal domain inhibitors (BETis) induced 
BPDCN apoptosis as a result of disruption of the BPDCN-specific transcriptional 
network controlled by TCF4 [9]. In contrast, TCF4 has also been suggested as a 
tumorsuppressor gene, mostly in colorectal carcinomas [15-17]. TCF4 can both 
inhibit and activate transcription, depending on its binding partners. Possibly 
TCF4 exhibits multiple functions, depending on the cellular context.
A difficulty in the use of TCF4 expression as a prognostic factor in the clinic 
is the wide range of expression of TCF4. Identifying the highest or lowest TCF4 
expressors with RT-qPCR in a large cohort of patients that is analyzed simultane-
ously is feasible, but to determine the exact cut off point between high en low 
TCF4 expression uniformly in individual patients, is challenging. Especially since 
TCF4 expression has prognostic value divided by quartiles, median, and also as 
continues variable. It would be interesting to identify the upstream aberrations 
which leads to a high TCF4. Given that about 25% of AML patients have high 
TCF4 expression, it is unlikely that there is just 1 genetic aberration which leads 
to high TCF4 expression, since most known aberrations are not occurring in such 
a high frequency.
In chapter 3 of this manuscript, we show in the AMLSG cohort of 436 AML 
patients, that patients with a RUNX1 mutation have a high TCF4 expression, 
while patients with a t(8;21) ( RUNX1-RUNX1T1) have a low TCF4 expression. 
RUNX1 (also called AML1 or CBFalpha2) stands for runt related transcription 
factor 1 and is a transcription factor which belongs to the family of Runt-related 
transcription factors (RUNXs) [18]. RUNX1 directly contacts DNA via a N-
terminal RUNT domain, but the binding affinity for DNA significantly increases 
after dimerizing with its cofactor CBFβ. CBFβ does not contact DNA itself, but 
also binds to RUNX1 via the RUNT domain [19, 20]. RUNX1 plays a key role 
in definitive hematopoiesis [21-24] and disruption of RUNX1 results in abnormal 
hematopoiesis [19, 24]. In various hematological malignancies including acute 
myeloid leukemia (AML), myelodysplastic syndromes (MDS), myeloproliferative 
neoplasms (MPN) and chronic myelomonocytic leukemia (CMML), RUNX1 
mutations are frequently found [19, 25]. In addition, heterozygous germline mu-
tation of the RUNX1 gene is known to be causative for familial platelet disorder 
with a predisposition for the development of AML [26]. The mutational spectrum 
of RUNX1 includes N-terminal missense mutations, affecting mostly the RUNT 
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domain, and C-terminal truncating mutations, deleting the trans-activation do-
main. Both missense and truncating mutations were reported to have a dominant 
negative effect on the transactivational capacity of wild type RUNX1 [25, 27, 28]. 
Furthermore, chromosomal translocations affecting either RUNX1 or CBF-βare 
amongst the most common cytogenetic aberrations found in AML. A recurrent 
t(8;21)(q22:q22) results in a RUNX1-RUNX1T1 fusion gene in approximately 
10% of the cases, whereas an inv(16)(p13;q22)/ t(16;16)(p13.1q22) leads to a 
CBFβ-MYH11 fusion gene in approximately 8% of AML patients [19, 24, 29, 
30]. RUNX1-RUNX1T1 and CBFβ -MYH11 were incorporated in the world 
health organization (WHO) classification of myeloid neoplasms and acute leuke-
mia in 2008 [31] and in the European Leukemia Net (ELN) recommendations of 
diagnosis and management of AML [32]. In the recent WHO update, AML with 
a RUNX1 mutation has been added as a provisional entity [14] and this category 
of AML has also been included in the ELN recommendations as a poor prognostic 
group [33].
RUNX1 binding was identified on the TCF4 promoter in publicly available 
RUNX1 ChIP-sequencing of Kasumi cells. In a luciferase reporter assay we found 
that wild type RUNX1 represses the TCF4 promoter activity, while RUNX1 
R201Q mutation lost this repression. In addition, the RUNX1 R201Q is a 
missense mutation located in the DNA binding RUNT domain. This mutation 
is frequently found in AML and acts in a dominant negative fashion on the 
trans-activation capacity of wild type RUNX1. RUNX1-RUNX1T1, retained the 
repressive effect on the TCF4 promoter in this transactivation assay. This is in line 
with the respectively high and low TCF4 expression we found in RUNX1 mutated 
and RUNX1-RUNX1T1 AML patients. High expression of TCF4 has also been 
reported in gene expression profiling of AML blasts of patients with mutated 
RUNX1[27, 34, 35]. The correlation between RUNX1 and TCF4 expression does 
not seem to be limited to AML. In Juvenile Myelomonocytic Leukemia, constitu-
tive activation due to mutations in Shp2, led to activation of RUNX1 as results 
of increased dephosphorylation of RUNX1. In these patients, TCF4 expression 
was found to be strongly down regulated [36], which is in line with the repressive 
function of RUNX1 on the TCF4 promoter we identified. In a cohort of 96 low 
and intermediate-I risk MDS patients, we did not find a correlation between high 
TCF4 expression and RUNX1 mutations (Figure 2). In contrast to AML, we could 
not find a association between high TCF4 expression and RUNX1 mutations in 
MDS, this could be a result of a small clone size (measured by the variant allele 
frequency, VAFs) in which the RUNX1 mutations were found. In addition, in 
the AMLSG AML cohort we analyzed, we found that RUNX1 mutations with a 
VAF≥40% showed a significantly higher TCF4 expression than mutation with a 
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VAF<40%, indicating the RUNX1 mutation has to be present in a large enough 
clone to result in measurable TCF4 up-regulation. Nevertheless, perhaps there 
just is no association between RUNX1 mutations and TCF4 expression in MDS 
patients.
In a multivariate Cox regression analysis of the AMLSG AML cohort, includ-
ing TCF4 expression, age, WBC, cytogenetics and RUNX1 mutational status, 
we found that TCF4 expression remained an independent prognostic factor. In 
contrast, RUNX1 mutational status was not an independent prognostic factor 
in this model, indicating that TCF4 expression is a stronger factor predicting 
survival than RUNX1 mutations. Moreover, when adding t(8;21) and inv(16) into 
the model instead of cytogenetic risk group, TCF4 expression (and age and WBC) 
remained an independent prognostic factor, while both RUNX1 mutation and 
t(8;21) failed to show an independently significant impact on survival. Inv(16) 
remained an independent predictor of survival in this analysis, which is in line 
with the observation that inv(16) was not associated with TCF4 expression.
Since RUNX1 mutations and translocation are so closely correlated with TCF4 
expression, the known impact of RUNX1 might work partly via TCF4. Therefore, 
in future studies, we will investigateif the up-regulation of TCF4 is a prerequisite 
for the transformating effect of RUNX1 mutations.
Evidently, the majority of the AML patients with high TCF4 expression does 
not have a RUNX1 mutation, suggesting that there must be other pathways which 
can deregulate TCF4 expression as discussed earlier.
Figure 2. TCF4 mRNA expression of MDS patients with (n=12) or without an RUNX1 mutation 
(n=84)
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In chapter 4 of this manuscript we showed that TCF4 over-expression had no 
impact on white blood cell colony formation or replating capacity by CD34+ 
progenitor cells from umbilical cord blood (UCB). This indicates that enforced 
expression of TCF4 is not sufficient for malignant transformation. Interestingly, 
enforced expression of TCF4 did show an enhancing effect on red blood cell 
colony development, while megakaryocyte colonies were decreased. Moreover, 
the proportion of megakaryocyte-erythrocyte progenitors (MEPs), compared 
to common myeloid progenitors and granulocyte-macrophage progenitors, was 
not increased after enforced TCF4 expression. This indicates that TCF4 may be 
involved in lineage decisions in MEPs. Furthermore, TCF4 expression showed 
a correlation with hemoglobin (Hb) levels in low risk and intermediate-I MDS 
patients. Patients with high TCF4 expression showed higher Hb levels and were 
more likely to have a normal Hb or only a mild anemia compared to patients 
with a low TCF4 expression. Furthermore, patients with a high TCF4 expression 
showed a trend towards less dependency on red blood cell transfusions compared 
to patients with a low TCF4 expression.
So far, TCF4 has not been implicated in the regulation of erythropoiesis, 
but other bHLH proteins have [37]. For instance TAL1 (SCL), a hematopoi-
etic specific bHLH protein, plays a fundamental role in regulation of erythroid 
cell- and megakaryocyte- specific gene expression programs [37-39]. TAL1 is 
expressed in HSCs and hematopoietic progenitor cells and is down-regulated 
during differentiation, except during erythropoiesis and megakaryopoiesis [37].
TAL1, participates in a erythroid stimulating multiprotein complex with GATA1, 
LMO2 and LDB1, which binds DNA elements containing an E-box and a 
GATA-specific site, separated from each other by 9 or 10 base pairs [39, 40]. In 
this multiprotein complex, TCF3 (E2A) has commonly been identified as the 
binding E-protein [37, 39, 41], but also TCF4 has been reported as one of the 
proteins in this complex [42, 43]. Furthermore, direct binding of TAL1 to TCF4 
has been shown [44] and enforced expression of TAL1 also enhances erythroid 
differentiation [45]. E-box/GATA sites have been identified in DNA elements 
regulating the expression of various erythroid cell-specific proteins, like KLF1 and 
p4.2 [37]. Possibly, the enhancing effect of TCF4 on erythroid colony formation 
could be explained by the interaction of TAL1 and TCF4. The reduced number 
of megakaryocytic colonies we observed after over-expression of TCF4 might be a 
result of the mutual antagonism between the erythropoietic factor KLF1 and the 
megakaryocytic factor FLI-1 [46].
Another possible mechanism via which TCF4 could operate to enhance ery-
throid differentiation is through one of its direct downstream targets, BCL11A [9, 
47]. BCL11A is a major determinant in fetal-to-adult Hb switching, as it directly 
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represses human y-globin genes in concert with FOG1, SOX6 and GATA1 [48-
52]. BCL11A has been suggested as a direct target of KLF1 [52, 53], a crucial 
player in erythropoiesis [39]. Interestingly, in line with BCL11A being a direct 
downstream target of TCF4, we also found a diminished BCL11A expression after 
TCF4 knockdown in UCB cells (Figure 3A-B). Possibly, enforced expression of 
TCF4 in UCB CD34+ cells, enhances erythropoiesis due to the up-regulation of 
BCL11, since Bcl11acko/cko mice showed a mild anemic phenotype [52]. Interest-
ingly, BCL11A has also been suggested as a downstream target of TAL1 [54], 
which makes a cooperation of both suggested mechanisms possible. Of note, 
recently BCL11A has also been described as a prognostic marker in AML. Many 
of the characteristics of the AML patients with a high BCL11A expression were 
similar to the characteristics of patients with a high TCF4 expression from chapter 
2. For instance, both high TCF4 and high BCL11A expressors were more likely 
to be FAB M0 subtype, less likely to be FAB M3 subtype and more likely to 
carry a FLT3-ITD mutation [55]. Also, TCF4 and BCL11A cluster together in 
gene-expression profiling of AML patients [6, 27]. Therefore, we investigated (in 
the same HOVON cohort used in chapter 2) the correlation between TCF4 and 
BCL11A expression, as continuous variable in the whole cohort of 525 AML 
patients and specifically in the sub-cohorts. TCF4 expression was subdivided as 
75% lowest and 25% highest expressors (as in chapter 2) and BCL11A expression 
based on the median since this way BCL11A had the strongest impact of survival 
(Fig. 4A). There was a correlation between continuous TCF4 and BCL11A expres-
sion (Fig. 4B R2 = 0.51, p<0.0001) and between high and low TCF4 and BCL11A 
expression (Fig. 4C p<0.0001). Survival analysis according to the Kaplan-Meier 
A B
Figure 3. 
A. BCL11A mRNA expression in UCB samples with knock down of TCF4 (B.) (n = 2) (NT= non 
targeted, sh = short hairpin).
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A B
C
TCF4low (n=394) TCF4high (n=131) p-value
BCL11A expression <0.0001
Under median 235 (59.6%) 28 (21.4%) 
Above median 159 (40.4%) 103 (78.6%) 
D E
Figure 4.
A. Overall survival (OS) curves for AML patients with available follow-up data (n=518) stratified by 
BCL11A quartiles. B. Correlation between continuous TCF4 and BCL11A expression (spearman 
R2=0.51, p<0.0001). C. TCF4 mRNA expression correlated to BCL11A expression divided in low-
est 75% and highest 25% expressors. D. OS curves for AML patients with available follow-up data 
(n=518) stratified by BCL11Ahigh (n=129) and BCL11Alow (n=389). E. And event free survival (EFS)
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method showed that BCL11Ahigh patients had a worse survival than patients clas-
sified as BCL11Alow (5-year OS 28% vs. 47%,P<0.0001; 5-year EFS 22%vs. 36%, 
P<0.0001, respectively) (Fig. 4D-E). In a Cox regression multivariate analysis, 
including white blood cell count (WBC), age >60 years and ELN status, BCL11A 
was an independent prognostic value (OS: HR 1.4, p=0.003; EFS 1.4, p=0.005). 
When adding TCF4 to this analysis, TCF4high remained an independent prognos-
tic factor (OS: HR 1.5, p=0.001; EFS HR 1.5 p=0.001), as described in chapter 
2. BCL11A also remained an independent prognostic factor for OS but not EFS 
(OS: HR 1.3, p=0.043; EFS HR 1.2 p=0.055). Nevertheless, TCF4 was a stronger 
predictor of survival in these models than BCL11A (Wald OS 10.8 vs 4.1; EFS 
10.1 vs 3.7, respectively). Thus, BCL11A expression is correlated to TCF4 expres-
sion and has prognostic impact, but the prognostic relevance of TCF4 expressions 
in AML patients remains and is independent of BCL11A expression. This suggests 
that TCF4 must have other targets which influence prognosis in AML.
Enforced expression of TCF4 enhances erythroid differentiation at the expense 
of megakaryocytic differentiation. Possibly TCF4 is one of the switch factors in 
MEPs. Further research is warranted to pinpoint the function of TCF4 in dif-
ferentiation.
Post-remission treatment in normal karyotype AML subclassified by 
NPM1 and FLT3-ITD allelic ratio
AML is a very heterogeneous disease. Cytogenetics are one of the most important 
prognostic factors predicting outcome and guiding treatment decisions. Ap-
proximately 40% of AML patients, however, have a normal karyotype (NK) [56]. 
Therefore, molecular markers are very important to further dissect this NK group. 
Molecular markers could be used for diagnostic, prognostic, therapeutic purposes 
and to determine minimal residual disease (MRD) after treatment. In AML only a 
few molecular markers, like PML/RARα in acute promyelocytic leukemia (APL), 
RUNX1-RUNX1T1 and MYH11-CBFB have yet been established for diagnostic 
purposes [33]. Since 10% of (elderly) healthy individuals show clonal hematopoi-
esis, involving mutations in genes which can also be found in AML, like mutations 
in TET2, ASXL1 and DNTM3a [57-59], it is very difficult to distinguish clonal 
hematopoiesis from a hematological malignancy based on the presence of these 
molecular markers. People with clonal hematopoiesis are more likely to develop 
AML, however not all clonal hematopoiesis leads to a hematological malignancy 
(like MDS or AML). Consequently, restrained use of molecular markers for diag-
nostic purposes is recommended. For prognostics however, molecular markers are 
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widely used. NPM1, FLT3-ITD and bi-allelic CEBPBα mutations are generally 
used in the clinic [14, 33]. The new ELN criteria recognize the importance of 
mutations in RUNX1, TP53 and ASXL1 as prognostic markers for AML as well 
[33, 60, 61]. Furthermore, molecular markers can be used as predictive mark-
ers for response to specific forms of therapy. At the moment, various targeted 
therapies are making their way to the clinic, for example Flt3 inhibitors and IDH 
inhibitors [21]. Naturally, it is crucial to know if patients have aberrations in the 
involved genes to determine if they could benefit from these new targeted drugs.
The optimal molecular marker for MRD purposes should be stably expressed 
at diagnosis and at relapse, and should not be part of the non-malignant hemato-
poietic cells. Therefore, mutations in some epigenetic regulators are unsuitable as 
MRD markers, since they are often found in clonal hematopoiesis and potentially 
could be detected even after the malignant clone is completely eradicated. A better 
marker for MRD is mutated NPM1 as it is present in a large group of AML 
patients (30%) at diagnosis, is an early marker in leukemogenesis and almost 
always present during relapse and rarely observed in clonal hematopoiesis of 
undetermined potential [62, 63]. The absence or presence of MRD quantified by 
NPM1-mutated transcripts provides powerful prognostic information, and has 
been suggested to have more prognostic value than some molecular aberrations 
determined at diagnosis [63]. Furthermore, the remission status, based on absence 
or presence of MRD assessed by flow cytometry showed to be a more reliable pre-
dictor of MRD than conventional morphology-based complete remission (CR) 
assessment [33, 64]. Therefore, it could be proposed that the MRD status may 
be used as a rapidly assessable endpoint that may serve as a surrogate for relapse 
free survival (RFS) and help with planning post remission treatment (PRT) [33, 
63-65].
In chapter 5 of this manuscript we investigated the best post-remission treat-
ment (PRT) after complete remission 1 (CR1) in different molecular groups based 
on NPM1 and FLT3-ITDmutational status in NK AML patients. In agreement 
with previous reports, we found that the performance of patients with a NPM1 
mutation is also determined by the FLT3 status. Patients with a NPM1 mutation 
without a FLT3-ITDhad an improved overall and relapse free survival (OS, RFS), 
as shown by others [66-71]. The type of PRT in this group did not influence 
outcome. Patients with a high FLT3-ITD/FLT3wt allelic ratio (>0.5) performed 
very poorly in our cohort, as also reported by others [67, 71-75]. Therefore, FLT3-
ITD/FLT3wt allelic ratio should be included in AML risk classifications and the 
choice of treatment, as recently suggested in the 2017 ELN recommendations 
[33]. Limited numbers of patients in our study hampered the comparison of dif-
ferent PRT in this group. Nevertheless, improved outcome has been suggested, 
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when patients with high FLT3-ITD/FLT3wt allelic ratio were consolidated with 
alloHCT [67, 72, 75]. Furthermore, we identified an intermediate molecular 
group, which included NPM1wt/FLT3wt, NPM1mut/FLT3-ITDlow and 
NPM1wt/FLT3-ITDlowAML patients. This group had the least chance of relapse 
after an alloHCT after myeloablative conditioning (MAC). Because of the high 
non-relapse mortality in this group, OS did not differ compared to PRT with 
chemotherapy or autoHCT. For the patients in this group treated with an al-
loHCT after reduced intensity conditioning (RIC) the diminished risk for relapse 
remained, but no significantly higher non-relapse mortality was observed, which 
led to an improved OS.
Although PRT with autoHCT was not significantly associated with improved 
outcome as compared with chemotherapy or alloHCT after MAC, autoHCT 
may provide a valuable alternative PRT in the different subgroups, especially 
in patients lacking a well-matched donor or in patients at higher risk for non-
relapse mortality, like elderly or frail patients with several comorbidities [76-78]. 
Furthermore, the incorporation of MRD status assessed by flow cytometry [79, 
80] or molecular analysis [63] may add to optimally choose the preferred PRT in 
MRD negative, molecularly intermediate-risk patients. In addition, we reported 
that relapse free survival following autoHCT was about 40% in the intermediate-
risk group, while the overall survival was 47%. This indicates that a considerable 
number of relapsing patients may be rescued by an alloHCT in CR2, as previ-
ously reported in AML patients [81-83].Given the significantly lower non-relapse 
mortality associated with RIC, as shown in many studies, the analysis of alloHCT 
after RIC and alloHCT after MAC as two distinct categories that should be ana-
lyzed separately in future studies [84]. Although alloHCT after MAC is associated 
with a significantly stronger antileukemic effect, its negative effect on non-relapse 
mortality needs to be taken into account, especially in older patients with co-
morbidities. Therefore it is very important to determine the treatment based on 
disease characteristics (like WBC, cytogenetic risk, molecular risk) and patients 
characteristics (like age, co-morbidities, performance) [76, 85].
Collectively, our results suggested that alloHCT after RIC may provide better 
survival than PRT with additional chemotherapy in patients with NK AML with 
NPM1wt without FLT3-ITD or FLT3-ITD with a low allelic burden. AutoHCT 
could be applied if not eligible for alloHCT, or if no well-matched donor is avail-
able in CR1. In the current HOVON132 study (a Dutch-Belgian Cooperative 
Trial Group for Hematology-Oncology study), an autologous stem cell transplan-
tation is given as post-consolidation treatment, depending on the MRD status in 
the intermediate risk group.
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With the current and upcoming novel (targeted) therapies [86-88], the role 
of conditioning and transplantation might change drastically. With the current 
therapy regimens, a CR can be achieved in many patients. Relapse, however, 
remains the main cause of post-treatment failure. Therefore, it is very important 
that new strategies are explored to decrease the risk of relapse. The ideal agent 
for maintenance of CR is well tolerated, received only by those patients who 
would otherwise relapse and is able to modify the course of the disease (to achieve 
a sustained remission) [89]. To date many novel therapies are in pre-clinical or 
clinical development (as discussed in chapter 1) [33, 88]. These therapies are be-
ing studied, as single agent or in combination with conventional therapies [88]. 
For example, single-agent ABT-199 (venRUNX1T1clax, inhibitor of BCL-2) 
demonstrated a response in patients with AML, particularly in patients with IDH 
mutations [90] and is now investigated in combination with hypomethylating 
agents (HMA’s) [91]. Moreover, FLT3 mutated AML patients treated with post-
remission cycles of high dose Ara-C in combination with midostaurin, a FLT3 
inhibitor [92], showed promising results compared to addition of a placebo [93]. 
Furthermore, post-transplantation maintenance is explored using various thera-
peutic approaches [89]. In addition, the conditioning prior to the transplantation 
might also be of importance for the post-remission treatment possibilities. Addi-
tion of 10-Day Decitabine to Fludarabine/total body irradiation conditioning, 
induced tumor-associated antigen-specific T-Cell responses which may contribute 
to disease control post-transplantation [94].
In AML, new (molecular) findings will allow us to characterize and hopefully 
understand the disease better and thus be enable us to target these malignancies in 
a more individualized manner. Also here, patients characteristics as well as disease 
markers should be leading in treatment decisions. More studies are warranted to 
place the (new) molecular markers and therapies in the right perspective for the 
individual patient. We aim to maximize complete remission without (measurable) 
MRD and with minimal toxicity and to maintain this remission with optimal post 
remission treatment.
Conclusion
In this thesis we investigated molecular markers in AML and their impact on 
prognosis and treatment benefits. We identified TCF4 mRNA expression as a 
prognostic and predictive marker for type of post remission treatment in AML 
patients, with high TCF4 expressors performing poorly compared to patients 
with a low TCF4 expression. These patients benefited most from an allogeneic 
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hematopoietic cell transplantation, while low TCF4 expressors did best after an 
autologous hematopoietic cell transplantation.TCF4 expression was found closely 
related to aberrations in RUNX1 and TCF4 might be an important down-stream 
effector of RUNX1. In addition, RUNX1 was demonstrated to bind directly to 
the TCF4 promoter and regulate transactivation. Furthermore, we found that 
enforced expression of TCF4 enhances erythroid development,while at the same 
time inhibiting megakaryocytic development in UCB CD34+ cells. Moreover, 
MDS patients with a high TCF4 expression had higher Hb levels and a trend 
towards lower number of red blood cell transfusions than patients with a low 
TCF4 expression. Possibly TCF4 is one of the switch factors in MEPs.
For choosing the best post remission treatment in AML patients without 
cytogenetic abnormalities, FLT3 and NPM1 mutational status can help guiding 
treatment decisions. Furthermore, FLT3-ITDallelic ratio can further stratify AML 
patients, compared to merely absence or presence of FLT3-ITD. Based on these 
markers, a molecular intermediate risk group (NPM1wt/FLT3wt, NPM1mut/
FLT3-ITDlow and NPM1wt/FLT3-ITDlow) could be identified. These patients 
had the best survival after an allogeneic hematopoietic cell transplantation after 
reduced intensity conditioning.
With the current and upcoming novel (targeted) therapies, the role of con-
ditioning and transplantation might change drastically. Molecular markers will 
become even more relevant in determining which therapy is suitable for which 
patients and will play a major role in the development of new therapies.
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English summary
The production of bloodcells takes place in the bone marrow. Here we find a small 
pool hematopoietic stem cells, which can self-renew and differentiate into all other 
cells of the hematopoietic system. They can form red blood cells (erythrocytes), 
which are important for oxygen transport, various white blood cells, which play 
a role in our immune system and platelets, which are essential for coagulation. 
Mature blood cells will leave the bone marrow to travel the body via the peripheral 
blood. The production of these blood cells is a tightly regulated process called 
hematopoiesis.
Cell fate is regulated by epigenetic (meaning: on top of the genetic code) and 
genetic modifications, which result in changes in gene expression.During differ-
entiation, self-renewal genes are repressed, while genes stimulating differentiation 
are up-regulated. This is a tightly regulated process in which cell-type-specific 
transcription factors create a gene expression profile which promotes differentia-
tion towards a certain lineage, while hindering the development of other lineages. 
Daily, billions of cells are produced. Abnormalities in the normal production and 
development of blood cells can lead to hematological diseases, like acute myeloid 
leukemia (AML) or myelodysplastic syndromes (MDS).
AML is a hematological disease characterized by uncontrolled proliferation and 
a block in differentiation of blood cells (stem- and progenitor cells). This results in 
an excess of immature cells (blasts) in the bone marrow and often also in periph-
eral blood, causing a lack of functional mature blood cells (cytopenias). This can 
lead to anemia causing fatigue, thrombopenia causing bleedings, and leukopenia 
resulting in infections. AML a very heterogeneous disease, which can be subdi-
vided in multiple subgroups with a distinct prognosis. Cytogenetics at the time 
of diagnosis is one of the most important prognostic factors in AML. However, 
40-50% of AML patients have a normal karyotype, and molecular abnormalities 
are of major importance for further classification. For example, mutations in the 
NPM1 gene are generally considered as prognostically favorable, while mutations 
in FLT3(FLT3-ITD) and RUNX1are a poor prognostic factors.
Based on the prognosis of the patients, their fitness and whishes, the clinician 
and patient have to decide on the best treatment. Generally, fit patients start 
with a treatment of intense chemotherapy to achieve a remission of the disease. 
After this course, the remission is consolidated with a second course of intensive 
chemotherapy. As post remission treatment, favorable-risk patients are offered 
additional chemotherapy or an autologous (auto) hematopoietic stemcell trans-
plantation. Patients with an intermediate or adverse-risk disease are offered an 
allogeneic (allo) hematological cell transplantation. This is a transplantation with 
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the blood (stem) cells of a family member or a non-related donor. Currently, many 
new treatments are being developed, trying to target the disease more specifically, 
without harming the healthy cells. To be able to develop such specific treatments, 
it is crucial to understand which molecular aberrations are present in the leukemic 
cells that can be targetd.
In chapter 2 we show that AML patients with a high expression of the gene 
Transcription Factor 4 (TCF4) had a poor survival in comparison to patients with 
a low TCF4 expression. In addition, patients with a high TCF4 had a 2-fold 
lower 5-year overall survival compared to patients with a low TCF4 expression 
(18% vs 44%). In a multivariate survival model,where multiple prognostic fac-
tors were investigated in the context of each other, TCF4 expression appeared 
as an independent prognostic factor. Interestingly, when we investigated from 
which treatment patients benefited most, we found that patients with a high 
TCF4 expression survived longer after an allogeneic stem cell transplantation, 
while patients with a low TCF4 expression did better after an autologous stem cell 
transplantation.
In chapter 3we identified a correlation between aberrations of the RUNX1 gene 
and TCF4 expression levels in patients with AML. We found that patients with 
a RUNX1 mutation had a relatively high TCF4 expression. In contrast, patients 
with a translocation between chromosomes 8 and 21, t(8;21), which results in 
the fusion protein RUNX1-ETO, had a low TCF4 expression. We showed that 
RUNX1 binds directly on the TCF4 promoter and represses its activity. When 
RUNX1 is mutated, it loses the repression on the TCF4 promoter, in line with 
the high TCF4 expression found in AML patients with a RUNX1 mutation. The 
RUNX1-ETO fusion protein still repressed the TCF4 promoter, in line with the 
low TCF4 expression found in t(8;21) positive AML patients. Patients with a 
RUNX1 mutation had a poor overall survival, while patients with RUNX1-ETO 
had a relatively favorable prognosis. This matched with the prognosis of the high 
and low TCF4 expressing patients. When taken other known AML risk factors 
along in a multivariate survival model, TCF4 remained an independent prognos-
tic factor while RUNX1 mutations or translocation did not have an independent 
impact on survival. This indicates that TCF4 is a stronger predictor of survival 
than mutations affecting RUNX1. Since RUNX1 aberrations were so closely cor-
related to TCF4 expression and RUNX1 may directly bind and regulate the TCF4 
promoter, we hypothesize that the prognostic impact of RUNX1 works via TCF4. 
More research has to be conducted to confirm this hypothesis.
In chapter 4 of this manuscript we investigated the impact of TCF4 on blood 
development. We over-expressed TCF4 in CD34+ progenitor cells from umbilical 
cord blood (UCB) and stimulated those into myeloid differentiation. We found 
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that enforced expression of TCF4 enhanced red blood cell colony development, 
without increasing the proportion of megakaryocyte-erythrocyte progenitors 
(MEPs). Since MEPs have the potential to differentiate into both erythroid and 
megakaryocytic lineages, we subsequently investigated megakaryocyte (MK) de-
velopment and found that UCB cells with over-expression of TCF4 produced less 
MK colonies. This suggests that TCF4 does not produce more MEP cells, but may 
drive those cells into the erythroid lineage while inhibiting MK development.
Furthermore, TCF4 expression showed a correlation with hemoglobin (Hb) levels 
in low risk and intermediate-I MDS patients. Patients with high TCF4 expression 
showed higher Hb levels and were more likely to have a normal Hb or only a mild 
anemia compared to patients with a low TCF4 expression. In addition, patients 
with a high TCF4 expression showed a trend towards less dependency on red 
blood cell transfusions compared to patients with a low TCF4 expression. Further 
research is warranted to pinpoint the exact impact of TCF4 on differentiation and 
to reveal the underlying mechanisms.
In chapter 5 we in we investigated the best post-remission treatment (PRT) for 
AML patients with normal cytogenetics based on NPM1 and Flt3ITDmutational 
status . We found that the overall survival of patients with a NPM1 mutation is 
affected by the FLT3 status. Patients with a NPM1 mutation without a FLT3ITD-
had a improved survival compared to patients with NPM1 wild type (wt). The type 
of PRT in this group did not influence outcome. Patients with a high FLT3ITD/
FLT3wt allelic ratio (>0.5) performed very poorlyindependently of NPM1 status. 
The limited number of patients in our study hampered the comparison of different 
PRT in this group. Furthermore, we identified an intermediate-risk group, which 
included NPM1wt/FLT3wt, NPM1mut/FLT3ITDlow and NPM1wt/FLT3ITD-
low AML patients. This group performed benefited most from treatment with an 
allogeneic hematopoietic stem cell transplantation after reduced intensity con-
ditioning compared to additional chemotherapy, autologoushematopoietic cell 
transplantation, or an allogeneichematopoietic cell transplantation with myeloab-
lative conditioning. Autologous hematopoietic stem cell transplantation could be 
applied if these patients are not eligible for an allogeneic stem cell transplantation, 
or if no well-matched donor is available.
With the current and upcoming novel (targeted) therapies, the role of con-
ditioning and transplantation might change drastically. Molecular markers will 
become even more relevant in determining which therapy is suitable for which 
patients and will play a major role in the development of new therapies.
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Conclusion
TCF4 expression is a prognostic marker in AML patients. Patients with high 
TCF4 expression perform poorly compared to patients with low TCF4 expression. 
These patients benefit most from an allogeneic stem cell transplantation, while 
patients with low TCF4 expression do best after an autologoustransplantation.
TCF4 expression is closely correlated to aberrations in RUNX1 and might play an 
important role in the prognostic impact of RUNX1 mutations and translocations 
in AML. RUNX1 directly binds on the TCF4 promoter and regulates its transcrip-
tional activity. During hematopoiesis, TCF4stimulates erythroid differentiation at 
the expense of megakaryocytic differentiation.
In the choice of the best post remission treatment for AML patients without 
cytogenetic abnormalities, molecular markers play an important role. We could 
identify prognostically distinct patient groups based on NPM1 and FLT3 mu-
tational status. Furthermore, FLT3ITDallelic ratio can be used to better stratify 
AML patients, compared to mere absence or presence of FLT3ITD. Based on these 
markers, a molecular intermediate risk group (NPM1wt/FLT3wt, NPM1mut/
FLT3ITDlow and NPM1wt/FLT3ITDlow) was identified. These patients had 
the best survival after an allogeneic hematopoietic stem cell transplantation after 
reduced intensity conditioning.
With the current and upcoming novel therapies, molecular markers will become 
even more relevant in determining which therapy is suitable for which patients. 
Moreover, they will play a major role in stratification of patients and the develop-
ment of new (targeted) therapies.
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De productie van bloedcellen vindt plaats in het beenmerg. Hier vinden we 
hematopoëtische stamcellen die in staat zijn zichzelf te vernieuwen, maar ook 
kunnen differentiëren tot iedere andere bloedcel in ons lichaam. Zo kunnen ze 
rode bloedcellen (erytrocyten) vormen, die belangrijk zijn voor het vervoeren 
van zuurstof, verschillende soorten witte bloedcellen, die belangrijk zijn voor ons 
immuunsysteem en bloedplaatjes, die belangrijk zijn voor de stolling van bloed. 
Uitgerijpte bloedcellen verlaten het beenmerg naar het perifere bloed, om daar 
hun functie uit te voeren. De productie van deze bloedcellen is een nauw geregu-
leerd proces dat hematopoëse wordt genoemd.
Het reguleren van de lotsbestemming van een cel gebeurt via genetische en 
epigenetische (betekent: boven de genetische code) veranderingen. Gedurende de 
differentiatie worden genen die betrokken zijn bij het zelf-vernieuwen onderdrukt, 
terwijl genen die de differentiatie stimuleren worden opgereguleerd. Dit is een 
nauwkeurig gecontroleerd proces waarbij cel-type-specifieke transcriptie factoren 
een gen expressie profiel generen die de differentiatie naar een bepaald celtype 
stimuleert en juist de ontwikkeling van een ander celtype onderdrukt. Dagelijks 
maken wij miljarden (7 miljoen per seconde) nieuwe bloed cellen. Afwijkingen in 
normale productie en ontwikkeling van bloedcellen kan leiden tot hematologische 
ziekten, zoals acute myeloïde leukemie (AML) en myelodysplastische syndromen 
(MDS).
AML is een bloedziekte die gekarakteriseerd wordt door toename en een blok-
kade in de differentiatie van jonge bloedcellen (stam- en progenitor cellen). Dit 
resulteert in een buitensporige hoeveelheid niet uitgerijpte cellen (blasten) in het 
beenmerg en vaak ook in het perifere bloed, hetgeen een tekort aan functionele 
uitgerijpte bloedcellen veroorzaakt (cytopenieën). Een tekort aan rode bloed-
cellen (bloedarmoede of anemie) kan leiden tot vermoeidheid, een tekort aan 
bloedplaatjes (trombocytopenie) tot bloedingen en een tekort aan witte bloed-
cellen (leukopenie) tot infecties in AML patiënten. AML is een zeer heterogene 
ziekte, waarbinnen subgroepen bestaan met elk een eigen, specifieke prognose. 
Cytogenetische afwijkingen die aanwezig zijn op het moment dat de ziekte wordt 
vastgesteld, zijn een belangrijke prognostische factor in AML. Echter, 40-50% van 
de AML patiënten heeft geen cytogenetische afwijkingen, en het identificeren van 
moleculaire afwijkingen is belangrijk om de ziekte verder te kunnen classificeren. 
Zo worden bijvoorbeeld mutaties in het gen NPM1 over het algemeen beschouwd 
als een prognostisch gunstige marker, terwijl mutaties in FLT3 en RUNX1 juist 
ongunstige prognostische factoren zijn.
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Op basis van de prognose van de ziekte, de fitheid van de patiënt en diens wen-
sen, moet de dokter in samenspraak met de patiënt bepalen welke behandeling 
het beste is. Over het algemeen wordt er bij fitte AML patiënten een intensieve 
chemotherapie behandeling gestart om de ziekte in remissie te krijgen. Daarna 
wordt de remissie geconsolideerd door middel van een 2e ronde intensieve chemo-
therapie. Als post remissie therapie wordt een patiënt met een goede prognose een 
extra ronde chemotherapie of autologe stamcel transplantatie aangeboden. Dit is 
een transplantatie met de bloed (stam)cellen van de patiënt zelf. Patiënten met 
een intermediaire of slechte prognose komen in aanmerking voor een allogene 
cel transplantatie. Dit wil zeggen dat de transplantatie gebeurt met bloed (stam)
cellen van iemand anders (een familielid of een onverwante donor). Tegenwoordig 
worden er ook veel nieuwe behandelingen ontwikkeld die er op zijn gericht de 
zieke cellen specifiek aan te vallen, zonder de gezonde cellen te beschadigen. Om 
in staat te zijn deze specifieke behandelingen te ontwikkelen is het belangrijk 
dat we begrijpen welke moleculaire afwijkingen aanwezig zijn in de leukemische 
cellen, zodat we die specifiek kunnen attaqueren.
In hoofdstuk 2 hebben we gevonden dat AML patiënten met een hoge ex-
pressie van het gen Transcriptie factor 4 (TCF4) een slechtere overleving hebben 
dan patiënten met een lage TCF4 expressie. Zo hebben patiënten met een hoge 
TCF4 expressie een 2 maal lagere 5-jaar overleving dan patiënten met een lage 
TCF4 expressie (18% vs 44%). In een multivariaat model, waar de invloed van 
verschillende factoren tegelijk worden onderzocht, bleek TCF4 een onafhanke-
lijke prognostische factor. Een interessante waarneming was dat patiënten met 
een hoge TCF4 expressie langer leefden indien ze een allogene bloed (stam)cel 
transplantatie hadden ondergaan, terwijl patiënten met een lage TCF4 expressie 
het juist beter deden na een autologe bloed (stam)cel transplantatie.
In hoofdstuk 3 hebben we bij AML patiënten een correlatie gevonden tus-
sen afwijkingen in het RUNX1 gen, en TCF4 expressie niveaus. We zagen dat 
patiënten met RUNX1 mutaties een relatief hoge TCF4 expressie hadden. Daar-
entegen hadden patiënten die een translocatie hadden tussen chromosomen 8 en 
21, t(8;21), wat resulteert in het fusie eiwit RUNX1-RUNX1T1, juist een lage 
TCF4 expressie. We konden aantonen dat RUNX1 direct op de TCF4 promoter 
bindt en de activiteit van deze promoter onderdrukt. Als RUNX1 gemuteerd was, 
verloor deze zijn onderdrukkende uitwerking op de TCF4 promoter. Dit komt 
overeen met de hoge expressie van TCF4 die wordt gevonden in AML patiënten 
met een RUNX1 mutatie. Een RUNX1-RUNX1T1 fusie-eiwit gaf nog steeds 
een onderdrukking van de TCF4 promoter, hetgeen overeenkomt met de lage 
TCF4 expressie die we in patiënten met deze translocatie vonden. Patiënten met 
een RUNX1 mutatie hadden een slechte overleving, terwijl patiënten met een 
141
Nederlandse samenvatting
C
h
ap
te
r 
7
RUNX1-RUNX1T1 juist een relatief goede overleving hadden. Dit komt overeen 
met de prognose van de patiënten met een hoge en lage TCF4 expressie.Wanneer 
we behalve RUNX1 afwijkingen ookandere bekende prognostische factoren in 
AML in ogenschouw namen in een multivariaat overlevings model, bleef TCF4 
expressie een onafhankelijke prognostische factor, terwijl RUNX1 mutaties en 
translocaties geen onafhankelijke invloed hadden op de overleving. Dit duidt 
erop dat TCF4 een sterkere voorspeller is van de overleving dan RUNX1. Omdat 
RUNX1 afwijkingen zo nauw correleren aan TCF4 expressie en RUNX1 boven-
dien de TCF4 promoter reguleert, stellen wij de hypothese dat de prognostische 
impact van RUNX1 in belangrijke mate via TCF4 werkt. Meer onderzoek is nodig 
om deze hypothese the bevestigen.
In hoofdstuk 4 hebben wij onderzocht wat de invloed van TCF4 is op de 
normale bloeduitrijping. Hiervoor hebben we TCF4 tot overexpressie gebracht 
in navelstrengbloed (stam)cellen en deze gestimuleerd om te differentiëren naar 
verschillende myeloïde bloedcellen. We zagen dat de overexpressie vanTCF4 in na-
velstrengbloed (stam)cellen leidde tot meer rode bloedcel kolonies in vergelijking 
tot cellen met een ‘normale’ TCF4 expressie. Overigens, cellen met een verhoogde 
TCF4 hadden geen verhoogde proportie van megakaryocyten-erytrocyten proge-
nitors (betekend: voorlopers) (MEPs). Aangezien MEPs de potentie hebben om te 
differentiëren naar zowel erytrocyten als megakaryocyten (cellen die bloedplaatjes 
maken), hebben we ook gekeken naar de megakaryocyten ontwikkeling en we 
ontdekten dat navelstrengbloed cellen met verhoogd TCF4 minder megakary-
ocyte colonies kon vormen. Dit suggereert dat TCF4 niet zozeer zorgt voor het 
ontstaan van meer MEP cellen, maar eerder dat hoog TCF4 er voor zorgt dat deze 
MEPs preferentieel in de erytrocyten richting uitrijpen, ten koste van uitrijping in 
de richting van megakaryocyten. Interessant genoeg vonden wij ook een correlatie 
tussen TCF4 expressie en hemoglobine (Hb) waarden in patiënten met laag-riscio 
MDS, waar een hoge TCF4 expressie gecorreleerd is aan een hoger Hb. Ook leken 
deze MDS patiënten met een hoge TCF4 expressie minder rode bloedcel transfu-
sies nodig te hebben. Meer onderzoek is nodig om de precieze invloed van TCF4 
op differentiatie te identificeren en het onderliggende mechanisme te ontrafelen.
In hoofdstuk 5 onderzochten wij de beste post-remissie behandeling voor ver-
schillende moleculaire subgroepen binnen AML met een normale cytogenetica, 
op basis van NPM1 en FLT3 mutatie status. We vonden dat de overleving van 
patiënten met een NPM1 mutatie mede wordt bepaald door de FLT3 mutatie 
status. Patiënten met een NPM1 mutatie zonder FLT3ITD hadden een gunsti-
gere overleving dan patiënten zonder een NPM1 mutatie. Het type post-remissie 
behandeling had geen invloed op de overleving in deze groep. Patiënten met 
een hoge FLT3ITD/FLT3wt allelische ratio (>0.5) hadden, onafhankelijk van 
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NPM1status, een zeer slechte overleving. Vanwege het lage aantal patiënten in 
deze groep, konden wij echter geen vergelijking maken tussen de verschillende 
post-remissie behandelingen. Wel konden we een intermediare risico groep identi-
ficeren, die bestond uit NPM1wt/FLT3wt, NPM1mut/FLT3ITDlaagenNPM1wt/
FLT3ITDlaag AML patiënten. Deze groep had een betere overleving na een 
allogene stamcel transplantatie na niet-intensieve conditionering dan na extra 
chemotherapie, een autologe stamcel transplantatie of een allogene stamcel 
transplantatie na myeloablatieve (volledige vernietiging van alle bloedvormende 
cellen in het beenmerg) conditionering. Een autologe stamcel transplantatie kan 
voor deze groep overwogen worden als de patiënt niet geschikt is voor allogene 
hematopoëtische cel transplantatie of als er geen passende donor beschikbaar is.
Conclusie
TCF4 expressie is een prognostische factor in AML patiënten. Patiënten met een 
hoge TCF4 expressie hebben een slechtere overleving dan patiënten met een lage 
TCF4 expressie. Deze patiënten hebben het meeste baat bij een allogene stamcel 
transplantatie, terwijl patiënten met een lage TCF4 expressie het juist beter doen 
na een autologe hematopoëtische stamcel transplantatie. TCF4 expressie is nauw 
gerelateerd aan afwijkingen in RUNX1 en zou een rol kunnen spelen in de prog-
nostische impact die RUNX1 mutaties en translocaties hebben in AML. RUNX1 
bindt direct aan de TCF4 promoter en kan deze reguleren. In de hematopoëse, 
stimuleert TCF4 de erytrocyten differentiatie ten koste van de megakaryocyten 
ontwikkeling.
Om de beste post-remissie behandeling te kiezen in AML patiënten met normale 
cyogenetica, spelen moleculaire markers een belangrijke rol. We konden patiënten 
classificeren op basis van hun NPM1 en FLT3 mutatie status. Bovendien konden 
we de FLT3ITD allelische ratio gebruiken om de AML patiënten nog verder te 
classificeren. Op basis hiervan konden we een moleculaire intermediaire risico 
groep identificeren die bestond uit NPM1wt/FLT3wt, NPM1mut/FLT3ITDlaag 
en NPM1wt/FLT3ITDlaag AML patiënten. Deze patiënten hadden de beste 
overleving na een allogene hematopoëtische cel transplantatie na conditionering 
met een gereduceerde intensiteit.
Bij de huidige en toekomstige therapieën, zullen moleculaire markers steeds 
belangrijker worden om te kunnen bepalen welke therapie het beste past bij welke 
patiënt. Ze zullen een steeds grotere rol krijgen in het classificeren van patiënten, 
maar ook in de verdere ontwikkeling van nieuwe ‘targeted’ therapieën.
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Dankwoord
Het meest gelezen, doch minst gesuperviseerde onderdeel van mijn proefschrift. 
Niets in het leven doe je alleen en zeker promoveren niet. Dank aan iedereen 
die mij heeft geholpen met: leren, ontwikkelen, zoeken, blijven drinken, omgaan 
met tegenslagen, intomen van onrealistische plannen, balans houden, genieten, 
sparren, gezond eten, optimaliseren, ontspannen.
Ook ik wil toch graag wat mensen specifiek noemen:
Beste Gerwin. Ontzettend bedankt voor het vertrouwen wat je in mij hebt 
(gehad) en de kans die je me hebt gegeven door me deze baan aan te bieden. Ik 
had totaal geen idee waar ik aan begon toen ik onderzoek ging doen, maar nu wil 
ik niet meer zonder. Jij bent een fantastisch voorbeeld hoe je arts, onderzoeker en 
super leuk persoon kunt zijn. Dank voor alle werk-related en unrelated gesprek-
ken die we hebben gehad. Eerst nog in Nijmegen, later via de telefoon (jij bent 
de enige hippe persoon die ik ken die via whatsapp belt). Natuurlijk ook heel veel 
dank voor het begrip en de steun toen mijn leven even op zijn kop stond. Je bent 
een inspiratie en een mentor. Ik hoop dat je dat, nu we dit project bijna afsluiten, 
wilt blijven.
Beste Joop. Jij kreeg mij opeens in de maag gesplitst toen Gerwin naar het hoge 
noorden vertrok. Natuurlijk ben jij altijd betrokken geweest, maar nu werd het 
wel ineens full force. Je hebt mij ontzettend veel geleerd, oa over mezelf. Jij weet 
precies hoe je mij moet aanpakken en hebt mij echt een spiegel voorgehouden. 
Mijn stuiter gedrag werd omgeschoold, maar niet weggenomen. Sorry dat ik je 
af en toe in de rol van kritische, remmende baas heb gestopt. Ik heb ontzettend 
veel van je geleerd op wetenschappelijk en menselijk gebied en heb enorm veel 
respect hoe je jouw werk invult (met humor!). Ook jou wil ik graag heel erg 
bedanken voor de steun en het begrip rondom mijn thuissituatie en de onzekerhe-
den daaromtrent. Ik vind het een ontzettende eer dat je het aandurft om nog wat 
langer met mij in zee te gaan en kijk heel erg uit naar alle projecten die we zullen 
aanpakken in de toekomst!
NB. Gerwin en Joop: super bedankt dat jullie mij de kans hebben gegeven aan 
TCF4 te werken. Ik geloof(de) er zo in en ben heel erg blij dat ik hier mijn PhD 
aan heb mogen besteden en van jullie de kans heb gekregen er out of the box ons 
eigen project te maken!
Beste Walter, ik wil je tocheven noemen. Heel erg veel dank voor het overne-
men van mijn grootste zorg. Daardoor heb ik mij gewoon op mijn werk kunnen 
storten en zie hier het resultaat. Je bent een fantastische dokter en ik heb (ondanks 
mijn toch wat controlling nature) nooit de behoefte gevoeld dat ik dingen moest 
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nakijken/uitzoeken.Heel veel dank voor je goede zorgen! Ik kijk er erg naar uit om 
(ooit) met je samen te werken!
Beste Bert, dank voor je kritische vragen en (goede) ideeën! Je hebt mij ook 
altijd erg geholpen met alle databases en ik kon altijd terecht voor vragen. Dank 
ook voor de gezelligheid rondom de ASH!
Beste collegaatjes. Zonder jullie was ik natuurlijk nergens geweest. Allereerst 
Gorica. Jij hebt mij wegwijs gemaakt op t lab en dat is het fundament geweest 
voor alles wat ik heb gedaan. Daarnaast hebben we altijd goed kunnen kletsen en 
discussiëren, waarbij we veel van elkaar hebben geleerd. Anne, wij hebben in ons 
hokje ook altijd veel kunnen delen, ook van jou heb ik veel geleerd wat het is om 
onderzoeker te zijn. Jullie allebei bedankt voor alle taartjes die we hebben gedeeld. 
Nu de grote onthulling: ik lust eigenlijk helemaal geen bruidstaartjes, maar ik heb 
ze altijd gewoon naar binnen gewerkt, want ik vond het zo gezellig!
Leonie, jij was mijn statistiek maatje en ook voor de leuke klets. Sorry dat ik je 
soms van je werk hield. Maaike, allereerst : bedankt voor de thee! Dankzij jou leef 
ik nog. Daarnaast ben je een heerlijke vrolijke energie en fijne collega! Rinske, jou 
hoef ik eigenlijk niets te zeggen. Je bent m’n (hockey) maatje en gewoon een heel 
fijn persoon. Ik vond het super dat wij samen naar de ASH zijn geweest. Zal jou 
woorden nooit vergeten “Back to civilization!”
Dear Nicco. In the beginning I never knew how to interpreted everything you 
said and that hasn’t changed haha. But you were always warm and hospitable and 
I really fun as a colleague. Dear Pedro. I still remember that the first thing you 
even said to me was: “drop dead”. You are the strangest but best guy ever! The 
only one who is allowed to call me kaboutertje and who will probably already have 
corrected the English (and Dutch) I just wrote. You’re such a lovely warm dear 
person. Don’t stand in your own way. Thanks for being my walking encyclopedia. 
Dear Davide. You could drive me insane from frustrations and laughter (at the 
same time?). Thanks to you everyone knows the proportion of my buttocks to 
rest of my body falls out rather positive (fat ass!) and that I look like a boy when I 
cut my hair (Billy!). But as long as you say that with your awesome Italian accent 
(which I still think you exaggerate) I don’t mind it. Everyone always says I’m such 
an enthusiastic person, but when our first comprehensive screen showed 40% 
GFP+, you were jumping around like a little kid, while I had no idea that was such 
a big deal (don’t worry… I totally learned). Thanks for being the best colleague 
and our great talks! I still love it when we catch up!
Beste analisten. Jullie mag ik natuurlijk absoluut niet vergeten! Jolanda, we heb-
ben samen door velen UCB gezwoegd! Je bent altijd enorm toegewijd en flexibel 
geweest en dat heeft het super fijn gemaakt om met je te werken! Blijf maar lekker 
zitten waar je nu zit, dan komen we elkaar hopelijk over een paar jaartjes weer 
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vaak tegen! Saskia, je bent altijd mijn lopende databases geweest. Ongelofelijk 
wat jij allemaal nog weet te vinden terwijl ik echt al heel goed had gezocht! Dank 
dat je altijd wilde inspringen als ik even hulp nodig had! Ruth, toen ik opeens 
analist-loos was bood je mij gelijk aan om me te helpen. Heel veel dank voor het 
uit mijn handen nemen van de door mij zo geliefde (not) Western blots! Thessa, 
ik vond onze gesprekken en discussies altijd erg leuk. Je bent enorm behulpzaam. 
Heel veel dank voor de hulp in de laatste weekjes van mijn Phd traject en vooral 
voor de mooie plaatjes!
Beste dames en heer van de diagnostiek. Ik vond het altijd heel erg gezellig als 
ik (om wat voor reden dan ook) even bij jullie kon binnenlopen! Jullie creëren een 
geweldige sfeer en zijn altijd extreem behulpzaam en betrokken geweest!
Louis, van jou heb de basis voor qPCR-en geleerd. Dit heb ik erg veel gebruikt 
en als ik (of Emma) er niet uit kwamen ben jij altijd onze redder in nood geweest. 
Dank daarvoor! Marion, Ellen, Adrian en Patricia, jullie heel veel dank voor de 
hulp bij het bepalen van de FLT3-ITD ratio’s!
En last, but (zeker) not least: Evelyn….Bedankt! Gewoon om dat je bent wie je 
bent! En voor al je hulp met de samples!
Aniek, ik vind het ontzettend leuk dat ik je beter heb leren kennen in Amerika. 
We delen veel dezelfde passies en (vooral) frustraties en het is heerlijk om daar 
ongegeneerd met iemand over te sparren. Ik hoop dat wij in de toekomst onze 
politieke lunches kunnen voortzetten!
Beste studenten, Eline en Emma. Heel veel dank voor jullie gezelligheid, inzet 
en flexibiliteit. Jullie hebben beide al snel zelfstandig moeten werken en dat deden 
jullie geweldig. Bedankt voor jullie enthousiasme en fijne contact!
Beste collega’s van de GVL, BMT, IFT, TH, morfologie. Hartelijk dank voor 
jullie hulp en de goede samenwerking! Vooral Rob voor het sorteren, Eugenie voor 
de antibodies en Mia voor het inloggen!
Ok. Dit was het werk-gedeelte. Maar mijn leven bestaat (goddank) uit meer dan 
werk.
Lieve Aukje en Ivan. In zo’n dankwoord zeggen wat je wil zeggen is een beetje 
als reageren op “hoe gaat het?” op whatsapp. Toch wil ik graag wat schrijven, want 
jullie verdienen wel een bedankje. Jullie zijn een enorme steun, support en joy 
geweest bij zo ongeveer alles wat er de afgelopen jaren is gebeurd. Jullie voelen als 
familie. Dank voor alles!! Aukie, zonder jou was ik sowieso verhongerd en zeker 
vitamine deficiënt geworden. Jij leert me even stil staan en bent (de enige?) die een 
rem kan zetten op mijn gedachtenstroom. Ik ben zo trots op jou dat je jouw eigen 
levenspad volgt. Je bent (natuurlijk!) mijn paranimf en dat is een eer! Bovendien 
wilde ik graag (weer) een reden hebben voor gezamenlijke toilet bezoekjes.
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Lieve Nina, jij bent mijn andere paranimf! Ondanks dat je alweer een tijdje in 
Utrecht woont is ben je nog steeds ‘n bestie. We kunnen heel veel lol hebben, 
maar ook de diepte in gaan. Ik heb ontzettend veel bewondering voor je doorzet-
tingsvermogens en de keuzes die je maakt. Ik vind het heel bijzonder dat je mij 
zo betrekt bij die keuzes en vind dat een grote eer. Jij en Jurre zijn gewoon hele 
fijne mensen en ik ben blij dat je tijdens deze verschrikkelijke (leuke) dag aan mijn 
zijde wilt staan.
Lieve Bart en Stef. Jullie zijn mijn vriendjes van het eerste uur in Nijmegen. 
Gelukkig was er (ik quote) “een leuke en een stomme groep” en hebben jullie 
mij op willen nemen in de meest awesome groep ever. Jullie zijn de liefste en 
leukste en vooral muziek maakt mij altijd meer van jullie houden. Laten we alle 
concerten, stapavonden, songfestivalavonden, festivals en efteling bezoekjes nog 
1000x overdoen! Antoine en Loek mogen dan ook komen, want die vind ik ook 
lief.
Lieve Jolijn, Fenneke en Marcella. Mijn huisgenootjes for ever. Opeens moet je 
dan op eigen benen staan. Makkelijk is anders.. Niemand die de houdbaarheids-
datum meer controleert of mijn bedorven chololade op eet. Gelukkig zien we 
elkaar nog regelmatig, waarbij mijn algemene kennis rondom beroemde mensen 
altijd enorm wordt opgekrikt, en houden we onze weekendjes weg erin! Lieve 
Marcella jou zie ik natuurlijk nog het meeste, zeker nu wij allebei ons gezinnetje 
hebben uitbereid (met een puppy!). Jij hebt misschien wel het meeste van iedereen 
altijd proberen te begrijpen wat ik nu in godensnaam in dat lab aan het doen 
was. Dankzij jouw interesse heb ik zelf ook beter in de smiezen gekregen wat ik 
nu eigenlijk deed, aangezien ik eindelijk eens in begrijpbare woorden erover kon 
praten. Je bent een schatje en ik vind het superleuk om met jou naar (horror) 
toneel, het bos of gewoon de kroeg te gaan. Ook jij volgt je eigen pad en dat vind 
ik heel knap!
Lieve Jessica, mijn bestie uit Zwolle. Altijd goed je te zien! Of t nou tijdens 
sushi, Mexicaans of bier en kip (=my favorite) is.
Lieve Manoek. Ben heel blij met onze (herontdekte) vriendschap. Ik geniet 
altijd van onze reflectie op t leven tijdens een (aantal) biertje(s) of thee ;). Veel 
dank dat je mijn (klus) maatje wil zijn!
Lieve Lotte. Dank dat je al 1000 jaar mijn vriendinnetje bent! Ik vind het super 
dat we nu weer zo dicht bij elkaar wonen. En natuurlijk heel heel veel dank voor 
de prachtige voorkant van dit proefschrift!!
Lieve Dieke en Jamilah, bedankt voor alle fijne gesprekken! Ik hoop jullie snel 
weer ergens ter wereld weer te treffen!
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Lieve Felix en Eva, onze vergaderingen zijn voor mij nog steeds heel waardevol! 
Al zie ik wel een neerwaartse trend in de hoeveelheid chouffe die er doorheen gaat 
(good for me, want ik hield jullie toch al niet bij).
Dan is er natuurlijk nog de foundation van mijn bestaan. Mijn familie.
Lieve Manteltjes. Ik ben erg blij met jullie als mijn (extended) familie. Dank 
voor alle steun, gezelligheid en betrokkenheid!
Lieve broers. Dankzij jullie kan ik mij goed staande houden in de wereld. Jullie 
intelligentie en liefde voor discussies heeft mij gevormd. Ik heb veel bewondering 
voor dat jullie alledrie jullie je eigen weg zoeken en volgen in het leven. Jullie zijn 
allemaal op jullie eigen manier een enorme steun geweest toen mijn leven even 
overhoop lag en ik weet dat wij altijd op elkaar kunnen terugvallen. Heel veel dank 
daarvoor. Lieve Joris, jij bent natuurlijk mijn echte grote broer en hebt mij zoveel 
geleerd, onder andere Frans, pingpongen (ik maakte iedereen in hier op t lab) en 
doorzettingsvermogen. Ik vond het heel erg leuk dat ik in jouw team in België 
heb gespeeld en heb erg genoten van de quality time samen in de auto. Lieve Bas, 
ik geniet er erg van dat we steeds meer leuke dingen doen samen. Dank voor al 
je Nijmegen bezoekjes en de support die je ons hebt gegeven. Ik vind het fijn dat 
we samen kunnen filosoferen en hoop dat er nog veel avondjes en concerten in 
het verschiet liggen. Lieve Maarten, we zijn ondertussen 2 klushuizen verder en 
kunnen nog steeds door 1 deur! Ik heb me echt verbaasd wat jij allemaal voor 
elkaar kunt krijgen en de kwaliteiten die jij hebt. Vroeger konden wij botsen, maar 
nu kunnen we juist heel goed praten en samen dingen voor elkaar krijgen! Jij hebt 
me enorm geïnspireerd dat je alles kan, als je het gewoon probeert. Dankzij jou, 
wonen Verve en ik in een heel fijn huisje en ik hoop jou en Lizette daar nog vaak 
te zien! Lieve Lizette, ik ben nog steeds onder de indruk van mijn broer zijn versier 
skills, want hij heeft t toch goed voor elkaar met jou! Ik ben heel blij met jou als 
schoonzus! Sorry dat je zo weinig aan mij hebt voor de meer vrouwen dingetjes. 
Wel kunnen wij heel fijn praten en ik vind t altijd heerlijk om bij jullie te zijn.
Lieve papa en mama. Stom genoeg zeg ik nooit echt tegen jullie hoe erg ik 
jullie waardeer, dus dan moet het maar zo, publicly available en alles. Jullie heb-
ben mij natuurlijk gebracht waar ik nu ben, doordat ik altijd eigen keuzes heb 
mogen maken en mijn dromen heb mogen volgen. Jullie zijn mijn foundation en 
vangnet, waardoor ik vol zelfvertrouwen in het leven kan staan. Jullie zijn er altijd 
als ik jullie nodig heb, ook als ik dat zelf nog niet door heb. Ik hou van jullie. Lieve 
mama, wij kunnen het soms wel eens oneens zijn, maar weet dat ik ontzettend 
veel respect heb voor wat je doet en ik denk dat het jouw vrije en kritische geest is 
die mij zover heeft gebracht. Lieve papa, jij hebt me altijd gestimuleerd het beste 
uit mezelf te halen en mijn dromen te volgen. Ik vond het heel bijzonder dat wij 
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samen naar Nepal zijn geweest en hoop dat we nog eens zo’n tripje maken. Jij 
hebt zelf ook veel meegemaakt afgelopen jaren. Je bent een nieuwe balans aan 
het vinden en ik ben blij dat je tegenwoordig eindelijk eens een beetje naar mij 
luistert!
Then of course the most important one. Mijn leaf, branch, root. You gave me the 
chance to get this job in the first place, because that was when you decided to 
move to the Netherlands. I still can’t believe you did that for me, and can never 
thank you enough. I appreciate every day that we are together and I want you to 
know, believe and feel that I could not have done this without you!! You get out 
the best in me and make me want to be a better person than I actually am. You 
always supported me in every way possible. You taught me to look differently at 
the world (I introduced “look to the sky” at work too!). I am so proud of who you 
are. You are the kindest and strongest person I know. Thank you for getting this 
manuscript together with me. Thank you for being my best friend and husband, I 
am the luckiest girl alive! I love you mijn lief.
153
Curriculum Vitae
C
h
ap
te
r 
8
Curriculum Vitae
Florentien Elizabeth Margo in ’t Hout werd op 25 mei 1987 geboren te Eindhoven. 
Na het behalen van haar VWO diploma aan het Strabrecht college te Geldrop, 
startte zij in 2005 met de opleiding gezondheid- en levenswetenschappen van de 
Vrij Universiteit Amsterdam te Zwolle, om hier in 2006 weer mee te stoppen. In 
2006 is zij begonnen met de studie geneeskunde aan de Radboud Universiteit te 
Nijmegen. Na het behalen van haar bachelor diploma in 2009, is zij voor haar on-
derzoekstage naar het Melanoma Institute Australia in Sydney gegaan. Hier heeft 
zij onder leiding van L.E. Haydu en dr. J. J. Bonenkamp onderzoek gedaan met 
de titel: “Prognostic importance of the extent of ulceration in clinically localized 
cutaneous melanoma”. Alhier was de interesse voor onderzoek geboren.
Na het behalen van haar artsen-bul, is zij in 2013 begonnen aan haar promo-
tieonderzoek onder begeleiding van prof. dr. G. Huls en prof. dr. J. H. Jansen, 
waarbij ze heeft gekeken naar het prognostische belang van Transcriptie Factor 4 
(TCF4) en andere moleculaire factoren en hun impact op therapie uitkomsten in 
patiënten met acute myeloïde leukemie. De resultaten van dit onderzoek heeft u 
(als het goed is) net gelezen in dit proefschrift.
Tijdens haar promotieonderzoek heeft ze het PhD programma van het Radboud 
institute of Molecular Life Sciences (RIMLS) gevolgd. Daarnaast heeft zij de cur-
sussen ‘Management voor promovendi’ en ‘Statistiek voor promovendi’ gevolgd 
en masterstudenten geneeskunde begeleid tijdens hun onderzoeksstage.
In juni 2017 zal ze beginnen met de opleiding tot internist aan het Rad-
boudUMC te Nijmegen.
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